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ABSTRACT 
 
We have hypothesized that dietary modulation of intestinal miRNA expression 
may contribute to the chemoprotective effects of nutritional bioactives (fish oil and 
pectin). Using a rat colon carcinogen model, we determined miRNAs-let-7d, miR-15b, 
miR-107, miR-191 and miR-324-5p were modulated by fish oil + pectin. We also 
demonstrated that BACE1 and PTEN are targets of miR-107 and miR-21, respectively. 
To further elucidate the biological effects of diet and carcinogen on miRNAs, we 
integrated global miRNAs, total and polysomal gene expression datasets obtained from 
the above mentioned study and used four computational approaches. We demonstrated 
that polysomal profiling is tightly related to microRNA changes when compared with 
total mRNA profiling. In addition, diet and carcinogen exposure modulated a number of 
microRNAs and complementary gene expression analyses showed that oncogenic 
PTK2B, PDE4B, and TCF4 were suppressed by the chemoprotective diet at both the 
mRNA and protein levels.  
To determine the function of select diet and colon carcinogen modulated 
miRNAs and to validate their targets, we carried out a series of loss and gain of function 
experiments along with luciferase reporter assays. We verified that PDE4B and TCF4 
are direct targets of miR-26b and miR-203, respectively. PTK2B was determined to be 
an indirect target of miR-19b. In addition, microRNA physiological function was 
assessed by examining effects on apoptosis and cell proliferation.   
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To better understand how the colonic stem cell population responds to 
environmental factors such as diet and carcinogen, we investigated the chemoprotective 
effects of dietary agents on miRNAs in colonic stem cells obtained from Lgr5-EGFP-
IRES-creERT2 knock in mice injected with AOM. We demonstrated that based on 
relative expression of miR-125a-5p, miR-190b and miR-191 in stem cells vs. daughter 
cells and differentiated cells, these miRNAs may be stem cell specific miRNAs. We also 
identified miR-21 to be significantly reduced in stem cells compared to differentiated 
cells and selectively modulated by these dietary agents in stem cells. 
In summary, our results indicate for the first time that fish oil plus pectin protect 
against colon tumorigenesis in part by modulating a subset of miRNAs and their target 
genes (mRNAs) implicated in the regulation of the colon stem cell niche and tumor 
development. 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction of miRNAs 
MicroRNAs (miRNAs), a diverse class of highly conserved small non-coding RNAs 
(~22 nucleotides long), have been shown to play a critical role in several basic biological 
processes such as cellular differentiation, apoptosis, cell proliferation and stem cell 
development, and consequently are also believed to affect complex biological events 
such as carcinogenesis and immune modulation (1, 2). miRNAs regulate protein 
expression by acting through perfect or imperfect complementation to 3’ untranslated 
regions (UTRs) of their “target” mRNAs, which results in repression of target gene 
expression post transcriptionally (2, 3).  Currently, more than 800 human and mouse 
miRNAs have been identified (4).  miRNA studies over the last decade have shown their 
dysregulation in almost all human malignancies, either acting as oncogenes or tumor 
suppressors. 
 
1.2 Biogenesis of miRNAs 
The genomic regions from where the miRNAs are transcribed are largely intergenic 
regions, but small proportions are also found within exonic or intronic regions. 
“Mirtrons” is the word coined for those miRNAs that are transcribed from the intronic 
regions of the genome (5).  miRNAs are transcribed from the genome by RNA 
polymerase II (RNA pol II)  from the promoter as long hair-pin shaped primary 
transcripts (pri-miRNAs) that are polyadenylated at the 3’ end and capped at 5’ end 
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(7MGpppG) (Cai et al, 2004). Pri-miRNA is then cropped to pre-miRNA (~70 
nucleotide long) by the enzymatic activity of cellular RNAse III-type protein 
endocnuclease, Drosha, together with DGCR8/Pasha protein (DiGeroge syndrome 
critical region gene) known as microprocessor complex (6). This pre-miRNA, which has 
a 2-nt 3’ overhang, is recognized by Ran-GTP-dependent transporter exportin 5 and 
exported from the nucleus to the cytoplasm (7, 8).  In the cytoplasm, the pre-miRNA is 
then further cleaved by RNAse III enzyme Dicer which is associated with TRBP (TAR 
RNA-binding protein) and Argonuate (AGO1-4) to generate a double stranded (ds) 
miRNA:miRNA* duplex. This ds duplex is then loaded onto the miRNA associated 
RNA-induced silencing (RISC) complex and with the help of AGO proteins is delivered 
to the target mRNA. The guiding miRNA strand is then unwound by a helicase and is 
referred to as “mature” miRNA. This mature miRNA can then hybridize with the 3’ 
UTR of its “target mRNA” either with imperfect complementarity or with a higher 
degree of complementarity. If bound with imperfect complementarity, it leads to 
translational repression, whereas if it binds with high complementarity, it leads to 
cleavage of target-mRNA (9) (Figure 1). Recent studies have demonstrated that 
miRNAs may also bind to 5’ UTR or even the open reading frame (10, 11). Moreover, it 
has been recently shown that exosomes may contain both mRNA and miRNAs and 
mediate the exchange of genetic material with other cells (12). 
 
There is also evidence to suggest that there are alternative pathways for non-
canonical mirtron biogenesis, which are Drosha independent pathways (13).  Mirtrons 
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can be spliced by spliceosomes and then debranched into pre-mRNA hairpin structures. 
These hairpin structures are then acted upon by Dicer and thus bypass the 
microprocessor complex. They are then exported from the nucleus to the cytoplasm, 
which is mediated by Exportin-5, where it is processed as mentioned above (14) (Figure 
1).  Alternative mechanisms of generating miRNAs also involve snoRNA, shRNA and 
tRNA derived pathways (15, 16). Also, it is suggested that miRNAs can be processed by 
Dicer independent pathways i.e. AGO dependent pathway and tRNaseZ-dependent 
pathway (17-20) (Figure 1). With respect to intercellular microRNA transport, vesicles 
of endocytic origin can contain mRNA and miRNAs (12). These exosomes are shuttled 
between cells to transport miRNAs. Overall, these findings suggest that much remains to 
be determined regarding the biogenesis of miRNAs. 
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Figure 1. Biogenesis of miRNAs. The processing of miRNAs is mediated by Dicer and Drosha 
endonucleases. In the first step, the microprocessor complex (Drosha and DGCR8) mediates the 
nuclear processing of primary-miRNAs (pri-miRNA) into stem-loop precursors of ~70 
nucleotides (pre-miRNA). The nuclear export of the precursors is subsequently mediated by 
exportin-5 in a Ran-GTP dependent manner. In the second step, the pre-miRNA is cleaved in the 
cytoplasm by Dicer into ~22 nucleotides mature miRNA, which incorporates as single-stranded 
RNA into the RNA-induced silencing complex (RISC). This complex directs respective miRNAs 
to their “target mRNAs”, which leads either to translational repression or degradation of the 
target transcripts. Processing of mirtrons by alternative pathways is depicted. miRNAs-
dependent repression of gene expression occurs in P-bodies which are also depicted. miRNAs 
are relocalized to the nucleus, where they may regulate transcription or splicing of transcripts 
(dotted line). Exosomal shuttle RNA is also represented as budding vesicles containing miRNAs. 
Image adapted from (21). 
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 Colorectal cancer ranks as the third leading cause of death among adults. Every 
year in the United States, more than 150,000 cases of colorectal cancer are diagnosed 
and around 57,000 patients die of the disease (22). Several molecular events drive the 
initiation, promotion and progression of colon cancer. These molecular events are 
influenced by several environmental factors, germ-line mutations in genes and 
transcriptional factors, which dictate individual cancer susceptibility and causes 
accumulation of somatic changes in the colorectal epithelium. Also, genomic instability, 
specifically, chromosomal instability, DNA repair defects and aberrant DNA 
methylation are involved in colon cancer (23-29). Changes in chromosomal copy 
number, germ-line and somatic inactivation of mismatch-repair genes and tumor 
suppressor genes such as APC, p53, SMAD4, MLH1, TGF-β, ABX and MYH lead to 
initiation, promotion and progression of colon cancer (30-33). Also, the modest 
depletion of cytosine methylation and aberrant methylation in certain promoter-
associated CpG islands contribute to the epigenetic silencing of gene expression (28). 
Moreover, mutational inactivation of key tumor suppressor genes have been 
demonstrated to affect key signaling pathways, which contribute to tumor formation 
(Figure 2). 
 
 
 
 
 
1.3 Colorectal cancer 
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Figure 2 Genes and growth factor pathways that drive the progression of colorectal cancer. 
In the progression of colon cancer, genetic alterations target the genes that are identified at the 
top of the diagram. The microsatellite instability (MSI) pathway is initiated by mismatch-repair 
(MMR) gene mutation or by aberrant MLH1 methylation and is further associated with 
downstream mutations in TGFBR2 and BAX. Aberrant MLH1 methylation and BRAF mutation 
are each associated with the serrated adenoma pathway. The question mark indicates that genetic 
or epigenetic changes specific to metastatic progression have not been identified. Key growth 
factor pathways that are altered during colon neoplasia are shown at the bottom of the diagram. 
CIN denotes chromosomal instability, EGFR epidermal growth factor receptor, 15-PGDH 15-
prostaglandin dehydrogenase, and TGF-β transforming growth factor β. Image adapted from 
(34). 
 
 
 
According to the literature, there are three major steps involved in progression and 
promotion of colon cancer. The first event is associated with APC, which is a well-
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known tumor suppressor gene involved in suppressing -catenin activity in normal colon 
epithelium and is commonly mutated in colorectal cancer either due to germ line or  
somatic mutations (35, 36). This leads to constitutive activation of Wnt signaling, which 
leads to promotion of colorectal cancer. The next step involves TP53. Inactivation of 
TP53 gene, a well-known tumor suppressor gene has been demonstrated to be one of the 
main causes of progression of colon cancer, i.e., transition of large adenomas into 
invasive carcinomas (37). The last step involves TGF-β-tumor suppressor pathway. 
There is somatic mutational inactivation of TGF-β signaling, which coincides with the 
transition from adenomas to carcinoma (38). Apart from mutation inactivation of tumor 
suppressor genes, activation of oncogenic pathways such as MAPK signaling, PI3K 
signaling and GTPase activity also contributes to development of colon cancer (37, 39-
42).  
1.4  Effect of polyunsaturated fatty acids (PUFA) in colon cancer 
Clinical, experimental and epidemiological evidence demonstrate the significant role 
of PUFA in colon cancer (43, 44). A plethora of studies have shown that consumption of 
a diet rich in omega- 3 fatty acids (n-3 PUFA) enriched in fish oil may reduce the risk of 
colon cancer compared to omega-6 fatty acids (n-6 PUFA) (45-48).  Fish oil contains 
significantly higher amounts of eicosapetaenoic acid (EPA, 20:5∆5,8,11,14,17) and 
docosahexaenoic acid (DHA, 22:6∆4,7,10,13,16,19) compared to corn oil which has higher 
amounts of linoleic acid (LA, 18:2∆9,12), an important source of n-6 in the western diet 
(49). Recent investigations have demonstrated that highly saturated fatty acids present in 
fish oil have effects on apoptosis, signal transduction, reactive oxygen species (ROS) 
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production, transcriptional and translational regulation (50-53). Another dietary agent, 
fermentable fiber is also considered to be one of the most important nutritional factors 
considered to be protective against colon cancer (54-56). Butyrate, a short chain fatty 
acid produced in the intestinal lumen due to bacterial anaerobic fermentation has also 
been demonstrated to have chemoprotective effects (57).  Moreover, we have 
demonstrated that dietary fish oil and fermentable fiber work synergistically to protect 
against colon carcinogenesis, primarily by enhancing apoptosis (52, 58-60). Despite all 
the scientific evidence indicating the protective effect of fish oil and fermentable fiber, 
there is lack of information regarding the molecular mechanisms by which this 
combination exerts its protective effect against colon tumorigenesis. 
1.5 miRNAs and cancer 
It was reported for the first time in 2002 by Calin et al., that a region on chromosome 
13q14 frequently deleted in chronic lymphocytic leukemia (CLL), was transcribed into 
miR-15 and miR-16 (61). Subsequently, miRNAs were shown to be differentially 
expressed in cancer cells, in which distinct and unique miRNA expression profiles were 
documented (62).  High throughput miRNA profiling studies have determined the 
implications of aberrant expression of miRNAs in organ development, e.g., colon, (63-
67), liver (68, 69), lung (63, 70, 71), breast (72-74), prostate (75-77), pancreas (65, 78-
80). Moreover, miRNAs are shown to be correlated to the tumor location and mutation 
status of several tumor suppressor genes /oncogenes and cancer disease stages. There is 
also evidence suggesting that miRNA profiles are able to predict disease outcome and 
response to therapy (81, 82).  Hence, these small molecules have been the focus of 
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scientific attention to determine their potential as clinical biomarkers, with diagnostic, 
and predictive potential. 
1.5.1 Mechanisms affecting miRNA expression 
Several factors have been reported to regulate miRNA expression in cancers. 
One of the key factors is chromosomal abnormality. Genomic regions where miR-15a 
and miR-16-1 were mapped and are reported to be frequently deleted in cancer (61). 
Single nucleotide polymorphisms have also been reported to regulate miRNA expression 
in several types of cancer (83). Apart from structural genetic alterations, miRNA 
expression can also be deregulated by some key epigenetic events like hypomethylation, 
which has been demonstrated to increase expression of miRNAs in cancer (84-86) . 
Moreover, miRNAs have been shown to regulate several components of the epigenetic 
machinery creating a feedback loop (87-90).  
Another mechanism by which miRNA expression is altered is due to defects in 
miRNA biogenesis machinery (91). Overexpression or loss of Dicer and/or Drosha is 
either positively or negatively correlated with outcome in colorectal cancer (92, 93) and 
several other types of cancer (94-96). Alteration in the activity of transcription factors, 
such as p53, MYC and ZEB1 has been shown  to affect miRNA expression (97-99). 
1.5.2 Role of select miRNAs in cancer 
High throughput miRNA profiling studies have detected aberrant expression of 
miRNAs in development of colon (63, 65-67, 100), liver (68) (69, 101), lung (70, 71, 
102), breast (72-74), prostate (75-77), and pancreatic cancer (65, 78-80). Moreover, 
miRNAs are also correlated with tumor location, mutation status of several tumor 
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suppressor genes /oncogenes and cancer disease stages. For example, miR-31 expression 
was found to be significantly higher in Stage IV tumors as compared to stage II tumors, 
while miR-21 was positively correlated with colorectal cancer metastasis (64). 
Several miRNAs such as miR-21 have been shown to be aberrantly expressed in 
almost all types of cancer. Two key “tumor suppressors miRNAs, miR-143 and miR-
145, are dysregulated in several cancers (64, 66, 67, 103-108). Functional studies 
identified several key targets such as ERK5, KRAS, MAPK7, DNMT3A, TGFBRE, 
APC, IRS1, STAT1, YES1 and FLI1 (107, 109, 110). Moreover, overexpressing these 
miRNAs leads to inhibition of cell growth by increasing apoptosis and decreasing cell 
proliferation (111, 112).  
A diverse array of cellular activities has been shown to be modulated by the let-7 
family. For example, it has been demonstrated that members of the let-7 family act as a 
tumor suppressoror oncogene based on the tissue type and histological grade of cancer as 
compared to normal tissue (109, 113-120). Some of the well-defined targets of the let-7 
family are RAS, HMGA2, Blimp-1 and eIF4F (118, 121-127). Moreover, Ibaraa et al. 
showed that let-7 is a marker for differentiated cells and is undetected in stem cells 
(128). 
miR-21 is a well described “oncogenic” miRNA. High expression of miR-21 has 
been reported in breast (129-131), glioblastomas (132-134), pancreatic (135-137) and 
colon cancer (138-140). miR-21 has anti-apoptotic properties by targeting several tumor 
suppressors,  PTEN, PDCD4, BCL2, TIMP3, TGFβR2, SPRY3 and RECK (64, 103, 
139, 141).  miRNA profiling in five gliobastoma cell lines revealed increased expression 
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of miR-21, known to target hTERT, PTEN, PDCD4 and TIMP3  (142).  Also, inhibition 
of miR-21 caused disruption in glioma growth and increased caspase activity (143). 
One of the well-known polycistronic miRNA clusters is miR-17-92, which 
consists of six individual miRNAs, miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 
and miR-92a (144). Overexpression of this cluster has been observed in several tumor 
types (63, 144, 145). Moreover, miR-17-92 suppresses c-myc induced apoptosis in 
colorectal adenoma and progenitor B-cells and thus is considered an oncomir (146, 147). 
Using miR-17-92  knockout mice, Ventura et al. showed that each of the miRNA 
components in the cluster may have its own specific functions apart from some common 
function with the entire cluster (148). 
Recently, two other miRNA clusters formed from miR-200 family members (1st 
cluster consisting of miR-200a, miR-200b and miR-429 and 2nd cluster consisting of 
miR-200c and miR-141) have gained attention. miRNA profiling studies have showed 
that these clusters are downregulated in breast (149, 150), colon (99, 100, 151-153), 
pancreatic (154, 155), and prostate cancer (156, 157). One of the mechanisms by which 
miR-200 exerts its effect is through a double negative feedback loop between miR-200 
family members and transcription factors ZEB1 and ZEB2 (99, 158-160). Inhibition of 
ZEB1 and ZEB2 by these miRNAs caused an increase in a key epithelial maker, E-
cadherin, resulting in the altered acquisition of an epithelial phenotype (160, 161). 
Moreover, an extensive study conducted on NCL-60 cell lines suggested that miR-200 
was a marker of epithelial phenotype (153). Several studies have also identified that 
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miR-200/ZEB association also affects pathways that play a key role in cancers, e.g., 
TGFβ (99, 162) and p53 (163-165). 
1.6  Modulation of miRNAs by bioactive dietary agents 
There is clinical, experimental and epidemiological evidence that suggests that diet is 
one of the most important modifiable determinants for developing a number of chronic 
diseases. Various natural dietary chemopreventive agents have been identified and 
shown to exert pleiotropic actions in cancer cells. Also, studies utilizing several dietary 
agents such as resveratrol, curcumin and EGCG have shown that these compounds have 
neuroprotective properties. Recent literature has suggested that environmental agents, 
specifically bioactive food components (BFC) and exercise play a role directly or 
indirectly  in the modulation of miRNA expression (140, 151, 166-168).  
1.6.1  Modulation of mRNA and miRNAs by fatty acids 
There are compelling data indicating a functional link between dietary fat intake and 
colon cancer risk (47, 169). It is well known that n-3 PUFA are modulators of several 
genes known have a role in inflammation, lipid metabolism and energy utilization (170). 
Moreover, in order to elucidate the molecular mechanisms by which n-3 PUFA inhibit 
azoxymethane (AOM) induced colon carcinogenesis, we have shown that dietary n-3 
PUFA uniquely alter colonic gene expression profiles (50).  For example, n-3 PUFA 
modulate signaling pathways, which promote cell cycle reentry of stem progenitor cells 
and regulate mitogenic activity in the colon (171). Further studies are needed to 
understand how the colonic stem cell population responds to diet and carcinogen 
exposure.  
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In glioblastoma cells, following treatment with three different types of PUFAs 
(GLA, AA and DHA), several miRNAs including miR-16, miR-143, miR-22, miR-20b, 
miR-31, miR-145, miR-182, miR-183, miR-200c, miR-26a, miR-206, miR-140, miR-17, 
miR-29c and miR-34 were differentially expressed. Specifically, in PUFA treated cells, 
miR-143 was reduced, while miR-20b was elevated when compared to untreated cells 
(172). Vinciguerra et al. observed that unsaturated fatty acids (oleic, palmitoleic and 
linoleic acid) reduced PTEN expression in hepatocytes (173). They reported that 
treatment with oleic acid (18:2∆9) also upregulated miR-21 synthesis by activating the 
miR-21 promoter via a mTOR/NF-κB65-dependent mechanism. These findings were 
corroborated in the liver of Wistar rats fed a high-fat diet. In mice fed CLA and 
standard-or-high fat diets, a significant correlation was observed between miR-103 and 
miR-143; miR-103 and miR-107 and miR-221 and miR-222 (174).  In vitro studies in 
breast cancer cell lines (MCF-7 and MDA-MB-231) showed that DHA inhibits 
expression of CSF-1 (colony stimulating factor-1). Moreover, PTEN regulated CSF-1 
expression through PI3K kinase/Akt signaling via a transcriptional mechanism. 
Moreover, DHA treatment inhibited miR-21, which was associated with increased PTEN 
protein levels. This in turn attenuated expression of CSF-1. In vivo studies in mice breast 
tumors also demonstrated similar results as the in vitro study (175). To date, the effect of 
fatty acids on miRNAs in the context of colon cancer has not been investigated. 
 
1.6.2 Modulation of miRNAs by butyrate 
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Diet-derived butyrate, a short chain fatty acid (SCFA) is produced via fermentation 
of dietary fiber in the distal intestine.  With respect to epigenetic effects, butryate acts as 
a histone deacetylase inhibitor and can decrease proliferation and increase apoptosis in 
colorectal cancer cells (176-179). Studies have demonstrated that these effects are 
mediated in part through induction of p21 expression (59).  Recent, evidence suggests 
that the protective effects of butyrate may be mediated in part by modulating miRNA 
expression. Hu et al. showed that on treatment of human colon cancer cells (HCT116) 
with butyrate, expression of miR-17, miR-20a, miR-20b, miR-93, miR-106a and miR-
106b were significantly reduced (180). Also, p21 was determined to be a direct miR-
106b target. These data indicate that SCFA regulate host gene expression by modulation 
of miRNAs implicated in intestinal homeostasis and in carcinogenesis. Another study by 
Humphreys et al. explored the effects of several histone deacetylase inhibitors (HDI) on 
miRNA expression in human colon cancer cell lines (HCT116 and HT-29). They found 
that these HDIs also decreased miR-17-92 cluster miRNAs, while their target genes, e.g., 
PTEN, BCL2L11, CDKN1A, were increased. When miR-17-92 cluster miRNAs were 
overexpressed in presence of the HDIs, the protective effects of HDIs were diminished 
(181).  
1.6.3  Modulation of miRNAs by other dietary agents 
There is evidence suggesting that several other bioactive agents such as vitamins A, 
B, D, E; polyphenols, curcumin, resveratrol, catechins, isoflavones, indoles and 
isothiocynates modulate cancer risk (182-196) by altering gene expression and signal 
transduction pathways. In the last five years, a plethora of studies have examined the 
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effect of these agents on miRNA expression in different types of cancer (155, 197-217). 
Seven microRNAs, let7a, miR-21, miR-26, miR-34, miR-125, miR-146 and miR-200 
were shown to be modulated by at least five of the above mentioned dietary agents. 
These studies concluded that the bioactive dietary agents cause reduction in the 
expression of several miRNAs that are overexpressed in cancer, which subsequently 
modulated genes acting as tumor suppressors or oncogenes, thus conferring protection 
against cancer. 
1.7 Colonic stem cells 
The adult stem cells of the colon are of particular interest because they sustain self-
renewal and are target cells for cancer initiation mutations (218, 219).  Therefore, 
perturbations in the stem cell dynamics are generally believed to represent the earliest 
step towards colon tumorigenesis. In general, the intestinal epithelium is constantly 
being replaced, undergoing apoptosis and shedding (exfoliation) into the lumen (220). 
The replacement of epithelial cells is regulated by the stem cells residing at the base of 
the crypts.  These cells are under constant microenvironmental (niche) influence (221, 
222). Stem cells can undergo asymmetrical or symmetrical cell division to give rise to 
both stem cells and daughter cells. In the case of asymmetrical division, one of the 
daughter cells is identical to the original cell (maintains stemness), and the other 
daughter cell (also called progenitor cell) further differentiates and migrates to the top of 
the crypt. This hierarchical organization is also seen with other tissues that undergo 
constant renewal (223).  Although the exact identity of the stem cells has been proven to 
be controversial over the last 30 years, in the last few years, significant progress has 
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been made to identify, isolate and characterize the stem cells of the colon. Currently, it 
has been proposed that there are two pools of stem cells located in an intestinal crypt 
(224). One of the pools consisting of fast cycling cells is located at the base of the crypt 
and recently, Lgr5 was identified as a functionally validated marker for these cells by 
crossing stem-cell-specific Lgr5-EGFP-IRES-creERT2 knockin mice to Apcflox/flox mice 
(225). Interestingly, lineage tracing has revealed that Lgr5+ stem cell activity in mouse 
intestinal adenomas (226).  Lgr5 is a leucine–rich repeat containing G protein-coupled 
receptor 5 and is overexpressed in colon cancer stem cells (227). Moreover, the 
distribution of Lgr5+ cells within stem cell-derived adenomas indicate that a stem 
cell/progenitor cell hierarchy is maintained in early neoplastic lesions (228). Also, single 
Lgr5+ intestinal stem cells can generate continuously expanding, self-organizing 
epithelial structures reminiscent of the normal gut (229, 230). The other pool consists of 
slow cycling cells that are located at +4 position and Bmi-1 and Tert have been 
identified as markers of these cells (231-233)  
1.7.1 Role of miRNAs in colonic stem cells 
There is emerging evidence that suggests a role for miRNAs in regulating the post-
transcriptional genetic programs in stem and progenitor cells. A recent study 
systematically examined miRNA expression profiles in adult tissue-specific stem cells 
and their differentiated counterparts (231). A common signature of miRNA expression 
in blood, muscle and neural stem cell populations was detected.  This suggests that 
miRNA signatures mark the transition from self-renewing and quiescent stem cells to 
proliferative and differentiating progenitor cells, implying an extensive role of miRNAs 
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in regulating self-renewal, proliferation, and quiescence programs in the cells (234). 
Moreover, miRNA profiling in cancer stem cells isolated from human colon cancer cell 
lines (HT-29) using the CD133 surface marker revealed 11 overexpressed miRNAs and 
eight underexpressed miRNAs such as miRR-429, miR-155, and miR-320d, some of 
which may be involved in regulation of stem cell differentiation (235). 
1.8 Summary and purpose of the study 
Evidence emerging from many clinical and experimental studies shows that diets 
rich in n-3 PUFAs, found in fish oil, have chemoprotective effects against colon 
carcinogenesis. This protection has been shown to be conferred in part by modulating 
transcription and translation of apoptotic and Wnt related signaling pathways (171, 236). 
However, the precise molecular mechanism of action is still obscure. Recently, several 
studies have shown that transformation of adult stem cells is an extremely efficient route 
towards initiating intestinal cancer (228). However, the impact of the above mentioned 
chemoprevention agents on adult intestinal stem cell biology has not been determined.  
Therefore, the main objective of this study was to determine whether the effects of 
chemoprotective dietary n-3 polyunsaturated fatty acids (PUFA) are mediated in part by 
miRNA signatures.  Specifically, the effects of omega-3 and omega-6 PUFA on the 
global targets of select miRNAs were investigated.  In addition, the effects of the 
chemoprotective dietary agents on miRNA expression in adult colonic stem cells were 
documented. In an attempt to elucidate the molecular mechanisms of action the 
following hypothesis and aims were designed. 
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Hypothesis 1: The effects of chemoprotective n-3 PUFAs are mediated, in part, via 
modulation of miRNA signatures in the colon. 
 Aim 1. Determine the targets of miR-15b, miR-21 and miR-107 
Aim 2. Identify protective and promotive intestinal microRNAs based on 
carcinogen and diet treatment in a rat colon cancer model. 
Aim 3. Validate the targets of miR-19b, miR-26b and miR-203; and elucidate the 
effect of chemoprotective dietary agents (fish oil (DHA)+pectin (butyrate)) on 
the levels of these microRNAs. 
 
Hypothesis 2: Chemoprotective diets containing n-3 PUFA plus pectin will protect the 
colon from carcinogen-induced microRNA and mRNA dysregulation in adult colonic 
stem cells. 
Aim 1. Determine the effects of a chemoprotective diet on the global expression 
of microRNAs in stem cells isolated from Lgr5-EGFP mice injected with a colon 
carcinogen (AOM). 
Aim 2. Compare the expression of microRNAs in adult colonic stem cells to 
“global” expression of microRNAs in the entire colonic crypt. 
 
 
 
 
 
1.9 Hypotheses and specific aims 
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2.1 Introduction 
Colorectal cancer continues to pose a serious health problem in United States. 
Every year more than 108,000 cases are diagnosed and more than 50,000 deaths occur 
annually due to colon cancer (22).  From a dietary perspective, a growing number of 
clinical and experimental studies indicate a protective effect of dietary fish oil, 
containing n-3 polyunsaturated fatty acids (PUFA), with respect to colon cancer risk (43, 
50, 169, 237-243). Eicosapetaenoic acid (20:5∆5,8,11,14,17 ) and docosahexaenoic acid 
(22:6∆4,7,10,13,16,19 ) are typical n-3 PUFA (found in fish oil), defined according to the 
position of the first double bond from the methyl end of the molecule, which is 
designated ‘n-3. In contrast, dietary lipids rich in n-6 PUFA (found in vegetable oils) e.g. 
linoleic aicd (18:2∆9,12 ) and (meats) arachidonic acid (20:4∆5,8,11,14 ), enhance the 
development of colon tumors (43, 44). These effects are both exerted at both the 
initiation and post-initiation stages of carcinogenesis (43, 244). In addition, it has been 
reported that consumption of fiber, a source of butyrate, may confer protection against 
colorectal cancer (245). Butyrate, a major source of energy for colonocytes is also 
known to have chemoprotective qualities in colon cancer and animal models (246). 
 
  
 
_________________ 
* Reprinted with permission from “n-3 Polyunsaturated fatty acids modulate carcinogen-directed 
non-coding microRNA signatures in rat colon” by Davidson LA, Wang N, Shah MS, Lupton JR, 
Ivanov I, Chapkin RS, Carcinogenesis.12, 2077-2084, 2009. Copyright 2009 by Oxford 
Journals. 
2. DETERMINATION OF TARGETS OF miR-15B, miR-21 AND miR-107* 
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Consumption of fish oil and fiber together may reduce colon cancer risk in humans (237, 
241). In a series of seminal experiments, we have demonstrated that pleiotropic bioactive 
components generated by fish oil (n-3 PUFA) and fermentable fiber (butyrate) act 
coordinately to protect against colon cancer in part, by enhancing apoptosis (59, 60, 239, 
247, 248).  
Aberrant expression of miRNAs are believed to be one of the key epigenetic 
events involved in colon tumor development. Over the last several years, there has been 
an increasing amount of evidence demonstrating the modulation of miRNA and their 
targets by several bioactive dietary agents in cancer. But no studies have examined the 
chemoprotective effects of n-3 and n-6 PUFA on miRNA expression in colon. Recently, 
we reported for the first time that combined fish oil and pectin treatment modulates a 
subset of miRNAs and their predicted targets (mRNA) implicated in the regulation of the 
colon stem cell niche and tumor evolution (140).  
In order to determine the significantly altered miRNAs in various stages of 
colorectal cancer, Sprague Dawley rats were injected with azoxymethane (AOM), a 
colon carcinogen determined to generate colonic tumors. To observe the changes taking 
place in the early stages of colorectal cancer, rats were sacrificed and total RNA was 
extracted from mucosal scrapping from the colon after 10 weeks of AOM injections. It 
has been well documented that this time point high multiplicity aberrant crypt foci 
(ACF) are evident (50). Comparison of the miRNA expression profiles in rats injected 
with AOM versus saline, revealed that twenty-seven miRNAs were found to be 
overexpressed, while nineteen miRNAs were downregulated in AOM injected rats as 
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compared to the saline injected rats. To assess the protective effects of omega-3 PUFA, 
rats injected with either AOM or saline were fed with fish oil or corn oil, along with 
either pectin or cellulose. Ten weeks after the AOM injection, miRNA profiling was 
carried out. Initial analysis determined that five miRNAs,let-7d, miR-15b, miR-107, 
miR-191 and miR-324-5p were downregulated in the corn oil AOM treated group as 
compared to the fish oil AOM treated group (140).  
 In order to understand the function of the differentially expressed miRNAs, we 
determined the gene targets of these diet modulated miRNAs. Hence, we carried out 
knockdown studies to document the changes taking at the protein level of the putative 
targets. 
 
2.2 Materials and methods 
 2.2.1 Identification of established targets of significantly modulated diet miRNAs 
Empirically established miRNA targets were identified using miRecords 
(http://mirecords.biolead.org/), an integrated resource for miRNA-target interactions. 
2.2.2 Cell culture 
HCT116 cells were cultured in McCoy’s 5A medium supplemented with 10% 
fetal bovine serum and 2 mM glutamax (Gibco, Carlsbad, CA) at 370C in 5% CO2. Cells 
were plated at 1-2x105 wells per well in a 12-well plate on the day of transfection. 
Subsequently, cells were transfected with 5’ FITC-labeled miRNA inhibitors (Exiqon, 
Denmark) anti-miR-107, anti-miR-21, anti-miR-15b (20 nM) using Hiperfect 
transfection reagent (Qiagen, Valencia, CA). Scrambled miR was utilized as a negative 
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control. Twelve hours after the transfection, the media was changed. The experiment 
was repeated in triplicate. 
2.2.3 Total RNA isolation and Real time PCR 
Twenty-four hours after transfection of miRNA inhibitors in HCT116 cells, 
media was removed and the cells were washed thrice with phosphate -buffered saline 
(PBS) (Gibco, Carlsbad, CA). 600ul of RNA lysis buffer provided with miRVana 
miRNA isolation kit was added to each well and the cells were scrapped with the help of 
cell scrapper. Total RNA was isolated using miRVana miRNA isolation kit following 
the manufacturer’s protocol. RNA quantity and quality were measured by nanodrop and 
Agilent 2100 Bioanalyzer (Agilent Technologies, CA) respectively. Real time PCR was 
carried out by using miRNA Taqman PCR assay (Applied Biosystems) to determine the 
expression of mature miR-15b, miR-21 or miR-107 in treated and untreated samples. 
Normalization was carried out by using the 2∆∆CT method relative to 18S rRNA.  
2.2.4 Western blotting 
In order to determine the change in protein expression after miRNA knockdown, 
western blotting was carried out. 2-4x106 cells were seeded in 100 mm dishes on the day 
of transfection. Transfection with 20 nM miRNA inhibitors was carried out as described 
above. Seventy-two hours after the transfection, media was removed and cells were 
washed thrice with PBS. 300 ul of lysis buffer containing 50 mM Tris-HCL (pH 7.2), 
250 mM sucrose, 2 mM ethylenediaminetetraacetic acid (pH 7.6), 1 mM ethyleneglycol-
bis(aminoethylether)-tetraacetic acid (pH 7.5), 50 µM NaF, 1% Triton-X, 100 µM 
sodium orthovanadate, protease inhibitor cocktail and 10 mM β-mercaptoethanol were 
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added to the cells. The lysate was then passed through a 27 gauge syringe and incubated 
on ice for 30 minutes. Subsequently, the lysate was centrifuged at 16,000g for 20 
minutes. The supernatant was collected and the protein concentrations were determined 
by Bradford method. 20-80 µg of samples were loaded onto a 4-20 % Tris-Glycine gels 
(Invitrogen, Carlsbad, CA). After blotting, the membrane was incubated overnight with 
goat BACE1 antibody at 1:1000 (R&D systems, Minneapolis, MN), PTEN antibody at 
1:1000 (Cell signaling Technology, Boston, MA) or Bcl-2 at 1:1000 (Stressgen, Ann 
Arbor, MI) and horseradish peroxidase linked (Jackson Immunoresearch Laboratories, 
West Groove, PA) secondary antibody at 1:10,000 dilution and chemoluminescent 
detection was performed. Unless noted, all the other reagents were from Sigma. 
2.2.5 Statistics 
The effect of two independent variables (treatment effects) was assessed using 
Student’s t-test.  The graphs were plotted using means and standard error of 4 cell 
culture wells (data points) obtained two different experiments (performed in triplicate). 
Standard error bars were plotted in order to document the variation in the population 
mean. P-values < 0.05 were considered to be statistically independent. 
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2.3 Results 
2.3.1 miRNA functional target analysis 
Established targets of let-7d, miR-15b, miR-107, miR-191 and miR-324-5p were 
identified using miRecords (http://mirecords.biolead.org/).  miRecords is an integrated 
resource for miRNA-target interactions (249).  Since insilico analysis is not accurate and 
generates numerous false positives (250), we opted to determine the change in 
expression of those targets that were already validated in other tissues (Table 1). From a 
cancer perspective, miR-15b has been shown as a natural antisense interactor with Bcl-2, 
a well documented anti-apoptotic protein (251). Functional analyses have demonstrated 
that miR-107 contributes to the regulation of beta-site amyloid precursor protein-
cleaving enzyme (BACE1) in Alzheimer's disease (252). 
 
 
 
Table 1. Diet modified miRNAs and their established mRNA targets. Experimentally 
validated mIRNA targets were identified using the miRecords data base 
(http://mirecords.umn.edu/). This data base lists over 301 miRNAs and 902 target genes in 9 
species. 
miRNA 
 
Established 
Target 
Pathway/Func
tion 
Disease/Process Reference 
let-7d 
 
Sept3 
 
 
 
Cytokinesis 
 
 
 
Brain GTPase controlling 
cytoskeletal and 
membrane organization 
Jeyaseelan, 
2008 
 
 
   miR-15b 
 
 
 
Bcl2 
 
 
CCNE1 
Apoptosis 
 
 
Cell cycle 
Gastric cancer cells 
 
 
Glioma cancer cells 
Cimmino, 
2005; Xia, 
2008 
Xia, 2009 
miR-107 
 
Bace1 
 
Protease 
 
Brain Voltage-gated Na+ 
channels 
Wang, 2008 
 
miR-107 Serbp1 Plasminogen 
activation 
Ovarian cancer Beitzinger, 
2007 
miR-191 None identified - - - 
miR-324-5p None identified - - - 
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2.3.2 Colonic miRNA functional target analysis: BACE1 is a target of diet-modulated 
miR-107 
To further assess targets for select diet-modulated miRNAs, we determined whether 
BACE1 is targeted by miR-107 in coloncytes. BACE1 was selected because it is highly 
expressed in HCT116 human colon cancer cells. Hence, we transfected cells with anti-
miR-107 or control anti-miR. On average, transfection efficiency was >70% (Figure 3). 
Twenty-four hours after knockdown, miR-107 levels were reduced by ~70% (Figure 4). 
Correspondingly, 72 hours after transfection, BACE1 levels were increased by >100% in 
knockdown compared with negative control (Figure 5). These results suggest that 
BACE1 is a target of diet-responsive miR-107 in the colon. In complementary 
experiments, we also determined whether Bcl2 is targeted by miR-15b. Since Bcl-2 has 
been shown to be a target of miR-15b in gastric cancer cells (251), we knocked down 
miR-15b. Twenty-four hours after transfection, miR-15b levels were reduced by ~90% 
as compared to the untreated cells and control anti-miR (Figure 4). However, Bcl-2 
levels were unchanged 72 hours following transfection (Figure 5), suggesting that it 
may not be a target of miR-15b in the colon. 
 
 
(A)                                                                     (B) 
 
 
Figure 3. Images after transfection of miRNA inhibitors. (A) Bright-field image of HCT116 
cells (40X magnification). (B) Fluorescence microscopy of HCT-116 cells transfected with 20 
nM miR-107 (40X magnification). Transfection efficiency was approximately 70%. 
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Figure 4. miRNA expression following transfection with miRNA inhibitors.  HCT116 cells 
were transfected with either (A) 20 nM anti-miR-107, (B) 50 nM anti-miR-21 or (C) 50 nM anti-
miR-15b or a control anti-miR. After 24 h, total RNA was isolated and analyzed for miRNA 
expression as described in the Materials and Methods. Asterisk indicates P < 0.05, n = 4 cultures 
from two separate experiments. 
 
 
 
2.3.3 PTEN is a target of miR-21 in the colon 
miR-21 is a well known oncogenic miRNA in the colon and was significantly 
upregulated in rat colon adenocarcinomas compared to normal colonic mucosa (253). 
We subsequently determined if PTEN is a target of miR-21 in the HCT116 colon cancer 
cell model system. PTEN levels were observed to be ~80% higher in the miR-21 
knockdown samples compared with control samples (Figure 5), confirming that PTEN 
is a functional target of miR-21 in the colon. 
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Figure 5. Target protein expression following knockdown of miRNAs. Representative 
immunoblots of HCT116 cells transfected with either (A) anti-miR-107, (B) anti-miR-21 or (C) 
anti-miR-15b or a control anti-miR. After 72 h, proteins were extracted to detect BACE1, PTEN 
or Bcl-2 levels by western blotting. Bar graphs represent the corresponding quantitative analysis 
of (D) BACE1, (E) PTEN and (F) Bcl-2 western blots. Asterisk indicates P < 0.05, n = 4 cultures 
from two separate experiments.  
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2.4 Discussion 
 
In order to determine the targets of the diet modulated miRNAs, we used 
miRecords, an online database to identify the validated targets of miRNAs of interest. 
We report for the first time that upon knock down of miR-107, there was an increase in 
the protein levels of BACE1 in colonic epithelial cells. BACE1 is a validated target of 
miR-107 in Alzheimer's disease in human brain tissues (252) and has been shown to play 
a role in cancer (254). Also, we confirmed that PTEN is a target of miR-21. PTEN is 
frequently mutated or deleted in solid cancers, including colon cancer (255). It is the 
upstream regulator for both PI3K/AKT and MEK/ERK signaling pathways (256, 257). 
Also, miR-21 has been demonstrated to inhibit PTEN expression, which in turn causes a 
decrease in AKT and ERK activation, which results in tumor angiogenesis (258).   
Upon inhibition of miR-15b, Bcl-2 protein levels did not change, even though it 
was shown to be a target in gastric cancer cells. There is evidence suggesting that 
miRNAs have tissue specific targets, which could be one of the reasons why Bcl-2 was 
unchanged (259).  
In summary, these findings indicate the need to consider the impact of dietary 
bioactive agents when examining the role of miRNAs in the biology and pathobiology of 
the gastrointestinal tract. Also, using complementary analysis by comparing expression 
of significantly differentially modulated miRNAs and mRNA across treatments will help 
to shed some light on the underlying global epigenetic changes and further elucidate the 
biological effects of chemoprotective diets. 
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3. INTEGRATED miRNA AND mRNA EXPRESSION PROFILING IN A RAT 
COLON CARCINOGENESIS MODEL: EFFECT OF A CHEMOPROTECTIVE 
DIET* 
3.1 Introduction  
miRNAs are a diverse class of highly conserved small non-coding RNAs (~22 
nucleotides long), shown to play a critical role in fundamental biological processes 
including cellular differentiation, apoptosis, cell proliferation and development.  
Currently, greater than 800 human and mouse miRNAs have been identified (4).  
MiRNAs regulate protein expression by acting through perfect or imperfect 
complementarity to 3’ untranslated regions (UTRs) of their target mRNAs, resulting in 
post-transcriptional repression of gene expression (2, 3).  With respect to chronic 
diseases, it has been shown that the miRNA gene-silencing pathway influences the 
processes of carcinogenesis and immune modulation (1, 2).  With regard to mechanisms 
of oncogene activation, loss of miRNA complementary sites due to widespread 
shortening of 3’ UTRs by alternative cleavage and polyadenylation selectively activates 
oncogenes and drives malignant transformation (260).  Along these lines, several studies 
have shown that dysregulation of miRNAs and their mRNA targets contribute to the 
initiation and progression of colon carcinogenesis (100, 261).  For example, miR-145 
and miR-143 have been shown to act as tumor suppressors in the colon, while miR-21 
 
_____________ 
*Reprinted with permission from “Integrated microRNA and mRNA expression profiling in a rat 
colon carcinogenesis model: effect of chemo-protective diet” by Shah MS, Schwartz SL, Zhao 
C, Davidson LA, Zhou B, Lupton JR, Ivanov I, Chapkin RS, Physiol Genomics 43, 640-654, 
2009. Copyright 2009 by the American Physiological Society. 
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can act as an oncogene by repressing several tumor suppressor genes including PTEN, 
Pdcd4 and TPM1 (138, 262). 
 Several clinical and experimental studies have demonstrated that diets rich in n-3 
polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), found in fish oil, are protective against colon 
tumorigenesis (43, 239, 263, 264).  In contrast, n-6 PUFAs such as linoleic acid (LA) 
and arachidonic acid (AA), found in vegetable oils, have been shown to enhance both 
the initiation and promotion of colon cancer (44, 253, 265).  These findings are 
supported by a growing list of clinical and epidemiological studies indicating a 
functional link between dietary fat intake and colon cancer risk (47, 169, 237).  In 
addition, it has been reported that the consumption of fiber, a source of butyrate in the 
intestinal lumen, may confer protection against colorectal cancers (245).  Intriguingly, 
the protective effect of n-3 PUFAs with respect to colon tumor development is enhanced 
when a highly fermentable fiber, pectin, rather than a poorly fermentable fiber, cellulose, 
is added to the diet (59, 266).  With respect to non-coding RNAs, we recently reported 
that these chemoprotective dietary agents favorably modulate carcinogen-directed non-
coding miRNA signatures in the rat colon (140).  Several recent studies have also 
documented the chemoprotective effects of other dietary agents such as folate, retinoids 
and curcumin (diferuloylmethane) on miRNA expression in different cancers (187, 201, 
267).  Collectively, these data suggest a pervasive effect of diet in miRNA mediated 
oncogenic transformation.  
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 It has been shown that several tumor suppressors and proto-oncogenes can 
influence the formation of mature ribosomes and thereby regulate the activity of 
translation factors. Translational regulation plays an important role in 
repression/activation of gene expression during malignant transformation.  In addition, 
some miRNAs which target mRNAs have been shown to be associated with polysomes 
and shuttle in the polysomal spectrum as a consequence of miRNA regulation (268-274).  
To date, a genome-wide perspective of the effects of miRNAs on actively translated 
(polysomal) mRNA populations in the colon has not been performed.    
 To elucidate the biological function of intestinal miRNAs, it is necessary to infer 
miRNA activity by combining gene expression with miRNA target prediction.  Since 
miRNAs interact with complementary mRNAs (post-transcriptional level), resulting in 
either degradation or translational repression of their mRNA targets (275, 276), it is 
reasonable to expect that genome wide profiling of gene expression and miRNAs will 
allow for the investigation of genomic changes in cancer development.  Therefore, when 
mRNA and miRNA levels are measured in the same sample, an integrative analysis can 
be performed to compare both profiles and determine their interactions.  Various 
computational algorithms are currently used in order to predict the target genes of 
miRNAs.  However, since a single miRNA can directly target greater than 200 genes 
and each mRNA may be regulated by several miRNAs (261, 277), computational 
challenges in miRNA-mediated regulation persist.  As a result, there have been several 
approaches taken to analyze miRNA and gene expression data, such as performing 
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cluster analysis or computing correlation coefficients for miRNA and mRNA target 
expression (3, 278-280).   
 In the absence of comprehensive human data, the azoxymethane (AOM) 
chemical carcinogenesis model serves as one of the most definitive means of assessing 
human colon cancer risk (281, 282).  Therefore, in this study, we determined the effect 
of carcinogen and diet on targets of colonic miRNAs in rats at 10 and 34 weeks post 
initiation. miRNA expression was quantified using a qPCR approach and mRNA 
expression was quantified using a CodelinkTM microarray platform.  For the purpose of 
determining the effect of cancer progression and dietary chemoprevention on genomic 
profiles, we specifically examined the effect of carcinogen, n-6 vs n-3 fatty acid effects, 
and fat x fiber interaction on global colonic miRNA and mRNA expression profiles. 
Four complementary computational approaches were utilized to test the hypothesis that 
miRNAs and their post-transcriptionally regulated mRNA targets, i.e., both total 
mRNAs and actively translated mRNA transcripts (in polyribosome complexes), are 
differentially modulated by carcinogen and diet treatment.  Specifically, gene 
enrichment analysis was used to obtain those miRNAs significantly enriched by the 
change in expression of their putative target genes across carcinogen and diet 
comparisons.  This was complemented with canonical pathway analyses to further assess 
miRNA and mRNA interaction.  In addition, cumulative distribution function (CDF) 
plots were used to evaluate the impact of diet/carcinogen on mRNA levels induced via 
miRNA alterations.  For validation purposes, a subset of the gene targets was also 
examined at the protein level.  Lastly, linear discriminant analysis (LDA) was used to 
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identify the best single, two and three-miRNA combinations for classifying diet effects 
and colon tumor development.   
 
3.2 Materials and methods 
3.2.1 Animals 
Fifty-four weanling male Sprague Dawley rats (Harlan, Houston, TX) were 
acclimated for 2 wks in a temperature and humidity controlled facility on a 12 h 
light/dark cycle.  The animal use protocol was approved by the University Animal Care 
Committee of Texas A&M University.  The study was a 2 x 2 x 2 factorial design with 
two types of dietary fat (n-6 PUFA or n-3 PUFA), two types of dietary fiber (cellulose or 
pectin) and two treatments (injection with the colon carcinogen, AOM, or with saline).  
Animals (n=6 per group) were terminated 10 wks after AOM injection.  For generation 
of colonic tumors, a second group of rats (n=6 per treatment) were continued on diet for 
34 wks post-injection.  All tumors were independently classified as adenocarcinomas by 
a board-certified pathologist. 
3.2.2 Experimental diets 
After a one week acclimation on standard pelleted diet, rats were assigned to one 
of four diet groups, which differed in the type of fat and fiber as previously described 
(140).  Diets contained (g/100 g diet):  dextrose, 51.00; casein, 22.40; D,L-methionine, 
0.34; AIN-76 salt mix, 3.91; AIN-76 vitamin mix, 1.12; choline chloride, 0.13; pectin or 
cellulose, 6.00.  The total fat content of each diet was 15% by weight with the n-6 PUFA 
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diet containing 15.0 g corn oil/100 g diet and the n-3 PUFA diet containing 11.5 g fish 
oil/100g diet plus 3.5 g corn oil/100 g diet to prevent essential fatty acid deficiency. 
3.2.3 miRNA analysis 
Total RNA enriched with miRNA was isolated using mirVana miRNA Isolation 
Kit (Ambion, Austin, TX).  Expression of 368 mature miRNAs was determined using 
TaqMan Human MiRNA Panel Low Density Arrays (Applied Biosystems, CA).  
miRNA expression was normalized to RNU6B expression.  Two-hundred fifteen 
miRNAs were disqualified due to low (close to background level) expression. The 
resultant readings were further quantile normalized within each experimental condition, 
and one-way ANOVA analysis (t-test) was performed followed by false-discovery rate 
correction. Adjusted p- and q-values were obtained, and significantly altered miRNAs (q 
< 0.05) with a fold change >1.3 or <0.7 were selected for further analysis. 
3.2.4 mRNA analysis 
Polysome and total RNA were isolated from diet and carcinogen-treated animals 
as previously described (283). Upon termination, each colon was cut open 
longitudinally, flushed clean with PBS, 1 cm from the distal colon was collected for 
fixation and embedding for immunohistochemical assays, an adjacent cm was taken for 
total RNA isolation and the remainder of the colon was used for polysome RNA 
isolation. For polysome RNA isolation, colons were incubated for 5 min at room 
temperature in PBS containing 100 μg/ml cycloheximide, an inhibitor of translation 
which locks the mRNA/ribosome complex, facilitating its isolation and preventing RNA 
degradation. Following incubation in PBS containing 100 µg/ml cycloheximide, colonic 
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epithelial cells were allowed to swell in LSB (20 mM Tris pH 7.5, 10 mM NaCl and 3 
mM MgCl2) containing 1 mM dithiothreitol and 50 U RNase inhibitor for 2 min 
followed by lysis in LSB containing 0.2 M sucrose and 1.2% Triton X-100.  After 
removal of nuclei by centrifugation, the supernatant was layered over a 15-50% linear 
sucrose gradient (in LSB) and centrifuged at 247,000 x g for 2 h at 4°C in a swinging 
bucket rotor.  Gradients were fractionated, aliquots were taken for absorbance at 254 nm, 
and three volumes of denaturation solution (Ambion Totally RNA kit) was immediately 
added to the remainder of each fraction.  Samples were frozen at -80°C until RNA was 
isolated using the Totally RNA kit (Ambion) as per manufacturer’s instructions followed 
by DNase treatment.  Both total RNA and polysome RNA were analyzed on an Agilent 
2100 Bioanalyzer (Agilent Technologies, CA) to assess RNA integrity.  CodeLink rat 
whole genome bioarrays (Applied Microarray) were used to assess gene expression 
(253). 
 Only genes with a G flag (good quality) from the microarrays were selected for 
further analysis. Expression values were median normalized per array. Similar to the 
case of miRNA, both total and polysomal RNA expression values were quantile 
normalized within each experimental condition. A within-treatment quantile-
normalization was then applied to all non-outlying observations  Mixed-effect ANOVA 
was applied to the data to obtain p-values. P values <0.05 were considered to be 
statistically significant(284). 
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3.2.5 miRNA target prediction 
Since routine identification of an overlap between miRNA target prediction 
algorithms is discouraged (285), Target Scan (http://www.targetscan.org/) was used to 
identify putative miRNA targets in rat.  This program predicts biological targets of 
miRNAs by searching for conserved 8-mer and 7-mer sites that match the seed region of 
the miRNA (286).  The predictions are ranked based on the putative efficacy of targeting 
as calculated using context scores of the sites (287).  Specifically, this algorithm 
generates PCT scores for the probability of any seed match being selectively maintained 
due to miRNA targeting.  The higher the PCT score, the greater the probability that a 
miRNA could target a particular gene.   In addition, the DIANA-microT 3.0 algorithm 
was utilized to verify Target Scan output (288). 
3.2.6 Overview of analysis pipeline showing the computational analyses 
In order to infer the regulatory activities of miRNAs in the colon, microarray 
expression data was integrated with miRNA target prediction.  For this purpose, three 
main biological comparisons were examined: (A) carcinogen effects (tumor versus 
saline), (B) dietary fat effects in the presence of carcinogen (corn oil+AOM versus fish 
oil+AOM), and (C) dietary fat x fiber interaction in the presence of carcinogen (corn 
oil+cellulose+AOM vs fish oil+pectin+AOM).  The global impact of diet and carcinogen 
on miRNAs and mRNA tissue profiles was systematically elucidated using four 
complimentary computational methods.   
In the first approach, we used Gene Set Enrichment Analysis (GSEA) 
(http://www.broad.mit.edu/gsea/index.jsp).  GSEA incorporates knowledge of known 
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gene networks/pathways and identifies significantly enriched miRNA putative target 
lists based on the change in putative target expression according to a t-test for 
differential expression (289, 290).  In experiments described herein, the target list 
corresponds to genes in the total or polysomal expression data sets which are ranked by 
the respective t-test for differential expression.  The gene sets are made up of the 
putative targets of miRNAs obtained from Target Scan.  GSEA calculates an enrichment 
score (ES) that reflects the degree to which the targets within the gene set are over-
represented in the respective gene list.  A p-value is assigned to the ES score by a 
permutation test, which states whether the enrichment is significant or not.  GSEA then 
calculates a normalized enrichment score (NES), which takes into account the number of 
genes within the independent gene set. Analysis of the biological role of putative targets 
of miRNAs was performed using Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) (Figure 6(A)). 
In the second approach, initially, highly abundant miRNAs exhibiting an inverse 
trend with their mRNA targets based on fold change were examined.  Treatment effects 
were examined relative to significantly altered total and polysomal mRNAs (p-value < 
0.05).  Next, miRNAs predicted to target mRNAs based on Target Scan were selected.  
Finally, the list of significantly altered total and polysomal mRNAs predicted to be 
targeted by several miRNAs was intersected with the list of significantly altered highly 
abundant miRNAs in order to obtain non-coding RNAs which were inversely related to 
their significantly altered target total and polysomal mRNAs.   Network eligible 
molecules were also combined into canonical pathways that maximize connectivity.  
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Specifically, datasets containing significant differentially expressed genes and miRNAs 
(fold changes) for the three comparisons were uploaded into the Ingenuity Pathway 
Analysis (Ingenuity Systems, www.ingenuity.com) knowledge base.  Separate core 
analyses were performed using miRNA and total mRNA datasets.  The miRWalk 
(previously known as Argonuate) algorithm was used to predict the association of 
miRNAs with gene targets (291).  Molecules from each dataset that met the 1.5 fold 
change cut-off and were associated with biological functions and/or diseases in the 
Ingenuity’s Knowledge Base were used to generate networks.  Right-tailed Fisher’s 
exact test was used to calculate p-values determining the probability that biological 
functions and/or diseases assigned to each data set were not due to chance alone.  For a 
general overview of this analysis, refer to Figure 6(B). 
In the third approach, we examined the global influence of miRNA differential 
expression across the various diet/carcinogen treatments using cumulative distribution 
function (CDF) plots of fold change for putative mRNA target lists. For each 
comparison group (i.e., Tumor/Saline, CA/FA, and CCA/FPA), both polysomal and total 
mRNA expression data sets were created using appropriate samples (rows=probes, 
columns=rats).  Each data set was individually median and quantile normalized using 
only rows containing all “good” probe readings.  Average probe values for each of the 
two treatments in the data set were computed, and then used as expression data (e.g., 
probe fold change between treatments would be the ratio of these averages).  Based on a 
previous analysis, differentially expressed miRNAs were identified for each comparison 
group, and for each  miRNA, mRNAs were classified according to Target Scan by 
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conserved 8mer, conserved 7mer types + non-conserved 8mer and 7mer types, and 
“other”. These groupings roughly correspond to “strong”, “weak”, and “non” targets 
(287).  Distributions of fold change between treatments for each of these groups were 
estimated using those mRNAs that are available in the data set.  A comparison of the 
empirical fold change distributions of conserved 8mer targets and “non” targets was 
made for selected miRNA’s of known interest using the Kolmogorov-Smirnov test, and 
p-values and their associated q-values (false discovery rate levels) were computed.  
In the final approach, we performed linear discriminant analysis (LDA) 
classification using miRNAs as features to discriminate between the conditions 
described in the comparisons (A), (B), and (C). For this analysis, the main goal was to 
determine if miRNA expression can be used to discriminate between the different 
experimental treatments: Tumor vs saline (T vs S), corn oil+AOM vs fish oil+AOM (CA 
vs FA) and corn oil+cellulose+AOM vs fish oil+pectin+AOM (CCA vs FPA).  We have 
previously used a linear classifier algorithm for feature set identification  (292, 293).  
For the purpose of identifying feature sets, we designed classifiers that categorize 
samples based on the expression values of the miRNAs from the intersection of the 
miRNAs altered in tumor versus (not altered) saline.  Classifiers for miRNAs feature 
sets of sizes 1, 2, and 3 were identified.  Generally, there are two reasons why it is 
desirable to design classifiers involving small numbers of features: (a) the limited 
number of samples often available in clinical studies makes classifier design and error 
estimation problematic for large feature sets (294) and (b) small miRNAs sets facilitate 
design of practical diagnostic panels.  For similar reasons, simple classifiers are 
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preferable for small samples; indeed, for small samples, if good classification is possible, 
then a simple classifier such as linear discriminant analysis (LDA) using a small number 
of miRNAs will typically outperform a complex classifier (295). 
Given a set of features on which to base a classifier, one has to address not only 
the classifier design from sample data but also the estimation of its error, i.e., the 
precision with which the error of the designed classifier estimates the error of the 
optimal classifier.  When data are limited, an error estimator may have a large variance 
and therefore may often be low even if it is approximately unbiased.  This can produce 
many feature sets and classifiers with low error estimates.  The algorithm used in this 
study mitigates this problem by applying the bolstered error estimation (296).  Basically, 
this approach “bolsters” the original empirical distribution of the available data by 
means of suitable bolstering kernels placed at each data point location.  The error can be 
computed analytically in some cases, such as in the case of LDA.  The result of the 
overall approach is a list of “best” feature sets from among all possible feature sets.  
Hence, the best feature set is the one possessing minimum classification error.  Because 
we only have data and not the underlying feature-label distributions, the errors have been 
estimated from the data.  This approach takes into account that, in small-sample settings, 
we do not have much confidence in any single feature set and that it is much more likely 
that, if there is an adequate sized collection of good performing feature sets, then there 
are likely to be some that perform well on the overall population  (295). 
  The general overview of the analysis pipeline is shown in Figure 6 
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Figure 6. Overview of analysis pipeline.  (A) Selection of enriched miRNAs based on the 
significant enrichment of their target mRNAs using GSEA. 
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Figure 6.Continued. (B). Selection of microRNAs based on coherent relationship with their 
target mRNAs.  
 
 
 
 
 
 
 
 
 
Figure 6.Continued. (C) Linear Discriminant Analysis (LDA) for classification of microRNAs 
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3.2.7 Immunoblotting  
To generate colonic protein extracts, the mucosa was scraped and homogenized 
in ice-cold buffer (50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM 
EGTA, 50 mM sodium fluoride, 100 mM sodium orthovanadate, 1% Triton X-100, 100 
µM activated sodium orthovanadate, 40 μL/mL protease cocktail and 10 mM β-
mercaptoethanol).  Samples were then processed and subjected to polyacrylamide gel 
electrophoresis in precast 4-20% Tris-glycine mini gels (Invitrogen, CA).  After 
electrophoresis, proteins were transferred onto a polyvinylidene fluoride membrane 
(PVDF) at 400 mA for 120 min.  After the transfer, the membrane was then incubated in 
blocking solution (5% nonfat dry milk and 0.1% Tween 20 in PBS) at room temperature 
for 1 h with shaking.  Following blocking, the membrane was  incubated overnight at 
40C with rabbit TCF4 at 1:1000 dilution (Cell Signaling Technology, MA), rabbit 
PDE4B at 1:200 dilution (Abcam, MA),  rabbit PTK2B at 1:200 dilution (Santa Cruz 
Biotechnology, CA), rabbit IGF1R 1:200 dilution (Santa Cruz Biotechnology, CA) or 
mouse β-actin at 1:8000 dilution (Sigma-Aldrich, MO).  Membranes were washed with 
PBS containing 0.1% Tween 20 and incubated with peroxidase conjugated anti-rabbit 
IgG secondary antibody at 1:8000 dilution (Jackson Immuno Research, PA) or goat anti-
mouse at 1:30,000 (Kirkegaard & Perry, Gaithersburg, MD) as per manufacturer’s 
instructions. Bands were then developed using Pierce SuperSignal West Femto 
maximum sensitivity substrate and imaged and quantified with a Fluor-S Max 
MultiImager system (Bio-Rad, Hercules, CA).  β-actin was used as a loading control.   
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The effect of two independent variables (treatment effects) was assessed using 
Student’s t-test.  The graphs were plotted using means and standard error of  values 
obtained from quantifying the immunoblot bands from five samples for each diet group. 
Standard error bars were plotted in order to document the variation in the population 
mean. P-values < 0.05 were considered to be statistically independent . The graphs were 
plotted using means and standard error of five different samples for each treatment. 
Standard error bars were plotted in order to document the variation in the population 
mean. 
 
3.3 Results 
3.3.1 miR-34a, miR-190, miR-193a, miR-214 and miR-215 are enriched based on target 
(total and polysomal) mRNA genome-wide expression analysis in carcinogen treated 
rats 
We have recently demonstrated that several colonic miRNAs are significantly 
altered in carcinogen (AOM) compared to saline treated rats (140).  To further elucidate 
the regulation of these miRNAs, we determined whether they targeted total mRNA 
and/or polysome mRNAs.  Utilizing a computational approach, Gene Set Enrichment 
Analysis (GSEA), which incorporates knowledge of known gene networks/pathways and 
identifies significantly enriched miRNAs based on the change in expression of their 
putative targets, we identified five enriched miRNAs, miR-34a, miR-190, miR-193a, 
miR-214, miR-215, out of 46 candidate miRNAs (Table 2(A)) in tumor versus saline 
treated rats.  Examples of enrichment plots are shown in Figure 7.  These non-coding 
 45 
 
RNAs were significantly enriched based on the change in expression of their total and 
polysomal mRNA targets.   By plotting the data as a ratio intensity (RI) profile map, 
miR-34a, miR-190, miR-193a, miR-214 and miR-215 were shown to be highly abundant 
in the colon (Figure 8(A)).   
3.3.2 Diet influences miRNA enrichment in carcinogen injected rats  
GSEA analysis was also used to further elucidate the impact of diet and 
carcinogen treatment on miRNAs.  With respect to the dietary lipid source comparison 
in the presence of carcinogen (CA vs FA), five miRNAs (miR-132, miR-146b, miR-192, 
miR-206, miR-218) were significantly enriched based on the change in the expression of 
their total and polysomal mRNA targets (Table 2(B)).  Of these, only miR-146b was 
highly abundant (Figure 8(B)).   With regard to the effect of dietary fat x fiber 
interaction in the presence of carcinogen (CCA vs FPA), five miRNAs (miR-19a, miR-
93, miR-98, miR-130b, miR-206) were significantly enriched based on the change in 
expression of their total and polysomal mRNA targets (Table 2(C)).  In addition, three 
miRNAs (miR-26b, miR-30b, miR-206) were significantly enriched based on the change 
in the expression of their actively translated (polysome) mRNA targets (Table 2(C)).   
Of these, miR-26b and miR-30b were shown to be highly abundant in the colon (Figure 
8(C)).  Collectively, GSEA identified 16 miRNAs which were significantly enriched in 
three comparisons (Table 2), and nine miRNAs targeted polysomal mRNA.  These data 
indicate that both total and polysomal mRNAs are important for prediction of miRNA 
regulation with respect to experimental colon carcinogenesis.  Interestingly, miR-206 
was significantly enriched in both the dietary comparisons. 
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Figure 7. Enrichment plots of microRNAs in total vs. polysome mRNA datasets. Enrichment 
plots of microRNAs in total vs. polysome mRNA datasets. Polysome and total mRNA 
enrichment plots are shown for the three comparisons: tumor (T) vs. saline (S), corn oil + 
azoxymethane (CA) vs. fish oil + azoxymethane (FA) and corn oil + cellulose + azoxymethane 
(CCA) vs. fish oil + pectin + azoxymethane (FPA). Horizontal bars in graded color from left to 
right represent mRNA targets ranked from high expression in tumor vs. saline (A), dietary fat 
effects (B), and fat × fiber (C) interactions. At bottom of each panel is shown the biological 
processes in which the enriched genes play a role. The vertical gray lines represent the projection 
onto the ranked gene list of the targets for each microRNA (T over S, CA over FA, and CCA 
over FPA). The top curve corresponds to the calculation of the enrichment score (ES). The 
horizontal line indicates the 0 value for the ES. The greater the enrichment curve is shifted to the 
upper left of the graph, the higher the gene set enrichment in the T, CA, and CCA treatments. P 
values for the ES scores are shown in the ES plots along with the number of significantly 
enriched genes. 
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Table 2. Summary of colonic microRNAs significantly enriched using GSEA.  Data 
represent significantly enriched microRNAs based on the differential expression of their putative 
targets in either total or polysomal mRNA datasets for the three comparisons:  (i) Tumor (T) vs 
saline (S), (ii) corn oil+AOM (CA) vs fish oil+AOM (FA), and (iii) corn oil+cellulose+AOM 
(CCA) vs fish oil+pectin+AOM (FPA).  Size, indicates the number of differentially expressed 
mRNA putative targets; ES, enrichment score; NES, normalized enrichment score. 
 
(A) Tumor vs Saline Treatments  
Total / Polysomal microRNA Size ES NES p-value 
Total T miR-193a 17 0.511 1.688 0.025 
Total T miR-190 13 -0.545 -1.600 0.035 
Poly T miR-214 23 -0.482 -1.689 0.014 
Poly T miR-34a 13 -0.516 -1.591 0.022 
Poly T miR-215 1 -0.965 -1.312 0.029 
 
(B) Corn oil/AOM  vs Fish oil/AOM Treatments 
Total / Polysomal microRNA Size ES NES p-value 
Total CA miR-132 15 0.450 1.519 0.035 
Poly CA miR-218 55 -0.466 -1.592 0.030 
Poly CA miR-146b 2 -0.980 -1.517 0.008 
Poly CA miR-206 3 -0.809 -1.470 0.032 
Poly CA miR-192 9 -0.602 -1.463 0.047 
 
(C) Corn oil/cellulose/AOM vs Fish oil/pectin/AOM Treatments 
Total / Polysomal microRNA SIZE ES NES p-value 
Total CCA miR-206 8 0.675 1.650 0.017 
Total CCA miR-93 17 0.512 1.549 0.029 
Total CCA miR-130b 25 0.440 1.485 0.046 
Total CCA miR-19a 109 0.329 1.398 0.028 
Total FPA miR-98 6 0.786 1.692 0.015 
Poly CCA miR-26b 13 0.674 1.559 0.029 
Poly FPA miR-206 4 -0.768 -1.480 0.029 
Poly FPA miR-30b 3 -0.830 -1.438 0.034 
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Figure 8. Ratio intensity (RI) profile maps for colonic microRNAs from rats fed specific 
diets and injected with carcinogen or saline (control). Ratio intensity (RI) profile maps for 
colonic microRNAs from rats fed specific diets and injected with carcinogen or saline (control). 
Treatment effects on the expression of microRNAs are shown. The x-axis shows the intensity 
(abundance) of each microRNA, and the y-axis shows the fold change across treatments. 
MicroRNA expression is normalized to RNU6B. Each graph is divided into 4 quadrants where 
the top right quadrant contains those microRNAs that are highly abundant and exhibit a high fold 
change. For each comparison, there are 2 graphs: left, documenting all 384 microRNAs, and 
right, showing selected microRNAs with a fold change >1.3 and <0.7. 
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3.3.3 Global assessment of miRNA targets using cumulative distribution function 
analysis 
Using Target Scan, the putative targets of differentially expressed miRNAs were 
partitioned based on the miRNA-mRNA seed pairing, or lack thereof, in the 3’ 
untranslated region (UTR).  For each diet/carcinogen comparison, and for both total and 
polysomal mRNA, we compared CDF plots of fold change for each subset of the 
partitioned mRNA targets. This provides a visual examination of the global effects of 
colonic miRNA differential expression for the various diet/carcinogen comparisons.  
Three relevant examples, miR-214 for tumor vs saline, miR-18a for corn oil+AOM vs 
fish oil+AOM and miR-19a for corn oil+cellulose+AOM vs fish oil+pectin+AOM, are 
shown in Figure 9.  For the majority of miRNAs, the lengths of the partitioned target 
lists were not sufficiently large to allow for statistically detectable differences between 
the associated CDFs.  Overall, however, the qualitative visual representation of global 
miRNA provided from the CDF analysis was confirmatory of our GSEA findings. 
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Figure 9. Cumulative distribution function analysis(CDF). CDFs represent the fold changes 
for putative miRNA target lists portioned by 8mer(red), 7mer(blue) and no miRNA-
mRNA(black) seed pairing in 3’ UTR. CDFs for total and polysomal mRNA are shown for miR-
214 in tumor vs saline comparison, miR-18a in the corn oil+AOM vs fish oil+AOM comparison 
and miR-19a in the corn oil+cellulose+AOM vs fish oil+pectin+AOM grouping. 
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3.3.4 Identification of coherent colonic miRNA-mRNA modules   
miRNAs have been shown to have an inverse relationship (coherent) with their 
mRNA targets (276).  In order to infer the relative activity of colonic miRNAs, we 
examined expression changes in total and polysome mRNA target transcripts.  For (A) T 
vs S, (B) CA vs FA and (C) CCA vs FPA treatment comparisons, miRNAs were selected 
based on three criteria: (i) significant fold change (Tables 3 & 4), (ii) high abundance 
(Figure 8), and (iii) a shared coherent relationship (demonstrating inverse trends based 
on fold change) with their mRNA targets (Tables 3 & 4).  With the aid of the prediction 
algorithm, Target Scan, we identified a subset of miRNAs whose levels were inversely 
altered relative to their putative mRNA targets (Tables 3, 4 & 5).   With respect to total 
and polysomal mRNA data, we selected only those mRNAs which satisfied the above 
criteria.  In the case of carcinogen treated animals (T vs S), miR-15b, miR-16, miR-103, 
miR-107, miR-141, miR-146b, miR-148b, miR-183, miR-193a, miR-195, miR-204 and 
miR-497 exhibited coherent responses relative to their putative targets (Table 3).  
Furthermore, miR-15b, miR-16, miR-103 and miR-107, all target RASSF5; while mir-
141, miR-183 and miR-204 target TCF12; both of which are linked to the total mRNA 
datasets.  miR-103 and miR-107 cluster together and are part of one miRNA family.   In 
contrast, from the polysome mRNA dataset, YWHAB can be targeted by miR-148b; 
SLC11A2 is a putative target of both miR-195 and miR-497 (miR-195 cluster), FLl1 and 
GR1D1 can be targeted by miR-193 and miR-146b, respectively.  With respect to the 
effect of dietary lipid source (CA vs FA), mir-18a, miR-19b, miR-27b, mir-93 and miR-
497 exhibited a coherent response at the total and polysomal mRNA levels (Table 4).  
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With regard to fat x fiber interaction in the presence of carcinogen (CCA vs FPA), miR-
19b, miR-26b and miR-203 were inversely associated with the total mRNA expression 
levels of PTK2B, IGF2R, PDE4B and TCF4, respectively (Table 4).  In order to further 
assess the biological processes impacted by carcinogen and diet, gene ontology analysis 
was carried out and the top terms for the GO categories for each of the miRNA target 
gene sets was determined (Table 7).  The fold changes and significance of the miRNA 
target gene sets are listed in Table 5.  We also processed protein samples from 
carcinogen-exposed animals fed corn oil+cellulose (control) or fish oil+pectin 
(chemoprotective) diets to determine if some of the predicted targets were altered at the 
protein level.  Specifically, we examined PTK2B and PDE4B, both of which are 
predicted targets of miR-19b (Table 4); TCF4, a predicted target of miR-203 (Table 4); 
and IGF1R, a predicted target of miR-19b (Table 4).  As expected, based on mRNA 
data, PTK2B, PDE4B2 and TCF4 were upregulated by ~2-fold in CCA as compared to 
FPA treatment (Figure 10).  In contrast, no change was observed in IGF1R levels. 
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Table 3. Selection of colonic microRNAs based on the inverse trend in fold change of 
putative targets in tumor vs saline treated rats.  MicroRNAs were selected based on three 
criteria: (i) a significant fold-change, (ii) high abundance, and (iii) inverse association with 
putative targets of microRNAs. 
Tumor vs Saline Effects 
 
Treat-
ment miRNA 
Fold-
change  
miRN
A 
p-value  
miRNA 
Significa
-nt  
target 
genes 
Fold-
change  
target 
genes 
p-
value  
target 
genes Pathway 
miRNA 
family/ 
cluster 
Total 
T-S miR-103 0.51 <0.001 RASSF5 1.32 0.023 Apoptosis 
miR-
103/miR107 
family 
Total 
T-S miR-107 0.27 <0.001 RASSF5 1.32 0.023 Apoptosis 
miR-
103/miR107 
family 
Total 
T-S miR-15b 0.60 <0.001 RASSF5 1.32 0.023 Apoptosis 
miR-15b-
miR 16-2 
cluster 
Total 
T-S miR-16 0.69 <0.001 RASSF5 1.32 0.023 Apoptosis 
miR-15b-
miR 16-2 
cluster 
Total 
T-S miR-183 0.68 0.002 TCF12 1.45 0.048 
Wnt 
signaling 
pathway 
miR-
96/182/183 
cluster 
Total 
T-S miR-204 0.29 <0.001 TCF12 1.45 0.048 
Wnt 
signaling 
pathway 
miR-204 
family 
Total 
T-S miR-141 0.32 <0.001 TCF12 1,45 0.048 
Wnt 
signaling 
pathway 
miR-
200c/141 
cluster 
Poly T-
S 
miR-
148b 0.44 <0.001 YWHAB 1.14 0.037 
Apoptosis, 
Cell cycle 
signaling 
miR-148/152 
family 
Poly T-
S miR-195 1.83 <0.001 
SLC11A
2 0.68 0.034 
Intestinal 
iron 
absorption 
miR-195 
cluster 
Poly T-
S miR-497 1.92 <0.001 
SLC11A
2 0.68 0.034 
Intestinal 
iron 
absorption 
miR-195 
cluster 
Poly T-
S 
miR-
193a 2.46 0.001 FLI1 0.64 0.001 
Wnt 
signaling 
pathway 
miR-193 
family 
Poly T-
S 
miR-
146b 9.17 <0.001 GRID1 0.54 0.001 
Glutamic 
acid 
signaling 
miR-146 
family 
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Table 4.  Diet effects on colonic microRNAs and their inversely associated gene targets in 
carcinogen-injected rats.  Refer to Table 2 for legend details. 
 
Corn Oil vs Fish Oil Effects 
 
Treatme
nt miRNA 
Fold-
change  
miRNA 
p-value   
miRNA 
Significan
t target 
genes 
Fold-
change 
target 
genes 
p-value  
target 
genes Pathway 
miRNA 
family/ 
cluster 
Total 
CA-FA miR-19b 0.45 <0.001 IGF1R 1.48 <0.001 Apoptosis 
miR-17-92 
cluster  
Total 
CA-FA miR-19b 0.45 <0.001 RUNX3 1.34 0.041 
Runt-related 
transcription 
factor 3 
miR-17-92 
cluster 
Total 
CA-FA miR-27b 0.75 0.043 ATP2B1 1.42 0.024 
Stem cell 
pathway 
miR-
23b/27b/24-
1 cluster 
Total 
CA-FA miR-27b 0.75 0.043 LIMK2 1.23 0.032 
Actin 
cytoskeleton  
reorganizatio
n 
miR-23b-24-
1 cluster 
Total 
CA-FA miR-27b 0.75 0.043 PARD6B 1.21 0.044 
Asymmetrica
l cell division 
and cell 
polarization 
miR-23b-24-
1 cluster 
Total 
CA-FA miR-27b 0.75 0.043 ZADH2 1.22 0.017 
Metabolic 
processes 
(oxidation 
reduction) 
miR-23b-24-
1 cluster 
Total 
CA-FA miR-497 0.64 <0.001 CASR 1.37 0.050 
Calcium 
homeostatsis 
miR-195 
cluster 
Total 
CA-FA miR-93 0.76 <0.001 NPAS2 1.23 0.024 
Signal 
transduction 
miR-106b-
25 cluster 
Poly CA-
FA miR-18a 0.65 
 
<0.001 LAT 1.37 0.016 
Ras protein 
signal 
transduction 
miR-17-92 
cluster 
Poly CA-
FA miR-27b 0.75 0.043 SLC6A6 1.35 <0.001 
Amino acid 
transporter 
miR-23b-24-
1 cluster 
Poly CA-
FA miR-27b 0.75 0.043 GATA2 1.17 0.045 
Transcription 
regulation 
miR-23b-24-
1 cluster 
Poly CA-
FA miR-27b 0.75 0.043 ATP2B1 1.42 0.024 
Stem cell 
pathway 
miR-23b-24-
1 cluster 
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Table 4. Continued 
 
Fat x Fiber Effects 
Treatmen
t miRNA 
Fold-
change  
miRNA 
p-value  
miRNA 
Signific
ant 
target 
genes 
Fold-
change  
target 
genes 
p-value 
target 
genes Pathway  
miRNA 
family/ 
cluster 
Total 
CCA-FPA   miR-19b 0.64 0.035 PTK2B 1.772 0.032 
Cell  
proliferation 
miR-17-92 
cluster 
Total 
CCA-FPA   miR-19b 0.64 0.035 IGF2R 1.664 0.034 Apoptosis 
miR-17-92 
cluster 
Total 
CCA-FPA miR-26b 0.65 <0.001 PDE4B 2.43 0.050 Apoptosis 
miR-26 
family 
Total 
CCA-FPA miR-203 0.61 <0.001 TCF4 2.16 0.043 Apoptosis 
__ 
Total 
CCA-FPA miR-27b 0.75 0.047 ATP2B1 1.42 0.025 
Stem cell 
pathway 
miR-23b-
24-1 cluster 
 
 
 
 
 
 
 
\ 
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Table 5. Fold changes and significance of microRNA target gene sets in CCA vs FPA 
comparison.  Only the highly abundant microRNAs (qPCR Ct value < 30) are included. 
Total CCA vs FPA     
microRNA 
Fold 
Change p-value 
Significant target 
genes 
Fold 
change p-value 
miR-98 0.77 0.043 SLC35D2 1.37 0.015 
miR-98 0.77 0.043 IGF1R 1.67 0.009 
miR-107 0.69 0.016 GALNT7 1.35 0.014 
miR-107 0.69 0.016 ANKFY1 1.19 0.035 
miR-107 0.69 0.016 ACVR2B 1.26 0.047 
miR-107 0.69 0.016 RASSF5 1.45 0.041 
miR-107 0.69 0.016 NEDD9 1.47 0.043 
miR-107 0.69 0.016 YWHAH 1.14 0.049 
miR-107 0.69 0.016 HTR4 1.46 0.048 
miR-130b 0.72 0.014 EPS15 1.25 <0.001 
miR-130b 0.72 0.014 SMAD5 1.57 0.022 
miR-130b 0.72 0.014 SNX5 1.13 0.024 
miR-130b 0.72 0.014 AKAP11 1.25 0.022 
miR-130b 0.72 0.014 PTPRM 1.39 0.046 
miR-130b 0.72 0.014 USP33 1.28 0.047 
miR-130b 0.72 0.014 UBL3 1.24 0.055 
miR-15b 0.72 0.027 IGF1R 1.67 0.009 
miR-15b 0.72 0.027 ZADH2 1.37 0.016 
miR-15b 0.72 0.027 SMAD5 1.57 0.022 
miR-15b 0.72 0.027 AP1GBP1 1.29 0.031 
miR-15b 0.72 0.027 GRIN1 1.56 0.043 
miR-15b 0.72 0.027 GNA12 1.33 0.048 
miR-15b 0.72 0.027 DNAJA2 1.33 0.056 
miR-195 0.57 0.006 BTG2 1.45 0.049 
miR-497 0.62 0.001 OSBPL7 1.35 0.034 
miR-16 0.74 0.008 GORASP2 1.3 0.049 
miR-20a 0.66 0.002 EZH1 1.42 0.023 
miR-20a 0.66 0.002 RIPK5 1.51 0.031 
miR-20a 0.66 0.002 BNIP2 1.49 0.038 
miR-20a 0.66 0.002 NAGK 1.23 0.042 
miR-20a 0.66 0.002 CXADR 1.21 0.051 
miR-93 0.65 <0.001 PTGFRN 1.23 0.012 
miR-93 0.65 <0.001 NPAS2 1.47 0.014 
miR-93 0.65 <0.001 HDAC4 1.51 0.022 
miR-93 0.65 <0.001 NEDD4L 1.16 0.057 
miR-18a 0.65 0.015 PTGFRN 1.23 0.012 
miR-18a 0.65 0.015 NOTCH2 1.45 0.013 
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Table 5. Continued 
 
microRNA 
Fold 
Change p-value 
Significant target 
genes 
Fold 
change p-value 
miR-18a 0.65 0.015 NCOA1 1.32 0.011 
miR-18a 0.65 0.015 LAT 1.55 0.018 
miR-18a 0.65 0.015 WBP2 1.33 0.019 
miR-18a 0.65 0.015 TMEM1 1.20 0.017 
miR-18a 0.65 0.015 AEBP2 1.19 0.024 
miR-18a 0.65 0.015 FNBP1 1.23 0.033 
miR-18a 0.65 0.015 NEDD9 1.47 0.043 
miR-19b 0.63 <0.001 GDA 1.26 0.011 
miR-19b 0.63 <0.001 WBP2 1.33 0.022 
 
 miR20a 0.66 0.002 RIPK5 1.62 0.034 
 miR20a 0.66 0.002 MTF1 1.52 0.013 
Polysomal CCA vs FPA    
      
microRNA 
Fold 
Change p-value 
Significant target 
genes 
Fold 
change p-value 
miR-130b 0.72 0.014 AKAP1 4.04 0.012 
miR-130b 0.72 0.014 MTF1 1.52 0.013 
miR-15b 0.72 0.027 GRID1 1.18 0.057 
miR-15b 0.72 0.027 SYNJ1 1.49 0.048 
miR-15b 0.72 0.027 SMAD5 1.25 0.046 
miR-15b 0.72 0.027 GGA3 1.40 0.044 
miR-15b 0.72 0.027 CYP26B1 1.52 0.042 
miR-15b 0.72 0.027 CDS2 3.55 0.038 
miR-15b 0.72 0.027 LYPLA2 1.58 0.031 
miR-15b 0.72 0.027 CASR 1.71 0.022 
          miR-15b 0.72 0.027 DLGAP2 1.23 0.011 
miR-15b 0.72 0.027 EIF4E 1.97 0.012 
miR-15b 0.72 0.027 ABCG4 1.95 0.008 
miR-15b 0.72 0.027 BCL9L 1.67 <0.001 
miR-15b 0.72 0.027 IHPK1 1.56 <0.001 
miR-16 0.74 0.008 ADRB2 1.37 0.043 
miR-16 0.74 0.008 CDC42EP2 1.21 0.012 
miR-16 0.74 0.008 RET 1.82 0.006 
miR-497 0.62 0.001 LPHN1 2.04 0.034 
miR-93 0.65 <0.001 PPP2R2A 1.41 0.046 
miR-93 0.65 <0.001 EGR2 1.45 0.041 
miR-93 0.65 <0.001 SLC9A2 1.4 0.022 
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Table 5. Continued 
 
microRNA 
Fold 
Change p-value 
Significant target 
genes 
Fold 
change p-value 
miR20a 0.66 0.002 SMOC2 1.66 0.007 
miR-182 0.74 0.013 GRID1 1.18 0.057 
 miR-182 0.74 0.013 ACCN1 1.42 0.046 
 miR-182 0.74 0.013 NCAM1 1.37 0.036 
 miR-182 0.74 0.013 PLCG1 1.24 0.032 
 miR-182 0.74 0.013 LPHN1 2.04 0.034 
miR-182 0.74 0.013 FOXO3 1.29 0.018 
 miR-182 0.74 0.013 SLC9A2 1.4 0.022 
 miR-182 0.74 0.013 PPP1R9B 1.39 0.013 
 miR-182 0.74 0.013 DLGAP2 1.23 0.011 
 miR-182 0.74 0.013 CDC42BPA 1.28 0.011 
miR-182 0.74 0.013 TGFBI 1.34 0.008 
   miR-182 0.74 0.013 STK10 1.39 0.012 
miR-183 0.74 0.009 SMPD3 2.1 0.037 
miR-183 0.74 0.009 SLC6A6 1.64 0.012 
   miR-183 0.74 0.009 CX3CL1 1.49 0.008 
miR-18a 0.65 0.015 MTF1 1.52 0.013 
 miR-18a 0.65 0.015 LAT 1.43 0.013 
 miR-18a 0.65 0.015 XYTLT2 1.46 0.002 
miR-19b 0.63 <0.001 MAPK6 1.6 0.033 
  miR-196b 0.70 0.002 HABP4 1.34 0.042 
 
 
 
Together, these data indicate that 25 highly abundant miRNAs exhibited a 
significant (p<0.05) inverse relationship with their putative polysome and total mRNA 
targets following diet and carcinogen exposure (Table 3, 4 & 5).  Furthermore, miRNAs 
which were not highly abundant (low expressors), miR-219 and miR-9, also exhibited a 
significant (p<0.05) inverse relationship with their putative total and polysomal mRNA 
targets (Table 6). 
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Figure 10. Suppression of PTK2B, PDE4B, and TCF4 in rats fed a chemoprotective diet. 
Suppression of PTK2B, PDE4B, and TCF4 in rats fed a chemoprotective diet. Expression of 
PTK2B (A), PDE4B (B), TCF4 (C), and IGF1R (D) in carcinogen-injected rats fed diets 
containing either (control) corn oil-cellulose or (chemoprotective) fish oil-pectin was analyzed 
by immunoblotting, n = 5 animals per treatment. 
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Table 6. Fold changes and significance of microRNA target gene sets in CCA vs FPA 
comparison.  Only the low abundance microRNAs (qPCR Ct value > 30) are included. 
 
Total CCA vs FPA    
      
microRNA 
Fold 
Change p-value 
Significant 
target genes 
Fold 
change p-value 
miR-219 0.44 0.008 NCOA1 1.32 0.011 
miR-219 0.44 0.008 DAZAP1 1.32 0.047 
miR-9 1.68 <0.001 AAK1 0.60 <0.001 
miR-9 1.68 <0.001 PAK6 0.59 0.042 
miR-9 1.68 <0.001 NMT2 0.63 0.047 
miR-9 1.68 <0.001 UHRF1 0.59 0.046 
miR-9 1.68 <0.001 DIO2 0.39 0.058 
 
Polysomal CCA vs FPA    
      
microRNAs 
Fold 
Change p-value 
Significant target 
genes 
Fold 
change p-value 
miR-219 0.44 0.008 PIP5K1C 1.62 0.044 
miR-219 0.44 0.008 GTPBP1 1.25 0.03 
miR-9 1.68 <0.001 ARFGEF2 0.61 0.048 
miR-9 1.68 <0.001 CPEB4 0.61 0.036 
miR-9 1.68 <0.001 PGRMC2 0.69 0.028 
miR-9 1.68 <0.001 CCNG1 0.77 0.019 
miR-9 1.68 <0.001 STK3 0.69 0.018 
miR-9 1.68 <0.001 CNOT6L 0.60 0.017 
miR-9 1.68 <0.001 SHC1 0.69 0.015 
miR-9 1.68 <0.001 TLK1 0.74 0.009 
miR-9 1.68 <0.001 SYNJ2BP 0.61 0.007 
miR-9 1.68 <0.001 EIF5 0.65 0.001 
miR-9 1.68 <0.001 XPO4 0.74 <0.001 
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Table 7. Association of direct microRNA targets with biological processes in the fat x fiber 
x carcinogen comparison.  GO analysis was performed to identify the enrichment of biological 
processes associated with the putative targets. 
 
microRNA ID Term 
p-
value 
miR-101 GO:0006468 protein amino acid phosphorylation 0.011 
  GO:0016310 phosphorylation 0.016 
  GO:0045859 regulation of protein kinase activity 0.018 
  GO:0051338 regulation of transferase activity 0.022 
  GO:0006796 phosphate metabolic process 0.025 
  GO:0006793 phosphorus metabolic process 0.025 
  GO:0010033 response to organic substance 0.032 
  GO:0044237 cellular metabolic process 0.034 
  GO:0042325 regulation of phosphorylation 0.038 
  GO:0043687 post-translational protein modification 0.042 
miR-107 GO:0007165 signal transduction 0.008 
  GO:0007242 intracellular signaling cascade 0.029 
  GO:0010817 regulation of hormone levels 0.049 
  GO:0019219 
regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic 
process 0.099 
miR-140 GO:0048468 cell development 0.004 
  GO:0016043 cellular component organization 0.013 
  GO:0044238 primary metabolic process 0.016 
  GO:0043170 macromolecule metabolic process 0.030 
  GO:0019538 protein metabolic process 0.030 
  GO:0008152 metabolic process 0.035 
  GO:0030154 cell differentiation 0.038 
  GO:0048869 cellular developmental process 0.042 
miR-15b GO:0030154 cell differentiation 0.006 
  GO:0048869 cellular developmental process 0.006 
  GO:0045935 
positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 0.013 
  GO:0010557 
positive regulation of macromolecule 
biosynthetic process 0.014 
  GO:0031328 
positive regulation of cellular biosynthetic 
process 0.015 
  GO:0009891 positive regulation of biosynthetic process 0.016 
  GO:0007166 
cell surface receptor linked signal 
transduction 0.029 
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Table 7. Continued 
 
 
 
3.3.5 Functional analysis of differentially expressed miRNAs 
To explore the functional relevance of select miRNA species and predicted 
targets in the context of colorectal cancer, miRNA and total mRNA data were analyzed 
using Ingenuity interactive pathway analysis (Ingenuity Systems, www.ingenuity.com) 
software.  With respect to the effect of dietary fish oil treatment on carcinogen-injected 
rats, the top associated (p<0.05) networks were NFAT, adenocarcinoma, Wnt/beta-
catenin signaling, phospholipase C and notch signaling.  Moreover, fatty acid 
metabolism in mitochondria was the top ranked canonical pathway.  With respect to the 
fat x fiber comparison, p38 Mapk signaling, RhoA signaling, and notch signaling genes 
were modulated (p<0.03).  In addition, Wnt/beta-catenin, carcinoma, and phospholipase 
C were the top ranked associated network functions (p<0.01).  For the dietary lipid (CA 
vs FA) comparison, fish oil feeding downregulated miRNAs -miR-18a, miR-19b, miR-
27b and miR-93 targeted several differentially expressed targets which are involved in 
pathways related to colorectal cancer, e.g., ERK-MAPK, Wnt/β-catenin, PTEN and  
microRNA ID Term 
p-
value 
  GO:0022604 regulation of cell morphogenesis 0.040 
  GO:0022414 reproductive process 0.016 
miR-93 GO:0048519 negative regulation of biological process 0.044 
miR-18a GO:0010556 
regulation of macromolecule biosynthetic 
process 0.023 
  GO:0010468 regulation of gene expression 0.024 
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Figure 11.  Functional analyses of differentially expressed predicted targets of significantly 
altered microRNAs. Functional analyses of differentially expressed predicted targets of 
significantly altered microRNAs. A: microRNAs miR-18a, miR-19b, miR-27b, and miR-93 were 
downregulated in CA vs. FA treatments (expression of CA divided by expression in FA). B: 
microRNAs- miR-16, miR-21, miR-26b, and miR-27b were downregulated in the CCA vs. FPA 
(expression of CCA divided by expression in FPA treatments). Their differentially expressed 
predicted targets (by mirWalk) are also shown. Signaling networks identified by IPA software 
are based on significant fold changes of the differentially expressed microRNAs. The intensity of 
the node (gene/microRNA) color indicates the degree of upregulation (red) or downregulation 
(green). Nodes are displayed using various shapes that represent the functional class of the gene 
product. Nodes without any color were not present in the input dataset but were present as a part 
of the network. Solid lines between genes/microRNAs represent a direct interaction based on 
experimental proven associations. Dashed line represent predicted interactions (indirect 
interactions) based on experimental evidence. Fx, functions and diseases; CP, canonical 
pathway. Symbols describing cell functions are shown in A. 
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apoptosis (Figure 11(A)).  These miRNAs also shared a coherent relationship with their 
predicted total mRNA targets (Table 4).  Moreover, the association of miR-19b and 
IGF1R shown by IPA analysis was also observed in the coherent analysis (Table 4).  Up 
regulation of IGF1R can lead to downregulation of genes such as SRC, INS, COL1A1, 
CXCR4, all of which have been associated with colorectal cancer (297, 298)(25, 61).  
With regard to fat x fiber interaction in the presence of carcinogen (CCA vs FPA), fish 
oil-pectin combination downregulated miR-16, miR-21, miR-26b and miR-27b, which 
targeted several differentially expressed genes associated with adenocarcinomas, 
colorectal cancer, mTOR signaling, PI3K/AKT signaling, and apoptosis (Figure 11(B)).  
Fat x fiber effects on miR-26b and miR-27b were also observed in GSEA and coherent 
analyses (Tables 2 & 4).   
3.3.6 miRNA expression and treatment classification 
For the purpose of classifying colon tumor development using miRNAs, we 
applied linear discriminant analysis (LDA).  The number of miRNAs (features) for each 
linear classifier was limited to three, which allowed for an exhaustive search while 
avoiding errors associated with small-sample setting feature extraction.  Using this 
approach, the top ten best single, 2- and 3-miRNA classifiers were queried as a means to 
distinguish phenotype; (i) T vs S, (ii) CA vs FA, and (iii) CCA vs FPA.  We noted 
several cases where single miRNAs can provide good (in terms of the error estimate) 
classification (Tables 8 & 9).  As expected, when considering these features as part of 2- 
or 3-gene classifiers, a significant decrease in the classification error was noted  
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Table 8. Classification of colonic microRNAs altered in tumors vs saline treated rats.  Top 
10 single, pair-wise and triplet-wise microRNA LDA classifiers are shown.  Ɛbolstered denotes 
bolstered resubstitution error for the respective classifier.  The classifiers are ranked according to 
the error measurement.  △(Ɛbolstered) denotes the decrease in error for each feature set relative to 
its highest ranked subset of features. 
 
                                                       Tumor vs Saline Effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
microRNA    Ɛbolstered △(Ɛbolstered) 
miR-21   0.001  
let-7c   0.001  
miR-200c   0.001  
miR-215   0.001  
miR-200a   0.001  
miR-30c   0.001  
miR-30e-3p   0.001  
miR-30b   0.001  
miR-422a   0.001  
miR-200b   0.020  
let-7g miR-21  <0.001 <0.001 
let-7a miR-200c  <0.001 <0.001 
let-7a miR-215  <0.001 <0.001 
let-7a miR-200b  <0.001 <0.001 
let-7c miR-141  <0.001 <0.001 
let-7c miR-200c  <0.001 <0.001 
let-7c miR-215  <0.001 <0.001 
let-7c miR-200a  <0.001 <0.001 
let-7c miR-30c  <0.001 <0.001 
let-7c miR-30b  <0.001 0.020 
let-7a let-7c miR-30c <0.001 <0.001 
let-7a let-7c miR-30b <0.001 <0.001 
let-7a miR-21 miR-215 <0.001 <0.001 
let-7a let-7c miR-215 <0.001 <0.001 
let-7a let-7c miR-200c <0.001 <0.001 
let-7a let-7c miR-375 <0.001 <0.001 
let-7a miR-141 miR-30b <0.001 <0.001 
let-7a let-7b miR-200c <0.001 <0.001 
let-7a let-7b miR-215 <0.001 <0.001 
let-7a let-7b miR-30b <0.001 <0.001 
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Table 9. Classification of microRNAs altered by dietary effects in carcinogen treated rats.  
Top 10 single, pair-wise and triplet-wise microRNA LDA classifiers are shown.  Refer to Table 
4 for legend details. 
 
Corn Oil vs Fish Oil Effects 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
microRNA    Ɛbolstered △(Ɛbolstered) 
miR-19b   0.133  
miR-93   0.152  
miR-497   0.181  
miR-18a   0.218  
miR-101   0.238  
miR-532   0.240  
miR-199b   0.266  
miR-146b   0.268  
miR-92   0.277  
miR-106b   0.285  
miR-19b miR-21  0.117 0.016 
miR-19b miR-15b  0.137 0.014 
miR-19b miR-93  0.138 0.042 
miR-19b miR-30c  0.147 0.071 
miR-18a miR-497  0.154 0.084 
miR-19b miR-92  0.154 0.085 
miR-93 miR-25  0.157 0.108 
miR-93 miR-15b  0.157 0.110 
miR-19b miR-106b  0.158 0.119 
miR-93 miR-106b  0.161 0.124 
miR-19b miR-21 miR-25 0.107 0.010 
miR-19b miR-22 miR-15b 0.109 0.027 
miR-19b miR-23 miR-92 0.110 0.028 
miR-19b miR-24 miR-106b 0.112 0.034 
miR-19b miR-25 miR-30c 0.126 0.028 
miR-19b miR-30c miR-15b 0.132 0.021 
miR-19b miR-21 miR-93 0.136 0.021 
miR-93 miR-324-5p miR-15b 0.140 0.017 
miR-93 miR-106b miR-15b 0.140 0.018 
miR-19b miR-93 miR-106b 0.141 0.020 
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Table 9. Continued 
 
Corn Oil Cellulose  vs Fish Oil Pectin Effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Table 9).   To identify sets of miRNAs that perform in a multivariate manner to provide 
strong classification, we specifically looked for pairs of miRNAs that performed better 
microRNA    Ɛbolstered △(Ɛbolstered) 
miR-27b   <0.001  
miR-30d   0.015  
miR-20a   0.018  
miR-200c   0.033  
miR-11   0.037  
miR-26b   0.048  
miR-93   0.060  
miR-30e-3p   0.066  
miR-195   0.069  
miR-196b   0.072  
miR-200c miR-26a  <0.001 <0.001 
miR-27b miR-30e-3p  0.001 0.014 
miR-20a miR-30d  0.001 0.017 
miR-200c miR-203  0.001 0.031 
miR-27b miR-182  0.003 0.033 
miR-30d miR-196b  0.004 0.044 
miR-146a miR-27b  0.004 0.055 
miR-27b miR-186  0.004 0.061 
miR-301 miR-20a  0.005 0.064 
miR-20a miR-26b  0.005 0.066 
miR-146a miR-27b miR-30e-3p <0.001 <0.001 
miR-200c miR-20a miR-203 <0.001 <0.001 
miR-200c miR-26a miR-148a <0.001 0.001 
miR-200c miR-26a miR-203 <0.001 0.001 
miR-200c miR-26a miR-15b <0.001 0.003 
miR-200c miR-203 miR-25 <0.001 0.004 
miR-17-3p miR-20a miR-30d <0.001 0.004 
miR-107 miR-20a miR-30d <0.001 0.004 
miR-200c miR-26a miR-200b <0.001 0.004 
miR-200c miR-203 miR-182 <0.001 0.005 
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than either of the miRNAs individually, and also triplets of miRNAs that performed well 
and substantially better than the best-performing pair among the three.  To estimate the 
improvements of the classification performance, we introduced two quantities for each 
feature set: bolstered and    ( )bolstered .  bolstered  denotes the bolstered resubstitution error 
for the LDA classifier for the respective feature set of size n (n = 1, 2, 3), and  
( )bolstered  denotes the decrease in error with respect to the highest ranked of its subset 
of features (in the list of features of size n-1, n = 2, 3).  The feature sets were ranked 
based on the value of bolstered .  The top T vs S (control) single-gene classifier (one-
feature), miR-21 (ranked 1st in the list of single-miR classifiers) had an estimated 
classification error of 0.001.  Interestingly, when this miRNA was combined with a 
poorly performing single-miRNA classifier, let-7g (ranked > 20 in the list of single-gene 
classifiers), it resulted in a two-non-coding gene classifier with a low estimated error, < 
0.001 (Table 9).  In addition, the let-7a, miR-141 and miR-375 triple classifier exhibited 
unique properties, as all three miRNAs performed poorly as single classifiers (ranked 
>15 in the list of single-gene classifiers).  This shows that when combined, these 
miRNAs increase the power of classification with a low estimated error, <0.001 (Table 
8).  Moreover, let-7a and let-7c appeared frequently in the top 10 triple classifiers.  For 
example, let-7 family members, let-7a and let-7c, performed well as classification 
features when combined with miR-215 and miR-21 (Table 8), well known colon cancer 
miRNAs (4, 67).  Interestingly, miR-215 was also significantly enriched as assessed by 
GSEA (Table 2).  miR-141, found to share a coherent relationship with its putative 
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targets, also classified with the let-7 family.  In summary, these miRNAs performed 
poorly as single classifiers, but when combined, they decreased the classification error 
(Figures 12(A) &(B)).  
With respect to the classification of the n-3 PUFA-enriched chemoprotective 
diet, comparison of the FA vs CA treatments revealed that miR-19b, miR-21 and miR-93 
appeared at the top of the single, double and triple classifier lists (Table 9, Figures 
12(C) & (D)).  These data combined with the fact that miR-19b and miR-93 exhibited a 
significant coherent relationship with their putative targets (Table 4); suggest an 
important role for these non-coding RNA.  In addition, miR-106b when combined with 
miR-93 and miR-19b produced a classifier with a low estimated error.  With regard to 
the fat x fiber interaction, for the CCA vs FPA comparison, miR-200c appeared 
bolstered = (0.033), double (0.001) and triple (< 0.001) LDA 
classifier lists (Table 9, Figures 12(E) & (F)).  In addition, miR-93 and miR-182 
exhibited significant coherent relationships with their putative targets (Table 4).   
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Figure 12. Linear discriminant analysis phenotype classification using microRNAs. Linear 
discriminant analysis phenotype classification using microRNAs. Panels represent examples of 
the top 2- and 3-microRNA classifiers. For example, tumor vs. saline comparison, miR-21 and 
let-7g (A), corn oil + AOM vs. fish oil + AOM comparison, miR-93 and miR-19b (C), and corn 
oil + cellulose + AOM vs. fish oil + pectin + AOM comparison, miR-26b and miR-20a (E) are 
the best performing 2-microRNA feature sets. Classification is between tumor, corn oil, corn oil 
cellulose (○) and saline, fish oil, fish oil pectin (▵)-treated rats (refer to Tables 4 and 5 for 
additional details). The axes represent the normalized intensity values of the indicated 
microRNAs. Note the clear separation between the 2 groups in each comparison. The best-
performing 3-microRNA feature sets are shown: tumor vs. saline comparison, miR-215, miR-21, 
and let-7a (B), corn oil + AOM vs. fish oil + AOM comparison miR-21, miR-93, and miR-19b 
(D), and corn oil + cellulose + AOM vs. fish oil + pectin + AOM comparison, miR-182, miR-
200c, and miR-203 (F). The 3-dimensional LDA hyperplane discriminates between the tumor, 
corn oil, corn oil cellulose (○)- and saline, fish oil, fish oil pectin (▵)-treated rats. 
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3.4 Discussion 
   We have recently demonstrated that n-3 PUFA uniquely modulate carcinogen-
directed non-coding miRNA signatures in the colon (140).  In this study, in order to 
further elucidate the global biological effects of chemoprotective diets on miRNAs, we 
used an integrated global approach to assess total and polysomal mRNA targets.  With 
regard to the computational methodology to predict target genes of miRNAs and infer 
functionality, we systematically assessed the complex regulatory factors mediating 
miRNA–mRNA interaction.  The large-scale prediction of targets across the whole 
genome allowed us to achieve a higher degree of specificity of prediction and to infer the 
regulatory activities of miRNAs in the colon.  Indeed, a number of studies have utilized 
statistical/systems biology methodologies to identify miRNAs which may target genes in 
response to a pathophysiological state (299-301).  However, there is a paucity of 
integrative miRNA and mRNA expression studies which focus on early stage colon 
cancer development and chemoprevention.  Since mammalian miRNAs predominantly 
act to decrease target mRNA levels (276), our analyses focused on total and polysomal 
mRNA targets during the early promotional phase of malignant transformation.  
We utilized four complementary approaches to elucidate the global effects of diet 
and carcinogen on miRNAs and total/polysomal mRNA profiles within the colon.  
Initially, GSEA was used to probe the effects of three biological conditions: (A) 
carcinogen (tumor versus saline), (B) dietary fat effects in the presence of carcinogen 
(CA versus FA) and (C) dietary fat x fiber interaction in the presence of carcinogen 
(CCA vs FPA).  We subsequently identified 18 miRNAs which were significantly 
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enriched in the three treatments based on the change in the expression of total or 
polysomal mRNA targets.  Out of 18 miRNAs, eight were significantly enriched, as 
assessed by their total mRNA targets, while nine miRNAs were significantly enriched 
with respect to their polysomal mRNA targets.  In addition, miR-206 was significantly 
enriched with respect to both its polysomal and total mRNAs targets.  These data suggest 
that polysome trafficking of transcripts and miRNAs plays an important role in 
experimental colon carcinogenesis.  The notion that miRNAs localize to polyribosomes 
is consistent with the translational down-regulation of specific mRNAs (302, 303).  We 
argue, therefore, that studies employing polysome purification/ribosome profiling and 
microarray analysis are needed in order to fully elucidate the mechanisms of 
translational deregulation associated with colon tumor development. 
For the purpose of inferring the relative activity of each miRNA, we also 
examined the expression level of target transcripts, assuming that if the target mRNA is 
down-regulated by treatment, then the miRNA activity is likely to be enhanced.  With 
the aid of miRNA-mRNA target prediction algorithms, Target Scan and DIANA-
microT, we identified the miRNA-mRNA coherent pairs using only those miRNAs 
which were highly abundant, significantly altered and shared a coherent relationship 
with their mRNA targets.  We avoided using the intersection of overlapping 
computational algorithms because enrichment is weak at best (285, 304).  In addition, 
Target Scan performs well in predicting targets for miRNAs (305, 306).  With respect to 
carcinogen effects on colonic miRNAs, miR-15b, miR-16, miR-107, miR-141, miR-204 
have been also shown to be down regulated in human colon cancer (18, 49, 77, 86).  
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Although there is no literature regarding the association of miR-146 and miR-148b with 
colorectal cancer, they are altered in CNS tumor derived cell lines (307)and thyroid 
tumors (308). 
Consistent with the inverse trend of putative targets in carcinogen-modulated 
miRNAs (Table 3), miR-15b/miR-16 and miR-107 have been linked with RASSF5 
(Ras-Association Domain Family) in other cancers (309, 310).  RASSF5 is a member of 
the RASSF family, which has been shown to be a tumor suppressor and is pro-apoptotic 
(311, 312).  Our data also suggest that TCF12, which is up-regulated in tumor samples, 
may be targeted by miR-141, miR-183, and miR-204.  TCF12 is a transcription factor 
abundantly expressed in Paneth cells of adult small intestinal crypts (313).  Interestingly, 
the activation of TCF12 may play a role in Paneth cell differentiation in colonic 
neoplasms (314).  Therefore, TCF12 targeting by miR-141, mir-183 and miR-204 may 
be associated in mediating the differentiation of the adult stem cells and disruption in 
this mechanism may contribute to colonic neoplasia.  Recently, it has been reported that 
miR-204 represses SIRT1 whose expression is regulated during embryonic stem cell 
differentiation (315).  We also noted a down-regulation of FLI1 and up-regulation of its 
targeting miR-193a, which may participate in tumor progression by activating β-catenin 
transcription (316).  Next, we applied linear discriminant analysis (LDA) to classify 
treatment effects on colonic miRNAs.  The number of gene features for each linear 
classifier was limited to 3, which allowed for an exhaustive search.  Using this 
technique, a number of miRNAs were strong single classifiers, including miR-21, a well-
known oncomir in colon cancer (138).  In contrast, several miRNAs did not classify 
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well, however, when paired with other poor single classifier), the pair-wise combination 
was strong with low estimated errors. 
With respect to the effect of dietary lipid source (CA vs FA), miR-18a, mR-19b, 
miR-27b, miR-93 and miR-497 were down-regulated in corn oil+ AOM compared to 
fish oil+AOM treated rats, reaffirming that n-3 PUFA modulate the effect of carcinogen 
with respect to both miRNA and target gene levels (140).  With respect to disease 
progression, several studies have reported the bivalent role for the miR-17-92 cluster, 
i.e., it has both tumor suppressor and oncogenic properties (317-319).  miR-18a and 
miR-19b are a part of the miR-17-92 cluster, and repression of mR-18a leads to an 
increase in cell proliferation and promotes anchorage independent growth in HT-29 
colon adenocarcinoma cell line (320).  Interestingly, even though miR-18a has been 
shown to be up-regulated in several cancers, studies have indicated that the expression 
level of the members of miR-17-92 cluster depends on the cell type (321-323).  
Furthermore, miR-19b was reported to be down-regulated in Crohn’s disease (324).  
Other notable observations include miR-27b, which shared a coherent relationship with 
total mRNAs ATP2B1, LIMK2, PARD6B, ZADH2 and polysomal mRNAs SLC6A6, 
GATA2 and ATP2B1.  Interestingly, n-3 PUFA fed animals injected with carcinogen 
exhibited an increase in miR-19b levels and decreased IGF1R levels which would 
favorably modulate apoptosis and cell cycle activity within the colon.  These findings 
are consistent with previous reports that fish oil blocks AOM-induced colon 
tumorigenesis by increasing apoptosis and suppressing cell proliferation (50, 244).  
Overall, the data are noteworthy, because in the absence of comprehensive human data, 
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the AOM chemical carcinogenesis model serves as a highly relevant means of assessing 
human colon cancer initiation and progression (281, 325). 
With regard to dietary combination chemotherapy, i.e., fat x fiber interaction in 
the presence of carcinogen (CCA vs FPA), we observed a coherent relationship between 
miR-15b, miR-16, miR-18a, mir-19b, miR-20a, miR-26b, miR-27b, miR-93, miR-98, 
miR-107, miR-130b, miR-182, miR-183, miR-195, miR-196b, miR-203, and miR-497, 
and their respective mRNA targets (Table 5).  Of these, miR-19b, mir-26b, miR-27b and 
miR-203 showed a strong coherent response with respect to total mRNAs, PTK2B, 
IGF2R, PDE4B, ATP2B1 and TCF4, respectively.  All four miRNAs were down-
regulated in corn oil+cellulose+AOM (CCA) compared to fish oil+pectin+AOM (FPA) 
treated rats.  Further, we examined a subset of these targets at the protein level and 
verified that PTK2B, PDE4B2 and TCF4 were also upregulated by ~2-fold in CCA as 
compared to FPA treatment, while the expression of their miRNAs were downregulated 
(Figure 10).  This is noteworthy, because TCF4 is a well-known transcription factor 
involved in Wnt signaling, and mutations in TCF4 are linked to colon cancer 
development (326).  We have previously demonstrated that colonic β-catenin signaling, 
an upstream mediator of TCF4, is suppressed in fish oil/pectin fed, AOM injected rats 
(247).  Therefore, fish oil+pectin is capable of blocking the AOM-mediated down-
regulation of miR-203, thereby suppressing TCF4 and preventing the further subversion 
of Wnt signaling.  PTK2B protein tyrosine kinase, a predicted target of miR-19b has 
been shown to be involved in several signaling cascades and is overexpressed in 
malignant gastrointestinal stromal tumors (327).  The level of PTK2B was upregulated 
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in CCA as compared to FPA at both the mRNA and protein level.  PDE4B2 (variant of 
PDE4B) which is a predicted target of miR-26b, was also up-regulated in CCA animals.  
This phosphodiesterase limits cAMP-associated apoptosis in a number of cancers (328, 
329).  In the integrative computational analysis, we also noted that IGF1R and IGF2R 
were predicted targets of miR-19b.  Interestingly, there was no change in IGF1R at the 
protein level in CCA vs FPA comparison.  Collectively, these findings support the claim 
that pleiotropic bioactive components generated by fermentable fiber (butyrate) and fish 
oil (DHA and EPA) work coordinately to protect against colon tumorogenesis (46, 58). 
 In summary, we have documented the combined effects of dietary bioactive 
agents and carcinogen on miRNA and mRNA expression profiles in the rat colon.  The 
fact that global miRNA expression patterns in human and rat AOM-induced tumors are 
similar (140), support the utility of this model.  Four complementary computational 
approaches were utilized to demonstrate that miRNAs and their putative mRNA targets, 
i.e., both total mRNAs and actively translated mRNA transcripts in polyribosome 
complexes, are differentially modulated by carcinogen and chemoprotective diets.  
Furthermore, immunoblot analyses were carried out and oncogenic targets of miR-19b, 
miR-26b and miR-203 were down-regulated by the chemoprotective fish oil+pectin 
containing diet.  These miRNAs will be the focus of future experiments involving 
knockdown and overexpression of strategies.  We also conclude that polysomal profiling 
is tightly correlated with miRNA changes when compared with total mRNA profiling.  
To our knowledge, this represents the first integrated analysis of miRNA and mRNA 
expression at an early stage of colon cancer development. 
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4. IDENTIFICATION OF miR-26B AND miR-203 GENE TARGETS IN COLON 
CANCER CELLS 
 
4.1 Introduction 
 miRNAs are a diverse class of noncoding RNAs involved in the regulation of 
several  key cellular processes such as signal transduction, apoptosis, cell proliferation, 
morphogenesis and the pathogenesis of cancer (1, 2). Structurally, these are 19-24 
nucleotide RNAs which are first transcribed as long primary miRNA, and then processed 
into 60-70nt miRNA precursor (pre-miRNA) by nuclear RNAse III Drosha. The pre-
miRNA complex is then transported to the cytoplasm where it is further processed by 
Dicer into a miRNA duplex. This miRNA duplex is then taken up by the RISC complex, 
and generally the guiding strand then binds to complementary sequences at the 3’ UTR 
of the mRNA and thus blocks translation of mRNA into proteins (2, 3). 
A plethora of studies have demonstrated that miRNAs and their targets are 
aberrantly expressed in colon cancer (63-67). For example, expression of miR-21, miR-
143 and miR-145 have been shown to be differentially expressed in human colonic 
tumors as compared to normal colon. These miRNAs have been shown to target several 
key signal transduction pathways that directly modulate malignant transformation (107, 
109, 110). 
 Over several decades, there is substantial experimental, epidemiological and 
clinical evidence indicating that fish oil containing diets, rich in n-3 polyunsaturated 
fatty acids (PUFAs), e.g. docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA), 
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are protective against colon tumorigenesis (45-48). It is likely that EPA and DHA 
function through multiple pathways to decrease colon cancer risk, including modulation 
of cyclooxygenase (COX) activity, changes in cellular oxidative stress, modification of 
gene expression and alterations in membrane dynamics and cellular surface receptor 
function. Work from our laboratory has demonstrated a role for n-3 PUFA in increasing 
the level of oxidative stress in colonocytes to activate apoptosis (330, 331). We have 
also demonstrated fundamental differences in gene expression profiles in rats fed a fish 
oil enriched diet compared to corn oil or olive oil enriched diets (50).  In addition, we 
have demonstrated that the chemoprotective effect of fish oil is enhanced when a highly 
fermentable fiber (pectin), capable of elevating colonic luminal butyrate levels, is added 
to the diet (59, 244, 248, 332). 
Recently, we examined the effects of colon carcinogenesis on non-coding RNAs 
in a rat model by cataloguing mucosal miRNA expression following diet and carcinogen 
exposure (140). For this purpose, global miRNA and target mRNA expression analyses 
were carried out. We demonstrated that the unique combination of chemoprotective 
dietary fish oil (containing EPA and DHA) plus pectin (fermented to butyrate in the 
large intestine) modulated a subset of mucosal miRNAs-miR-19b, miR-26b and miR-
203 and their predicted target genes -IGF1R, PTK2B, PDE4B and TCF4. Specifically, 
miR-19b, miR-26b and miR-203 were significantly downregulated by the corn oil 
cellulose diet in presence of carcinogen (CCA) as compared to fish oil pectin diet in the 
presence of carcinogen (FPA), whereas their predicted targets PTK2B, IGF1R, PDE4B 
and TCF4 were inversely upregulated. Immunoblotting analyses further revealed that the 
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targets were also modulated at the protein level (151). It is noteworthy that these diet 
modulated miRNAs are also aberrantly expressed in colon tumorigenesis and other types 
of cancers (333). 
To validate the predicted miRNA:mRNA associations observed in our earlier study 
(151), we conducted a series of loss and gain of function analyses by knocking down or 
overexpressing select miRNAs.  The global abundance of protein levels in the human 
colon cancer cell line (HCT116) model was subsequently assessed. As shown below 
(Table 10) , 100% homology exists between human (hsa), mouse (mmu) and rat (rno) 
for miR-19b, miR-26b and miR-203. The sequences in Table 10 were obtained from 
miRBase database (www.mirbase.org/). The accession number corresponding to each 
miRNA is noted in the parenthesis (334). 
 
 
Table 10. Alignment of  miR-19b, miR-26b and miR-203 sequences found in human , 
mouse and rat.  The sequences of miR-19b, miR-26b and miR-203 were obtained from 
miRBase database (334) in the three species. Hsa, human; mmu, mouse; rno, rat. 
 
(1) miR-19b: 
(MIMAT0000074) hsa: UGUGCAAAUCCAUGCAAAACUGA 
(MIMAT0000513) mmu: UGUGCAAAUCCAUGCAAAACUGA-miR-19b-2 
(MIMAT0000788) rno: UGUGCAAAUCCAUGCAAAACUGA-rno-mir-19b-1 
 
(2) miR-26b: 
          (MIMAT0000083) hsa: UUCAAGUAAUUCAGGAUAGGU 
    (MIMAT0000534) mmu: UUCAAGUAAUUCAGGAUAGGU 
    (MIMAT0000797) rno: UUCAAGUAAUUCAGGAUAGGU 
 
(3) miR-203: 
(MIMAT0000264) hsa: GUGAAAUGUUUAGGACCACUAG 
(MIMAT0000236) mmu: GUGAAAUGUUUAGGACCACUAG 
(MIMAT0000876) rno: GUGAAAUGUUUAGGACCACUAG 
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Our present study was designed to determine the function of select diet and colon 
carcinogen modulated miRNAs and to validate their respective miRNA:mRNA 
association.  Specifically, in order to determine the direct gene targets of miR-19b, 26b 
and 203, luciferase reporter assays were carried out. In addition, microRNA 
physiological function was assessed by examining effects on apoptosis and cell 
proliferation. We hypothesized that PTK2B, PDE4B and TCF4 are direct targets of miR-
19b, miR-26b and miR-203, respectively. 
 
4.2 Materials and methods 
4.2.1 Cell culture 
HCT116 cell line (p53+/+) was obtained from Dr. Bert Vogelstein, Johns 
Hopkins University, Baltimore, MD (335). These cells were cultured in McCoy’s 5A 
medium supplemented with 10% defined fetal bovine serum (Thermo Scientific, 
Wilmington, DE) and 2 mM glutamax (Gibco, Carlsbad, CA) at 370C in 5% CO2. A 
detailed protocol is included in Appendix B. 
4.2.2 Transfection 
Cells were plated at 1-2x105 cells per well in a 12-well plate on the day of 
transfection. Subsequently, 70% confluent cells were transfected with 5’ FITC-labeled 
miRNA inhibitors (Exiqon, Denmark) anti-miR-19b, anti-miR-26b or anti-miR-203 (30 
nM) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Scrambled miR was 
utilized as a negative control. Twelve hours following transfection, the media was 
changed. Transfection efficiency was assessed by images collected with a Zeiss 510 
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META NLO Multiphoton Microscope System consisting of an Axiovert 200 MOT 
microscope (Carl Zeiss Microimaging, Thornwood, NY). For overexpression of 
miRNAs, cells were transfected with miRNA mimics (30 nM) (Dharmacon, Lafayette, 
CO) for miR-19b, miR-26b, miR-203 or scrambled miR.  Each experiment was 
performed in triplicate. The working protocols can be found in Appendices C-F. The 
sequences of the miRNA mimics, inhibitors and scrambled controls are described in 
Appendix A. 
4.2.3 Total RNA isolation and Real Time PCR 
Forty-eight hours following transfection with miRNA inhibitors in HCT116 
cells, media was removed and the cells were washed with phosphate buffered saline 
(PBS) (Gibco, Carlsbad, CA). RNA lysis buffer (600 µl) provided with miRVana 
miRNA isolation kit (Ambion, Austin) was added to each well and cells were removed 
using a cell scraper. Total RNA was isolated using the miRVana miRNA isolation kit as 
per the manufacturer’s protocol. RNA quantity and quality were measured by Nanodrop 
(Thermo Scientific, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent 
Technologies, CA), respectively. Real time PCR was carried out using miRNA Taqman 
PCR assays (Applied Biosystems) to determine the expression of mature miR-19b, miR-
26b or miR-203 in treated and untreated samples. The detailed protocols for RNA 
isolation can be found in Appendix L. Normalization was carried out using the 2∆∆CT 
method relative to 18S rRNA. 
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4.2.4 Western blotting 
In order to determine the change in protein expression associated with miRNA 
knockdown, western blotting was carried out. 2-4x106 cells were seeded in 100 mm 
dishes on the day of transfection. Transfection with 30 nM miRNA inhibitors was 
carried out as described above. Forty-eight hours following transfection, media was 
removed and cells were washed thrice with PBS. Subsequently,  lysis buffer (300 µL) 
containing 50 mM Tris-HCl (pH 7.2), 250 mM sucrose, 2 mM 
ethylenediaminetetraacetic acid (pH 7.6), 1 mM ethyleneglycol-bis(aminoethylether)-
tetraacetic acid (pH 7.5), 50 µM NaF, 1% Triton-X, 100 µM sodium orthovanadate, 
protease inhibitor cocktail and 10 mM β-mercaptoethanol was added to the cells. The 
lysate was then passed through a 27 gauge needle and incubated on ice for 30 minutes. 
Subsequently, the lysate was centrifuged at 16,000g for 20 minutes. The supernatant was 
collected and the protein concentration determined by the Bradford method (336).  
Samples (20-80 µg) were loaded onto 4-20% Tris-Glycine gels (Invitrogen, Carlsbad, 
CA). After blotting, the membrane was incubated overnight with rabbit polyclonal 
PDE4B antibody at 1:200 (Abcam, Cambridge, MA), rabbit TCF4 monoclonal antibody 
at 1:1000 (Cell signaling Technology, Boston, MA) or rabbit PTK2B antibody at 1:1000 
(Cell Signaling Technology, Boston, MA) and horseradish peroxidase linked (Jackson 
Immunoresearch Laboratories, West Groove, PA) secondary antibody at 1:7000 dilution 
and chemoluminescent detection was performed. Unless noted, all other reagents were 
from Sigma. Detailed protocols for total cell lysate and western blotting are described in 
the Appendix M. 
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4.2.5 Dual luciferase reporter assay 
Cells were plated at 0.2 x 105 cells per well in a 96 well plate.  Cells were 
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with Renilla reporter 
plasmid containing 3’ UTR of PTK2B or PDE4B  (Switchgear Genomics, Menlo Park, 
CA) or dual luciferase reporter plasmid containing wild type or mutated 3’ UTR of 
TCF4 (Genecopoeia, Rockville, MD). For PTK2B and PDE4B constructs, firefly 
reporter plasmids for normalization were also cotransfected. A control 3’ UTR plasmid 
with a random non-conserved and non-repetitive 3’ UTR sequence (scrambled 3’UTR) 
was utilized as a negative control for reporter plasmids.  miR-19b, miR-26b, miR-203 or 
scrambled controlled miRNA mimics (30 nM) were subsequently co-transfected with 
cells according to the manufacturer’s instructions. Twenty-four hours after transfection, 
dual luciferase reporter assay (Promega) was carried out according to the manufacturer’s 
instructions, and firefly and renilla activity were measured using a SpectraMax L 
Luminescence Microplate Reader (Molecular Devices Sunnyvale, CA). Relative firefly 
luciferase activity was normalized to Renilla luciferase activity. To assess the direct 
binding of PDE4B with miR-26b, morpholinos (0.5 µM, also called target protectors) 
(Gene Tools, Philomath, OR) against PDE4B were also co-transfected along with a 
reporter plasmid containing 3’ UTR of PDE4B. All experiments were performed in 
triplicate.  Detailed protocols are described in Appendices G-H and J-K. The sequences 
of the miRNA inhibitors, miRNA mimics and 3’ UTR constructs are described in 
Appendix A. 
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4.2.6 Apoptosis assay 
Cells were plated at 0.2 x 105 cells per well in a 96 well plate and miRNA 
inhibitors or control inhibitors were transfected as described above, and 48 hours later, 
apoptosis was measured using a cellular fragmentation enzyme linked immune-sorbent 
assay (ELISA) (Roche). Floating cells were harvested, washed, lysed and centrifuged to 
sediment nuclei. Supernatants containing mono- and oligonucloesomes were incubated 
with substrate and subsequently analyzed by ELISA as previously described (337). To 
determine the effect of treatment on cell proliferation, equal numbers of cells were 
seeded in a 96 well plate and 48 hours later, the number of cells were counted using a 
hemocytometer. All experiments were performed in triplicate. 
4.2.7 Statistics 
 The effect of more than two independent variables (treatment effects) was 
assessed using the one-way analysis of variance test (ANOVA), and differences among 
the means were evaluated using Tukey’s and Bonferroni post-hoc of contrast. P values 
<0.05 were considered to be statistically significant. The graphs were plotted using 
means and standard error of 6 to 8 cell culture wells (data points) obtained from each 
treatment collected from three different experiments (performed in triplicate). Standard 
error bars were plotted in order to document the variation in the population mean. 
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4.3 Results 
4.3.1 PTK2B is not a direct target of miR-19b 
 To determine if PTK2B levels are modulated following miR-19b knockdown, 
HCT116 cells were transfected with anti-miR-19b inhibitor or with scrambled control 
miRNA inhibitor (negative control).  The predicted pairing of the target 3’ UTR gene 
region with miR-19b is shown in Figure 13(A). With a transfection efficiency of  >70% 
(±3.86), 48 hours following knockdown, miR-19b levels were significantly decreased by 
~90% as compared to scrambled control and non-transfected control (Figure 13(B)). 
Dose dependent knockdown of miR-19b was carried out to determine the optimal 
concentration of miR-19b inhibitor (Appendix Q1). Correspondingly, PTK2B protein 
levels were significantly increased by approximately 40% in miR-19b knockdown 
samples compared with negative control and non-transfected control (Figure 13(C, D)). 
Alternatively, HCT116 cells were transfected with miR-19b mimic or scrambled miR 
mimic control and 48 hours later, expression of miR-19b was significantly (P <0.05) 
increased by greater than 95% (Figure 13(E)). Dose dependent overexpression of miR-
19b was carried out to determine the optimal concentration of miR-19b mimic 
(Appendix Q4).  Following transfection, PTK2B protein levels were significantly (P 
<0.05) decreased by approximately 60% in cells overexpressing miR-19b compared to 
the negative control and non-transfected control (Figure 13(F,G)). These results indicate 
that PTK2B is inhibited by miR-19b. In order to further determine if PTK2B is a direct 
target of miR-19b, a 3’UTR reporter plasmid containing the miRNA binding site of 
PTK2B (Figure 13(A) and 13(A)) was utilized.  HCT116 cells were cotransfected with 
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miR-19b mimic, 3’UTR PTK2B Renilla reporter plasmid (PTK2B 3’ UTR) and 
normalized to control-firefly reporter plasmid (transfection control). Separately, a 
control plasmid, containing a 3’UTR with a scrambled sequence (scrambled 3’ UTR) 
that is non-conserved and non-repetitive, was co-transfected with miR-19b mimic in 
HCT116 cells. This served as a negative control. Twenty-four hours later, luciferase 
activity was unaffected relative to the negative control (Figure 14(B)).  These data 
indicate that PTK2B is not a direct target of miR-19b. 
4.3.2 PDE4B is a direct target of miR-26b 
To determine if PDE4B is directly targeted by miR-26b, HCT116 cells were 
transfected with anti-miR-26b inhibitor or with scrambled control miRNA inhibitor 
(negative control). Dose dependent knockdown of miR-26b was carried out to determine 
the optimal concentration of miR-26b inhibitor (Appendix Q2). Forty-eight hours 
following knockdown, miR-26b levels were significantly decreased (P <0.05) by 75% as 
compared to control (Figure 15(B)), and correspondingly, PDE4B protein levels were 
significantly (P <0.05) increased by 40% in miR-26b knockdown samples compared 
with negative control and non-transfected control (Figure 15(C) and (D)). In addition, 
in HCT116 cells transfected with miR-26b mimic or scrambled miR mimic control for 
48 h, miR-26b levels were significantly (P <0.05) increased by 95% (Figure 15(E)) and 
PDE4B protein levels were significantly (P <0.05) decreased by 45% in miR-26b 
overexpressed samples compared to the negative control and non-transfected control 
(Figure 15(F) and (G)). Dose dependent overexpression of miR-26b was carried out to  
 
 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. PTK2B expression following knockdown or overexpression of miR-19b 
expression. (A) Predicted binding of miR-19b to the 3’ UTR of PTK2B as assessed by Target 
Scan (http://www.targetscan.org/). (A) Knockdown of miR-19b was carried out by transfecting 
miR-19b inhibitor or scrambled miRNA inhibitor (control) in HCT116 cells.  48 h following 
transfection, miR-19b expression was measured by qRT-PCR. (C) PTK2B protein levels were 
measured by western blotting after miR-19b knockdown and β-actin was used as a loading 
control as described in the Materials and methods. (D) Quantification of PTK2B levels in control 
(no transfection), scrambled control or miR-19b knockdown samples from immunoblot images. 
(E) Overexpression of miR-19b was carried out by transfecting miR-19b mimic or scrambled 
miRNA mimic control and 24 h later, miR-19b expression was measured by qRT-PCR. (F) 
PTK2B protein levels were measured by western blotting following miR-19b overexpression, 
and β-actin was used as a loading control. (G) Quantification of PTK2B levels in control (no 
transfection), scrambled control or miR-19b overexpressed samples from immunoblot images. 
Data represent means + S.E. from six-eight replicate values obtained from three separate 
experiments. Mean values not sharing common letters are significantly different, P <0.05.  
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Figure 14. Validation of PTK2B as a gene target of miR-19b. (A) Schematic representation of 
the 3’UTR PTK2B Renilla reporter plasmid, scrambled 3’UTR Renilla reporter plasmid and 
normalization using a control-firefly reporter plasmid (transfection control). (B) Luciferase 
activity was determined 24 h following transfection. All luciferase values were normalized to 
firefly luciferase (transfection control). Data represent means + S.E. from nine replicate values 
obtained from three separate experiments. Mean values not sharing common letters are 
significantly different, P <0.05.  
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determine the optimal concentration of miR-26b mimic (Appendix Q5). These results 
indicate that PDE4B is downregulated by miR-26b. In order to determine if PDE4B is a 
direct target of miR-26b, a 3’UTR reporter plasmid containing the miRNA binding site 
of PDE4B (Figure 15(A) and 16(A)) was utilized.  HCT116 cells were cotransfected 
with miR-26b mimic, 3’UTR PDE4B Renilla reporter plasmid (PDE4B 3’ UTR) and a 
normalization control-firefly reporter plasmid (transfection control). Separately, a 
control 3’ UTR plasmid with a random sequence (scrambled 3’UTR) or a non-conserved 
and non-repetitive 3’ UTR sequence were co-transfected with miR-26b. This served as a 
negative control. Twenty-four hours later, luciferase activity was significantly (P <0.05) 
decreased by 50% relative to the negative control (Figure 16).  These data demonstrate 
that PDE4B is a direct target of miR-26b. In order to confirm this finding, target 
protectors were utilized. Target protectors are morpholinos which bind to target mRNA 
and mask the binding site, blocking the targeting of miRNAs, thereby increasing 
luciferase activity (338). HCT116 cells co-transfected with a morpholino targeting 
PDE4B mRNA, PDE4B 3’ UTR Renilla reporter plasmid, a normalization control-
firefly reporter plasmid (transfection control) and miR-26b mimic increased luciferase 
activity significantly (P <0.05) as compared to HCT116 cells co-transfected with miR-
26b mimic, 3’UTR PDE4B Renilla reporter plasmid (PDE4B 3’ UTR) and a 
normalization control-firefly reporter plasmid (transfection control) (Figure 16(B)). 
Separately, as a negative control, PDE4B target protector control was co-transfected 
with PDE4B 3’ UTR plasmid. This confirmed that PDE4B is a direct target of miR-26b. 
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Figure 15. PDE4B expression following knockdown or overexpression of miR-26b 
expression. (A) Predicted binding of miR-26b to the 3’ UTR of PDE4B as assessed by Target 
Scan (http://www.targetscan.org/). (B) Knockdown of miR-26b was carried out by transfecting 
HCT116 cells with miR-26b inhibitor or scrambled miRNA inhibitor (control) for 48 h.  miR-
26b expression was subsequently measured by qRT-PCR. (C) PDE4B protein levels were 
measured by western blotting following miR-26b knockdown.  β-actin was used as a loading 
control as described in the Materials and methods. (D) Quantification of PDE4B protein levels in 
control (no transfection), scrambled control or miR-26b knockdown cultures from immunoblot 
images. (E) Overexpression of miR-26b was carried out by transfecting miR-26b mimic or 
scrambled miRNA mimic control.  24 h post transfection, miR-26b expression was measured by 
qRT-PCR. (F) PDE4B protein levels were measured by western blotting following miR-26b 
overexpression and β-actin was used as a loading control. (G) Quantification of PDE4B protein 
levels in control (no transfection), scrambled control or miR-26b overexpressed samples from 
immunoblot images. Data represent means + S.E. from six-eight replicate values obtained from 
three separate experiments. Mean values not sharing common letters are significantly different, p 
<0.05.  
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Figure 16.  Validation of PDE4B as a gene target for miR-26b. (A) Schematic representation 
of the 3’UTR PTK2B Renilla reporter plasmid, scrambled 3’UTR Renilla reporter plasmid and 
normalization control-firefly reporter plasmid used in the study.  (B) Luciferase activity was 
determined 24 h after transfection. All luciferase values were normalized to firefly luciferase 
(transfection control). Data represent means + S.E. from nine values obtained from three separate 
experiments. Mean values not sharing common letters are significantly different, p <0.05.  
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4.3.3 TCF4 is a direct target of miR-203 
To determine if TCF4 levels are modulated following miR-203 knockdown, 
HCT116 cells were transfected with anti-miR-203 inhibitor or with a scrambled control 
miRNA inhibitor (negative control). Dose dependent knockdown of miR-203 was 
carried out to determine the optimal concentration of miR-203 inhibitor (Appendix Q3). 
Forty-eight hours following knockdown, miR-203 levels were significantly (P <0.05) 
decreased by 50% as compared to the controls (Figure 17(B)). Correspondingly, TCF4 
protein levels were significantly increased (P <0.05) by 43% in miR-203 knockdown 
samples compared with the negative control and non-transfected control (Figure 17(C) 
and (D)). In comparison, in HCT116 cells transfected with miR-203 mimic or scrambled 
miR mimic control, miR-203 levels were significantly (P <0.05) increased by greater 
than 95% (Figure 17(E)). Dose dependent overexpression of miR-203 was carried out to 
determine the optimal concentration of miR-203 mimic (Appendix Q6).  
Correspondingly, TCF4 protein levels were significantly decreased (P <0.05) by 55% in 
miR-203 overexpressed samples compared with negative control and non-transfected 
control (Figure 17(F) and (G)). These results indicate that TCF4 is downregulated by 
miR-203. In order to determine if TCF4 is a direct target of miR-203, a 3’UTR reporter 
plasmid containing the miRNA binding site of TCF4 (Figure 17(A) and 18(A)) was 
utilized. HCT116 cells were cotransfected with miR-203 mimic and 3’UTR TCF4 firefly 
reporter plasmid. In separate experiments, as a negative control, a control 3’ UTR 
plasmid with a random sequence (scrambled 3’UTR) was co-transfected with miR-203 
mimic. Twenty-four hours later, luciferase activity was significantly decreased (P <0.05) 
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by ~55% relative to the negative control.  These findings demonstrate that TCF4 is a 
direct target of miR-203. In order to confirm this result, the binding sites of miR-203 in 
3’ UTR of TCF4 were mutated. The miR-203 binding site in the 3’ UTR of TCF4, i.e., 
“catttcaa”, was mutated to “gcgatatc” (Figure 18(B)). When a mutated 3’ UTR version 
of TCF4 was co-transfected with the miR-203 mimic, there was no change in luciferase 
activity compared to the miRNA target clone control vector (Figure 18(C)), confirming 
the specificity of miR-203 binding. 
4.3.4 miR-19b and miR-26b induce apoptosis whereas miR-203 reduces cell 
proliferation 
Studies have shown that dietary fish oil and pectin diet combination promotes 
apoptosis (59, 247).  We demonstrated earlier that levels of miR-26b and miR-203 were 
reduced by the dietary combination of corn oil and cellulose (CCA) as compared to 
chemoprotective diet, fish oil combined with pectin (FPA), in the presence of AOM 
(151).  Hence, in order to elucidate how alterations in miRNAs in the colon alter cell 
phenotype, HCT116 cells were transfected with miR-19b, miR-26b mimic or scrambled 
control miRNA. A 66% increase (P <0.05) in apoptotic index was observed when miR-
19b and miR-26b were overexpressed compared to untreated control or scrambled 
control (Figure 19(A), whereas there was a modest increase of ~25% (P <0.05) in 
apoptotic index and a significant decrease in cell number when miR-203 was 
overexpressed (Figure 19(B)). Cell proliferation was not determined for miR-19b and 
miR-26b since studies have demonstrated that these miRNAs do not alter cell 
proliferation (339, 340). 
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Figure 17. TCF4 expression following knockdown or overexpression of miR-203 
expression. (A) Predicted binding of miR-203 to the 3’ UTR of TCF4. (A) Knockdown of miR-
203 was carried out by transfecting miR-203 inhibitor or scrambled miRNA inhibitor (control) in 
HCT116 cells.  48 h following transfection, miR-203 expression was measured by qRT-PCR. 
(C) TCF4 protein levels were measured by western blotting after miR-203 knockdown and β-
actin was used as a loading control as described in the Materials and methods. (D) Quantification 
of TCF4 levels in control (no transfection), scrambled control or miR-203 knockdown samples 
from immunoblot images. (E) Overexpression of miR-203 was carried out by transfecting miR-
203 mimic or scrambled miRNA mimic control.  miR-203 expression was measured by qRT-
PCR 24 h later. (F) TCF4 protein levels were measured by western blotting after miR-203 
overexpression and β-actin was used as a loading control. (G) Quantification of TCF4 levels in 
control (no transfection), scrambled control or miR-203 overexpressed samples from 
immunoblot images. Data represent means + S.E. from six- eight replicate values obtained from 
three separate experiments. Mean values not sharing common letters are significantly different, P 
<0.05.  
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Figure 18. Validation of TCF4 as a target gene for miR-203. (A) Schematic representation of 
the 3’UTR TCF4 Renilla reporter plasmid, scrambled 3’ UTR Renilla reporter plasmid and 
3’UTR mutant TCF4 Renilla reporter plasmid. (B) Schematic representation of 3’UTR of TCF4 
showing the putative miR-203 target site. The letters in red indicate the mutated base pairs. (C) 
Luciferase activity was determined 24 h after transfection. All luciferase values were normalized 
to Renilla luciferase. Data represent means + S.E. from nine values obtained from three separate 
experiments. Mean values not sharing common letters are significantly different, p <0.05.  
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Figure 19. Effects of miR-19b, miR-26b and miR-203 on colonocyte phenotype. (A) 
HCT116 cells were transfected with miR-19b, miR-26b, miR-203 (30 nM) or scrambled control 
mimic.  After 72 h, the apoptosis index was measured. (B) HCT116 cells were transfected with 
either miR-203 mimic or scrambled control mimic for 72 h and total cell number was counted.  
Data represent  means + S.E. from six culture wells obtained from two separate experiments. 
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4.4 Discussion 
We have recently demonstrated that n-3 PUFA uniquely modulate carcinogen-
directed miRNA signatures in the colon (140).  Also, previous studies have shown that 
the bioactive compounds associated with dietary fish oil (DHA and EPA) and 
fermentable fiber (butyrate) synergize to protect against colon carcinogenesis, primarily 
by enhancing apoptosis (59, 60, 239, 332, 341). With regard to dietary combination, i.e., 
fat x fiber interaction in the presence of carcinogen (CCA vs FPA), we observed a 
coherent relationship between miR-19b, miR-26b, miR-203 and PTK2B, PDE4B and 
TCF4, respectively (151). Since these miRNAs may exhibit distinct functions in 
different cell types, their role in colonic epithelial cells warrants investigation. 
Therefore, to further elucidate the biological effects of diet and carcinogen on miRNAs 
and their targets, an integrated targeted approach was used.  
In this study, by manipulating miRNA levels and performing luciferase reporter 
assays, we demonstrated that PDE4B and TCF4 are direct targets of miR-26b and miR-
203, respectively. Even though PTK2B protein levels were modulated by miR-19b, there 
was no change in luciferase reporter activity, suggesting the absence of direct binding 
between miR19b and PTK2B. These data suggest that miR-19b modulates PTK2B by 
modulating an upstream target(s) of PTK2B.  
We have previously documented the ability of dietary fish oil/pectin combination 
to increase miR-26b expression in the colon (151).  This is noteworthy, because the 
suppression of miR-26b expression has been reported in various cancers including colon 
cancer, hepatocellular carcinoma, breast cancer and prostate cancer (342-344). In 
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addition, miR-26b status has been associated with the invasiveness and metastasis of 
colorectal cancer cells (342). The increased expression of PDE4B (cAMP-specific 3',5'-
cyclic phosphodiesterase 4B) has been reported in colorectal cancer (345) and is known 
to act by limiting cAMP-associated apoptosis in a several types of cancer (328, 329). We 
observed that apoptosis was induced with increasing levels of miR-26b, which is 
consistent with published reports (342-344). In addition, previous studies from our lab 
have shown that fish oil - pectin combination act synergistically to induce apoptosis, 
both in vivo and in vitro, by recruiting a p53 independent, oxidation sensitive, Ca2+ -
mediated intrinsic mitochondrial pathway (59, 346).  Based on this evidence, we propose 
a putative mechanism of miR-26 action in the colon (Figure 20). By increasing mucosal 
levels of miR-26b, fish oil-pectin combination decreases PDE4B expression, which 
promotes cyclic adenosine monophosphate (cAMP) formation (347). This can lead to 
reduction of phosphorylation at threonine 308 and serine 473 of Akt (i.e. pAKT) (348) 
and activation of protein kinase A (PKA) (347). From a chemoprotective standpoint, 
PKA can promote apoptosis (349).   Moreover, decreased pAKT activity can result in a 
reduction in PIP3 levels and decrease the lipid kinase activity of PI3K (348). 
Interestingly, we have observed that other dietary chemoprotective agents, e.g., 
curcumin, are capable of blocking intestinal dextran sodium sulphate-induced increase in 
PDE4B (170). Also, EZH2, one of the targets of miR-26b has been shown to be 
modulated by curcumin in pancreatic cancer cells (343, 350), suggesting that miR-26b 
and its targets may be modulated by chemoprotective bioactive dietary agents.  
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Collectively, these findings suggest that miR-26b acts as a “tumor suppressor” by 
targeting PDE4B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Proposed mechanism of action of miR-26b.  Colonocytes from fish oil and pectin 
fed mice exposed to carcinogen exhibit an increased steady-state level of miR-26b, which 
directly targets and reduces PDE4B expression. This results in an increase in cAMP levels, 
which may antagonize pAKT levels and promote apoptosis. Increased levels of cAMP may also 
activate Protein Kinase A, which can promote apoptosis and delete mutated cells. 
 
 
The increased expression of miR-203 in HCT116 cells was associated with 
decreased levels of one of its predicted targets, TCF4. miR-203 has been reported to be 
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downregulated in a number of cancers and was upregulated in the colonic mucosa of rats 
fed a fish oil + pectin diet (151, 351-356). miR-203 downregulation appears to be 
mediated by epigenetic silencing.  For example, studies in breast cancer and multiple 
myeloma cells have shown that the miR-203 promoter is hypermethylated (351, 357). 
Moreover, Lena et al. demonstrated that miR-203 is downregulated during the epithelial 
commitment of embryonic stem cells (353). Through overexpression or knockdown of 
miR-203 levels in HCT116 cells, we showed that TCF4 levels were inversely correlated 
to the level of miR-203 expression. Also, luciferase reporter assays showed that miR-
203 directly binds to TCF4 and mutation of the miR-203 binding site in the TCF4 3’ 
UTR abolished the effect of miR-203. TCF4 is a well-known transcription factor 
expressed in the intervillus pocket of the developing intestine and is required to establish 
proliferative progenitor cells of prospective crypts in the embryonic small intestine 
(358).  TCF4 is regulated by the Wnt signaling pathway and controls stem cell fate in the 
intestine (359). Indeed, it is well appreciated that an increase in TCF4 levels promotes 
TCF4-β-catenin interaction, which can lead to the inappropriate activation of a TCF4 
target gene program (360). Previously, we have demonstrated that colonic-β-catenin 
signaling, an upstream mediator of TCF4, is suppressed in carcinogen injected rats fed a 
fish oil + pectin (FPA) as compared to control diet (247). Hence as shown in Figure 21 
(B), we predict that CCA combination will enhance hypermethylation of miR-203 
promoter resulting in the reduced expression of mature miR-203. Hence, TCF4 protein 
levels will be higher, thus increasing cell proliferation. Alternatively, as shown in Figure 
21(A), FPA combination will not induce hypermethylation of the miR-203 promoter, 
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thus decreasing cell proliferation by increasing expression of miR-203. Further work is 
needed in order to determine how FPA modulates the expression of mature miR-203.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Proposed chemoprotective mechanism of action of miR-203. (A) In the presence 
of carcinogen (AOM), fish oil + pectin diet, transcription of miR-203 is mantained, regulating 
TCF4 levels.  (B) In the presence of carcinogen (AOM), corn oil + cellulose (control) diet, miR-
203 expression is repressed, thereby decreasing the formation of pre-miR-203, ultimately 
reducing the levels of mature miR-203. This elevates TCF4 levels, which promotes cell 
proliferation and epithelial cell stemness. 
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 In summary, the chemoprotective effects of combined fish oil and pectin feeding 
antagonize the oncogenic effects of carcinogen, in part by modulating the expression of 
miR-19b, miR-26b and miR-203 and their targets.  
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5. MODULATION OF COLONIC STEM CELL MICRORNA EXPRESSION BY 
DIET 
 
5.1 Introduction 
The multicellular epithelium of the intestine is replaced every 4-6 days (361, 
362). The massive rate of cell proliferation in the crypts is maintained by cells 
undergoing mitotic division at the base of the crypts and in transit, prior to undergoing 
differentiation. This renewal process is maintained by multipotent intestinal stem cells 
(ISCs).  The exact identity of intestinal stem cell has proven controversial over the last 
30 years, and  mechanisms that regulate homeostasis are not fully elucidated, although 
plausible candidates have been proposed (363). Recently, advances have been made in 
the identification of adult stem cells that replenish the intestinal stem cell every four to 
six days (225, 228, 229, 364, 365). Barker et al. demonstrated for the first time that 
colon stem cells can be identified by specific expression  of Lgr5/GPR49, a G protein-
coupled receptor (225). Lgr5+ ISCs are long-lived, rapidly cycling cells in the crypt base 
columnar (CBC) region giving rise to all the epithelial subtypes in the small intestine 
and colon.  
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and poses 
a serious health problem in United States (22).  Current treatment consists of surgical 
resection of the tumor, chemotherapy, radiotherapy and palliative therapy (advanced 
stages). However, as many as 40% of patients may exhibit  relapse within 5 years of 
treatment, generally in the form of metastases (366). Colorectal cancers contain subsets 
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of cancer stem cells (CSC), which are identified by the expression of surface markers 
such as CD133 (221, 367) and/or CD44 (368) and can effectively propagate the disease 
after implantation in an immunodeficient host. A recent study showed that there is a 
common gene signature between EphB2 and Lgr5 sorted stem cells obtained from 
healthy intestine and colon tumors, suggesting that the intestinal stem cell program 
defines a cancer stem cell niche within colorectal tumors and may play a role in 
colorectal cancer relapse (369).  Hence, it has been suggested that the intestinal stem cell 
program defines a cancer stem cell niche within colorectal tumors and also plays a role 
in CRC relapse (369). Based on emerging evidence, cancer stem cells are primary 
therapeutic targets for colorectal cancer recurrence (370).   
Recent evidence indicates that intestinal crypt homeostasis results from neutral 
competition between symmetrically dividing Lgr5+ stem cells (371). By crossing stem-
cell-specific Lgr5-EGFP-IRES-creERT2 knock in mice to Apcflox/flox mice, it was 
unequivocally shown that crypt Lgr5+ stem cells are the cells-of-origin of intestinal 
cancer (228). Hence, perturbations in adult stem cell dynamics are generally believed to 
represent an early step in colon tumorigenesis. In addition, cell differentiation has been 
demonstrated to be an important event in carcinogenesis. The progression and 
aggressiveness of colorectal tumors has been shown to have an inverse relationship with 
the level of differentiation of tumor cells. Several studies have demonstrated that 
miRNA are key regulators of pluripotency and differentiation (372).  
miRNAs are a type of noncoding RNAs that act through partial complementarity 
to 3’ untranslated regions (UTRs) of target mRNAs, and regulate gene expression post-
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transcriptionally (2, 3). Recently, it has been demonstrated that genes translationally 
repressed by more than one third also display detectable mRNA destabilization (373, 
374). With respect to epigenetic mechanisms involved in colon tumor development, it is 
believed that non-coding miRNAs control the expression of approximately one-third of 
the mammalian messenger mRNA (mRNAs) (2). miRNAs play an important role in 
regulating stem cell renewal and differentiation by repressing the translation of selected 
mRNAs in stem cells and differentiated daughter cells (375-379). Also, a few studies 
have demonstrated the role of miRNAs in the maintenance of colon cancer stem cells 
(235, 380).   Therefore, it is highly likely that the search for specific miRNA expression 
signatures of colorectal cancers will better define specific subtypes and  hence can 
potentially influence cancer therapy (235, 342). 
 The overwhelming majority of colorectal cancers are initiated by activating 
mutations/deletions in the Wnt signaling pathway (381, 382). From a physiological 
standpoint, this pathway is essential for the maintenance of the intestinal stem cell niche, 
as exhibited by mice lacking the TCF4 transcription factor, lacking RNF43 deletion or 
expressing transgenically the secreted Dickkopf-1 Wnt inhibitor (383-386). Therefore, 
environmental factors that are capable of modulating Wnt signaling will likely have a 
unique and central role in the physiology and pathology of the intestinal stem cell. Along 
these lines, our laboratory (247) and others (387-389) have demonstrated that nutritional 
bioactives (n-3 fatty acids, folate, fermentable fiber) can modulate Wnt signaling by 
repressing coloncyte nuclear beta-catenin levels. In addition, we have recently 
demonstrated that a chemoprotective diet containing n-3 fatty acids may favorably 
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influence the stem cell niche and therefore suppress colon cancer development (171, 
390). Our lab was the first to examine the effects of colon carcinogen on rat mucosal 
miRNA expression profiles and to unravel the effects of bioactive dietary components 
on miRNA expression in the colon (151, 283). We demonstrated that the novel 
combination of fish oil/pectin protects the colon from carcinogen-induced miRNA 
dysregulation (151). However, to date, the effects of chemoprotective dietary 
components on colonic stem cell non-coding miRNA signatures have not been 
determined, nor has the miRNA expression profile in colon stem cells been documented.  
Hence, with the identification of Lgr5 as the first definitive intestinal stem cell marker in 
mice, we used the highly novel, recently described, Lgr5-EGFP-IRES-cre ERT2 knock in  
mouse model to visualize and isolate intestinal stem cells, examine their response to 
chemotherapeutic agents by measuring miRNA expression and establish their stem cell-
specific miRNA expression profile. This was contrasted with components of the stem 
cell “niche” i.e. daughter cells, which contribute to the physiological microenvironment 
consisting of specialized cells that physically anchor the stem cell and provide the 
necessary factors to maintain its stemness.  We hypothesized that a chemoprotective diet 
containing n-3 PUFA (fish oil) and butyrate (pectin) would modulate the stem cell 
miRNA profile resulting in a favorable shift in programmed cell death (apoptosis) and 
self-renewal in colonic crypts. Our overall goal is to better understand how the colonic 
stem cell population responds to environmental factors such as diet and carcinogen. 
Hence, we investigated the effects of disease progression on miRNAs in colonic stem 
cells by feeding mice injected with azoxymethane (AOM, a colon carcinogen)  a diet 
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containing n-3 PUFA and a fermentable fiber (fish oil + pectin) diet or n-6 PUFA and a 
poorly fermentable fiber (corn oil + cellulose). 
 
5.2 Materials and methods 
5.2.1 Animals 
All procedures involving animals followed guidelines approved by the 
Institutional Animal Care and Use Committee at Texas A&M University in accordance 
with EU Directive 2010/63/EU for animal experiments.   Lgr5-EGFP-IRES-creERT2 
originally described by Barker et al. (225) (10-15 wk of age) were used. The study was 2 
x 2 factorial design with two types of dietary fat fiber combination –corn oil (n-6 PUFA) 
+ cellulose and fish oil (n-3 PUFA) + pectin and two treatments (injection with colon 
carcinogen, AOM or saline). Animals (n=5 per group) were terminated eight weeks after 
the last AOM injection. Figure 22 shows the timeline of the treatments. 
 
 
 
 
 
 
 
 
 
Figure 22. Timeline of treatment. Lgr5-EGFP-IRES-creERT2 mice were provided with either 
corn oil / cellulose or fish oil / pectin diets for 2 weeks prior to treatment. The mice were then 
injected four times with AOM or saline at 10 mg/kg body weight for four weeks, one injection 
per week. Eight weeks after the last injection, the mice were terminated and the colon was 
extracted for stem cell isolation. CC, corn  oil cellulose;  FP, fish oil pectin. 
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5.2.2 Experimental diets 
 Lgr5-EGFP-IRES-creERT2 mice were assigned to one of the two diet groups 
(fish oil / pectin or corn oil / cellulose), which differed only in the type of fat and fiber. 
Diets contained (g/100 g diet):  dextrose, 51.00; casein, 22.40; D,L-methionine, 0.34; 
American Institute of Nutrition (AIN)-76 salt mix, 3.91; AIN-76 vitamin mix, 1.12; 
choline chloride, 0.13; pectin or cellulose, 6.00.  The total fat content of each diet was 
15% by weight with the n-6 PUFA diet containing 15.0 g corn oil/100 g diet  (Dyets, 
Bethlehem, PA) and the n-3 PUFA diet containing 11.5 g fish oil/100g diet (Omega 
Protein, Houston, TX) plus 3.5 g corn oil/100 g diet to prevent essential fatty acid 
deficiency. All diet ingredients except oils were obtained from Bio-serv (Frenchtown, 
NJ). To prevent the formation of oxidized lipids, diets were stored at -200C and provided 
fresh to animals every day. 
5.2.3 Determination of aberrant crypts  
Mice were euthanized by CO2 overdose, followed by cervical dislocation. The 
colon was removed and 1 cm of the distal colon was fixed in 4% paraformaldehyde 
(Electron Microscopy Services, Hatfield, PA) for immunohistochemistry (IHC). The 
remainder of the colon was prepared for determination of aberrant crypt foci (ACF). 
Enumeration of ACF was conducted as previously described (391). Briefly, the total 
number of ACF and high multiplicity aberrant crypt foci (HM-ACF) were counted from 
each colon for each treatment (n=10 per treatment). HM-ACF were considered to 
contain four or more aberrant crypts per focus (392). 
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5.2.4 Stem cell isolation from colonic crypt using fluorescence activated cell sorting  
Twenty-four hours prior to termination, 200 ul of 10 mg/mL tamoxifen (Sigma, 
CO) dissolved in corn oil (without tert-Butylhydroquinone (TBHQ)) was administered 
to each mouse via intraperitoneal injection using a 27 gauge syringe. The final dose of 
tamoxifen was 2 mg per mouse.  As a negative control, a mixed solution containing 198 
ul of corn oil and 2 ul of 100% ethanol was injected.  Colonic crypts were isolated by the 
method of Sato et al (229) with minor modification. The intact colons were everted on a 
disposable mouse gauge needle (Instech Laboratories) and incubated with 20 mM EDTA 
in PBS at 37°C for 30 min.  Following transfer to chilled Ca/Mg free HBSS, colons were 
vigorously vortexed to release crypts. The crypts were then incubated with 50 ul of 
DNase (stock concentration- 20 units/ml) in 10 ml of trypsin solution and single cells 
were then passed through a 40 micron cell strainer. The cells were counted and 
resuspended to a final cell density of 2 x106 cells/mL. FACS (Fluorescence activated cell 
sorting) was then carried out to sort the GFPhigh expressing stem cells, GFPlow expressing 
daughter cells and GPFnegative cells isolated from the colon using a BD FACS Aria II 
cytometer /sorter (BD Biosciences). Cells from wild type mice were used to set the gates 
for sorting (Figure 23(A)). For a detailed protocol, see Appendix N. 
5.2.5 Total RNA isolation and miRNA profiling 
Three populations of cells (GFPhigh, GFPlow and GPFnegative) from each colon were 
directly sorted into miRVana lysis solution provided by the mirVana miRNA Isolation 
Kit (Ambion, Austin, TX). Total RNA enriched with miRNA was isolated according to 
the manufacturer’s instructions (Figure 23(B)). The quantity of isolated RNA was 
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measured using Nanodrop (Thermo Scientific, Wilmington, DE) and by Quant-iTTM 
Ribogreen RNA Assay Invitrogen, CA). RNA quality was also assessed using an Agilent 
2100 Bioanalyzer (Agilent Technologies, CA). For protocol details, see Appendix L. 
5.2.6 miRNA profiling 
 The expression of 384 mature miRNAs was determined using the TaqMan 
Rodent Panel Low Density Arrays Panel A (Applied Biosystems, CA) according to the 
manufacturer’s instructions.  For a detailed protocol, see Appendix O. 
5.2.7 Statistics 
Two-hundred sixty-eight miRNAs were disqualified due to low (close to 
background level) expression.. The resultant readings were then normalized by global 
mean, global median, RNU6B (housekeeping gene) or a group of miRNAs whose 
expression were not altered in the treatments (Appendix N.7).  On comparing the four 
methods, global median was found to be an appropriate normalization method, since the 
overall variance was reduced. After normalization, the data were then analyzed by the 
Mann-Whitney or Wilcoxon signed rank non-parametric tests based on the 
comparisons(393). P values were obtained and significantly different miRNAs (P < 
0.05) with a fold change >1.3 or <0.7 were selected for further analyses. Fold change 
was calculated for different comparisons by taking the arithmetic mean of one treatment 
divided by the other. Standard error bars were plotted in order to document the variation 
in the population mean. The analysis pipeline is described in Appendix O. 
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Figure 23. Experimental design. (A) Lgr5high (stem cells), Lgr5low (daughter cells) and 
Lgr5negative (differentiated cells) from Lgr5-EGFP-IRES-creERT2 mice were sorted. (B) Using the 
TaqMan low density array (microfluidic card) platform, miRNA profiling was carried out on 
FACS sorted samples and data analyses were performed to determine the expression of miRNAs 
in the three different cell populations. 
 
5.3 Results 
5.3.1 Enumeration of aberrant crypts foci (ACF) in carcinogen injected mice fed 
bioactive dietary agents 
Whereas AOM-injected mice developed aberrant crypt foci, their saline treated 
counterparts did not. Therefore, all aberrant crypt results represent AOM-injected groups 
only. AOM injected mice fed the corn oil + cellulose diet exhibited a greater number of 
total ACF (P <0.05) and (high multiplicity) HM-ACF (P <0.05) compared to fish oil + 
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pectin + AOM treatment (Figure 24). This demonstrates that the fish oil + pectin diet 
suppressed the carcinogenic effects of AOM. 
 
 
  A                                                               B 
 
 
 
 
 
 
Figure 24.  Effect of diet on aberrant crypt foci (ACF). (A) Mice injected with AOM and fed 
with a corn oil + cellulose diet (CCA) had increased total ACF and (B) HM ACF compared to 
those fed with the fish oil + pectin diet (FPA). All mice were injected with AOM. Bars with 
different letters are significantly different (P <0.05). Data represent means + SEMs from 11 mice 
per treatment. 
 
 
5.3.2 Assessment of global miRNA expression in colon adult stem cells 
To globally assess the miRNA profiles in stem/progenitors cells, FACS sorting 
was used to isolate stem cells (GFPHigh), daughter cells (GFPlow) and differentiated cells 
(GFPnegative). Using a TaqManTM PCR approach, 111 mature miRNAs (critical threshold 
(ct) <35) were detected in all three cell types (n = 20 samples per each cell type) (Table 
11). In order to identify the spatial expression of miRNAs, expression profiles in 
intestinal stem cells vs. differentiated cells (GFPhigh vs. GFPnegative), daughter stem cells 
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vs. differentiated cells (GFPlow vs. GFPnegative) and stem cells vs. daughter stem cells 
(GFPhigh vs. GFPlow) were compared.  Expression profiles were used to identify miRNA 
programs that mark the transition from stem cells to differentiated cells (Table 12, 
Figure 25). As seen in Table 12, out of 111 miRNAs expressed in the colon, twenty-
nine were differentially expressed. Sixteen miRNAs were expressed at higher (P<0.05) 
levels in GFPhigh cells relative to GFPlow cells. In contrast, thirteen miRNAs were 
expressed at lower (P<0.05) levels in GFPhigh cells compared with GFPnegative cells. 
In order to determine whether there was evidence of differential expression of 
miRNAs in daughter cells, miRNA expression between GFPlow vs. GFPnegative were 
compared.  Twenty six miRNAs were significantly affected by location. Nine miRNAs 
were expressed at higher (P<0.05) levels in GFPlow compared to GFPnegative cells (Table 
13). In contrast, seventeen miRNAs were expressed at lower (P <0.05) levels in GFPlow 
compared with GFPnegative cells. 
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Table 11. Ct values of 113 miRNAs expressed in mouse colonic epithelial cells. Expression of 
miRNAs was quantified by reverse transcription using miRNA-specific primers followed by 
real-time PCR TaqMan low-density arrays. Ct values represent means of 60 samples, mmu, 
mouse; rno, rat; Ct, cross threshold. 
miRNA Ct values miRNA Ct values miRNA Ct values 
mmu-miR-31 11.44 mmu-miR-99a 26.67 mmu-miR-224 28.92 
rno-miR-190b 14.92 mmu-miR-671-3p 26.81 mmu-let-7g- 28.94 
mmu-miR-872 17.72 mmu-miR-215 26.81 mmu-miR-103 28.95 
mmu-miR-124 20.88 mmu-miR-151-3p 26.9 mmu-miR-320 29 
mmu-miR-124 20.88 mmu-let-7b 26.96 mmu-miR-218 29.02 
mmu-miR-128a 20.99 mmu-miR-203 26.97 mmu-miR-30d 29.2 
mmu-miR-429 21.89 mmu-miR-484 27.02 mmu-miR-125b-5p 29.2 
mmu-miR-148b 22.68 mmu-miR-29a 27.11 mmu-miR-125b-5p 29.2 
mmu-miR-324-5p 22.88 mmu-miR-29b 27.24 mmu-miR-205 29.63 
mmu-miR-322 23.04 mmu-miR-340-5p 27.41 mmu-miR-18a 29.63 
mmu-miR-142-3p 23.43 mmu-miR-139-5p 27.43 mmu-miR-195 29.68 
mmu-miR-142-3p 23.43 mmu-miR-15b 27.43 mmu-miR-28 29.7 
mmu-miR-192 23.51 mmu-miR-139-5p 27.43 mmu-miR-574-3p 29.83 
mmu-miR-200a 23.75 mmu-miR-93 27.49 mmu-miR-101a 29.83 
mmu-miR-423-5p 23.88 mmu-let-7e 27.55 mmu-miR-29c 30.01 
mmu-miR-375 23.94 mmu-miR-20b 27.71 rno-miR-345-3p 30.02 
mmu-miR-10b 24.03 mmu-miR-27b 28.01 mmu-miR-301b 30.12 
mmu-miR-19b 24.16 mmu-miR-30a 28.04 mmu-miR-146b 30.29 
mmu-miR-30c 24.31 mmu-miR-27a 28.04 mmu-miR-146b 30.29 
mmu-miR-92a 24.36 mmu-miR-148a 28.06 mmu-miR-744 30.34 
mmu-miR-191 24.43 mmu-miR-222 28.13 mmu-miR-331-3p 30.37 
mmu-miR-30b 24.75 mmu-miR-141 28.18 mmu-miR-186 30.38 
mmu-miR-24 24.78 mmu-miR-188-5p 28.19 mmu-miR-196b 30.39 
mmu-miR-126-3p 24.79 mmu-miR-106b 28.22 mmu-miR-340-3p 30.44 
mmu-miR-17 24.91 mmu-miR-19a 28.23 mmu-miR-301a 30.45 
mmu-miR-17 24.91 mmu-let-7d 28.23 mmu-miR-130b 30.49 
mmu-miR-194 24.92 mmu-miR-25 28.24 mmu-miR-193b 30.68 
mmu-miR-200b 24.99 rno-miR-196c 28.46 mmu-miR-155 30.77 
mmu-miR-34b-3p 25.05 mmu-miR-130a 28.46 mmu-miR-155 30.77 
mmu-miR-20a 25.16 mmu-miR-100 28.5 mmu-miR-152 30.8 
mmu-miR-106a 25.16 mmu-miR-30e 28.57 mmu-miR-23b 30.98 
mmu-miR-200c 25.38 mmu-miR-182 28.57 mmu-miR-183 31.39 
mmu-let-7c 25.74 mmu-miR-328 28.59 mmu-miR-125a-5p 31.84 
mmu-miR-16 25.98 mmu-let-7i 28.68 mmu-miR-181a 31.94 
mmu-miR-10a 26.11 mmu-miR-26b 28.84 mmu-miR-181a 31.94 
mmu-miR-145 26.32 mmu-miR-140 28.86 mmu-miR-181c 34.76 
mmu-miR-26a 26.33 mmu-miR-140 28.86   
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Table 11. continued 
 
miRNA 
Ct 
values miRNA 
Ct 
values miRNA Ct values 
mmu-miR-21 26.48 mmu-miR-146a 28.87   
 
 
Comparison of the significantly differentially expressed miRNAs between 
GFPhigh vs. GFPnegative, and GFPlow vs. GFPnegative cells revealed that seven miRNAs that 
were commonly downregulated and ten were upregulated in both stem cells and 
daughter cells compared to differentiated cells (Figure 25). These data suggest that stem 
cells and their daughter cells exhibit a similar miRNA profile. In contrast, miRNA 
profiles in stem cells and differentiated cells were quite distinct.  
 
 
 
 
 
 
 
 
Figure 25. Common differentially expressed miRNAs in GFPhigh and GFPlow cells.  The Venn 
diagram indicates the number of differentially expressed miRNAs in GFPhigh vs. GFPnegative cells 
and GFPlow vs. GFPnegative cells (n=20 mice per cell type). 
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Table 12. Differentially regulated miRNAs in GFP
high
 compared with
 
GFP
negative
 cells. 
Expression of miRNAs were quantified as described in Table 11. GFPhigh stem cells (n=20); 
GFPnegative cells (n=20). Only miRNAs with P <0.05 are shown.  mmu, mouse; rno, rat. 
 
Upregulated in GPFhigh   
 
Downregulated in GPFhigh   
miRNA 
Expression 
ratio 
GFPhigh/ 
GFPnegative P-value 
 
miRNA 
Expression 
ratio 
GFPhigh/ 
GFPnegative P-value 
mmu-miR-155 2.63 0.034 
 
mmu-miR-652 0.31 0.001 
mmu-miR-342.3p 2.29 0.000 
 
mmu-miR-27a 0.42 0.001 
rno-miR-345-3p 2.24 0.040 
 
mmu-miR-215 0.43 
5.72E-
06 
rno-miR-190b 1.99 0.027 
 
mmu-miR-30d 0.51 0.024 
mmu-miR-17 1.72 
6.29E-
05 
 
mmu-miR-7b 0.52 0.040 
mmu-miR-191 1.68 0.000 
 
rno-miR-224 0.53 0.002 
mmu-miR-20b 1.46 0.011 
 
mmu-miR-532 5p 0.53 0.008 
mmu-miR-106a 1.46 0.024 
 
mmu-miR-21 0.56 0.012 
mmu-miR-218 1.45 0.003 
 
mmu-miR-124 0.63 0.031 
mmu-miR-186 1.42 0.008 
 
mmu-miR-30a 0.63 0.001 
mmu-miR-125a-5p 1.39 0.031  mmu-miR-29a 0.64 0.019 
mmu-miR-92a 1.29 0.017 
 
mmu-miR-200b 0.65 0.008 
mmu-miR-146b 1.27 0.044 
 
mmu-let-7g 0.66 0.040 
mmu-miR-200a 1.27 0.019 
 
mmu-miR-103 0.69 0.031 
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Table 13. Differentially regulated miRNAs in GFPlow compared with GFPnegative cells. 
Expression of miRNAs were quantified as described in Table 11. GFPlow stem cells (n=20); 
GFPnegative cells (n=20). Only miRNAs with P <0.05 are shown.  mmu, mouse; rno, rat. 
 
 
 
 
 
 
 
       Upregulated in  GFPlow   
 
Downregulated in  GPFlow   
miRNA 
Expression 
ratio 
GFPlow/ 
GFPnegative P-value 
 
miRNA 
Expression 
ratio 
GFPlow/ 
GFPnegative P-value 
mmu-miR-155 2.88 0.029 
 
mmu-miR-27a 0.39 5.34E-05 
mmu-miR-342-3p 2.23 0.001 
 
mmu-miR-128a 0.41 0.008 
mmu-miR-106a 1.70 0.007 
 
mmu-miR-652 0.43 0.002 
mmu-miR-20b 1.63 0.001 
 
mmu-miR-215 0.47 0.001 
mmu-miR-31 1.55 0.013 
 
mmu-miR-29a 0.54 0.012 
mmu-miR-17 1.51 0.000 
 
mmu-miR-484 0.55 1.53E-05 
mmu-miR-218 1.37 0.004 
 
mmu-miR-30d 0.58 0.001 
mmu-miR-93 1.30 0.015 
 
mmu-miR-200c 0.62 0.001 
mmu-miR-92a 1.28 0.009 
 
mmu-miR-532-5p 0.62 0.036 
    
mmu-miR-30a 0.63 0.001 
    
mmu-miR-21 0.64 0.030 
    
mmu-miR-331-3p 0.66 0.027 
    
mmu-miR-365 0.66 0.040 
    
rno-miR-224 0.68 0.036 
    
rno-miR-196c 0.68 0.044 
    
mmu-miR-28 0.69 0.035 
   
mmu-miR-200b 0.69 0.015 
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5.3.3. miR-125a-5p, miR-190 and miR-191 are differentially expressed in stem cells 
compared to daughter cells 
 In order to determine if certain miRNAs were uniquely expressed in stem cells, 
miRNA in stem cells (GFPhigh) and daughter stem cells (GFPlow) were compared. We 
observed that miR-125a-5p, miR-190 and miR-191 were enriched in the stem cells 
compared to daughters cells (Figure 26). Interestingly, miR-190, miR-191 and miR-
125a-5p were also significantly (P <0.05) upregulated in stem cells compared to 
differentiated cells (Table 13). This suggests that miR-190, miR-191 and miR-125a-5p 
may be required by stem cells and their expression decreases as cells differentiate. 
 
 
 
 
 
 
 
 
 
Figure 26. miR-125a-5p, miR-190b and miR-191 are intestinal stem cell specific miRNAs. 
Data represent normalized miRNA expression (means + SEM, for details, see Materials and 
methods). miRNA profiling in stem cells (GFPhigh), daughter cells (GFPlow) and differentiated 
cells (GFPnegative) by real time PCR was used to quantify miR-125a-5p, miR-190b and miR-191 
expression. Bars with different letters are statistically different (P < 0.05). (n=20 per cell type).  
mmu, mouse; rno, rat.  
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5.3.4. Diet modulates stem cell miRNAs following  exposure to carcinogen and saline 
(control) 
To determine the effects of chemoprotective diets on stem cell miRNAs, single 
cells isolated from the colon of carcinogen injected mice fed corn oil + cellulose (CCA) 
or fish oil + pectin (FPA) diet were FACS sorted to obtain stem cells ,daughter cells and 
differentiated cells. Global miRNA profiling was subsequently performed. As shown in 
Table 14, seventeen miRNAs were differentially expressed (P <0.05), fifteen of which 
were upregulated and two miRNAs were downregulated in CCA vs. FPA treatment. 
These miRNAs were not significantly changed in the stem cells in presence of saline 
(CCS vs. FPS) (Table 14). Moreover, miR-21, that was downregulated in stem cells 
compared to differentiated cells, was upregulated in stem cells, specifically by CCA 
(Figure 27).  
With respect to dietary fat x fiber effects in presence of carcinogen (CCA vs. 
FPA) in differentiated cells (GFPnegative), nineteen miRNAs were significantly (P <0.05) 
altered (Table 15). Out of the nineteen miRNAs, miR-19b and miR-18a were 
significantly (P <0.05) downregulated in CCA compared to FPA. This is consistent with 
a previous study where colonic scraping was used to assess miRNA expression in CCA 
vs. FPA treatments in rats (151). These miRNAs were not altered in the differentiated 
cells (GFPnegative) when fat x fiber effects were analyzed in presence of saline (i.e CCS 
vs. FPS) (Table 15) 
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A                                                                          B 
 
 
 
 
 
 
 
 
Figure 27.  Diet and carcinogen modulate miR-21 in intestinal stem cells. (A) Expression of 
miR-21 in stem cells (GFPhigh), daughter cells (GFPlow), and in differentiated cells (GFPnegative), 
n=20 mice per cell type. (B) Expression of miR-21 in intestinal stem cells (GFPhigh) from Lgr5-
EGFP-IRES-creERT2 knock in mice injected with azoxymethane (AOM) and fed a corn oil + 
cellulose diet (CCA) or fish oil + pectin diet (FPA), n=5 mice per treatment). Bars with different 
letters are statistically different (P < 0.05). Data represent means + SEMs of normalized miRNA 
expression (for normalization and statistical analyses details, please refer to Materials and 
methods). 
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Table 14. Effect of diet on miRNA expression in GFP
high
 sorted cells. Expression of miRNAs 
was quantified as described in Table 11.  CCA, Corn oil + cellulose + azoxymethane (AOM) (n 
= 5); FPA, Fish oil + pectin + AOM (n = 5); CCS, Corn oil + cellulose + saline (n = 5); FPS, 
Fish oil + pectin + saline (n = 5); GFPhigh, stem cells. Only miRNAs with P <0.05 are shown. 
         
               Carcinogen injection 
               
 
 
 
 
 
 
 
 
 
 
                 
 
  Saline Injection 
 
 
 
 
 
 
 
miRNA 
Expression ratio  
CCA-GFPhigh / 
FPA-GFPhigh P-value 
mmu-miR-106b 2.46 0.028 
rno-miR-190b 2.32 0.050 
mmu-miR-27b 2.24 0.027 
mmu-miR-21 2.19 0.047 
mmu-miR-31 2.01 0.043 
mmu-miR-26b 2.00 0.028 
mmu-miR-200a 1.83 0.009 
mmu-miR-26a 1.68 0.016 
mmu-miR-29c 1.59 0.016 
mmu-miR-182 1.55 0.025 
mmu-miR-30c 1.47 0.047 
mmu-miR-203 1.47 0.016 
mmu-miR-30a 1.40 0.047 
mmu-miR-19b 1.33 0.034 
mmu-miR-24 1.29 0.047 
mmu-miR-181a 0.56 0.028 
mmu-miR-101a 0.49 0.050 
miRNA 
Expression ratio  
P-value 
CCS-GFPhigh / 
FPS-GFPhigh 
mmu-miR-188-5p 5.25 0.027 
mmu-miR-218 0.57 0.016 
mmu-miR-125a-5p 0.52 0.047 
mmu-miR-574-3p 0.47 0.028 
mmu-miR-200c 0.47 0.047 
mmu-miR-222 0.43 0.016 
mmu-miR-429 0.31 0.034 
mmu-miR-106a 0.12 0.047 
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Table 15.  Effect of diet and carcinogen combination on miRNA expression in GFPnegative 
sorted cells. Expression of miRNAs was quantified as described in Table 11.  CCA, Corn oil  + 
cellulose + azoxymethane (AOM) (n = 5); FPA, Fish oil  + pectin  + AOM (n = 5); CCS, Corn 
oil  + cellulose + saline (n = 5); FPS, Fish oil  + pectin  + saline (n = 5); GFPneg, differentiated 
cells. Only miRNAs with P <0.05 are shown. 
 
                             Carcinogen Injection 
 
 
 
 
 
 
 
 
 
 
 
                      Saline Injection 
 
 
 
 
 
 
miRNA 
Expression ratio  
CCA-GFPneg / 
FPA-GFPneg P-value 
mmu-miR-29b 3.84 0.025 
mmu-miR-142-3p 3.30 0.043 
mmu-miR-99a 2.38 0.050 
mmu-miR-188-5p 2.31 0.050 
mmu-let-7e 2.14 0.016 
mmu-miR-27a 1.84 0.034 
mmu-miR-186 1.47 0.050 
mmu-let-7c 1.33 0.047 
mmu-let-7d 1.26 0.034 
mmu-miR-10a 0.63 0.034 
mmu-miR-19b 0.61 0.009 
mmu-miR-484 0.54 0.028 
mmu-miR-365 0.45 0.014 
mmu-miR-103 0.45 0.034 
mmu-miR-19a 0.43 0.028 
mmu-miR-18a 0.41 0.050 
miRNA 
Expression ratio  
CCS -GFP neg / 
FPS-GFPneg P-value 
rno-miR-345-3p 2.90 0.014 
mmu-miR-146a 1.77 0.009 
rno-miR-196c 1.50 0.028 
mmu-miR-140 1.43 0.016 
mmu-miR-200b 0.61 0.028 
mmu-miR-181a 0.56 0.047 
mmu-miR-126-3p 0.37 0.025 
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5.4. Discussion 
Recent findings lend support to the concept that in some circumstances, 
carcinogen exposure can perturb homeostasis within the stem cell compartment and 
promote malignant transformation (394). “Adult” somatic cells of the colon are of 
particular interest because they sustain self-renewal capacity and are targets for cancer 
initiating mutations (218, 219). Lgr5 is regarded as a specific marker for identification of 
intestinal stem cells (225). Therefore it is important to know precisely how intestinal 
stem cell populations respond to environmental factors, specifically bioactive dietary 
agents. 
To date, the effect of n-3 PUFA/pectin on miRNAs in stem cells during initiation 
of colon cancer has not been documented. Hence, in this study we used the Lgr5-EGFP-
IRES-creERT2 knock in mouse model to examine miRNA expression profiles in stem 
cells, daughter and differentiated cells.  Moreover, since transformation of adult stem 
cells is an extremely efficient route towards initiation of intestinal cancer (228), Lgr5-
EGFP-IRES-creERT2 knock in mice were injected with azoxymethane (AOM, a colon 
carcinogen) and the response to a chemoprotective n-3 PUFA / fermentable fiber diet 
was assessed. The AOM-induced colon tumor model was selected because it provides a 
clear distinction between tumor initiation and promotion (43). 
We hypothesized that the miRNA expression profiles would differ between stem 
cells and differentiated cells. Of the 384 rodent miRNAs identified, twenty nine 
miRNAs in stem cells were significantly altered compared to differentiated cells (Table 
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12). Seventeen out of the twenty-nine miRNAs shared similar patterns of expression in 
daughter and differentiated cells (Figure 24). Also, miR-215 was reduced in both stem 
cells and daughter stem cells compared to differentiated cells. These results are 
consistent with recent findings that miR-215 regulates G1 and G2-M cell cycle arrest 
(395, 396). Stem cells need to proliferate to maintain the continuously self-renewing 
intestinal epithelium and hence components responsible for cell cycle arrest are 
generally repressed. 
miR-17 and miR-92a are members of a well-known miRNA cluster miR-17-92 
(397), and were highly expressed in both stem cells and daughter stem cells. In addition, 
miR-106a, a member of the miR-106a-363 cluster (a paralog of the miR-17-92 cluster) 
was also highly expressed in stem cells. Recent studies have reported similar findings 
wherein in the hematopoietic compartment, miR-17-92 is highly expressed in stem cells 
and early progenitors and decreased upon onset of myeloid and lymphoid differentiation 
(148, 322, 398) and during in vitro differentiation of acute leukemia blast cells (399, 
400). 
 To determine stem cell specific miRNAs, miRNA profiles were compared in 
GFPhigh and GFPlow cells. Interestingly, three miRNAs, miR-125a-5p, miR-190 and miR-
191 exhibited significantly (P <0.05) higher levels in the stem cells compared to the 
daughter cells and the differentiated cells (Figure 26). These miRNAs were not 
differentially expressed in daughter stem cells compared with differentiated cells, 
suggesting that they might serve a specific role in intestinal stem cells. Additional 
studies are needed to elucidate the role of these miRNAs in colon cancer.  
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An interesting outcome of this study was the fact that effects of the 
chemoprotective diet on miR-21 expression was dependent on cell location within the 
crypt. Upon comparison of miRNA expression profiles in stem cells obtained from mice 
fed a corn oil + cellulose vs fish oil + pectin diet in the presence of carcinogen (i.e. 
CCA-GFPhigh vs. FPA-GFPhigh), miR-21 was significantly upregulated in the CCA group 
compared to FPA. However, diet did not influence miR-21 levels in daughter cells or 
differentiated cells.  The fact that, diet and carcinogen in stem cells selectively increase 
miR-21 expression stem cells demonstrates for the first time that intestinal stem cells are 
uniquely sensitive to environmental factors. This is noteworthy because, miR-21, a well-
known “oncomiR” upregulated in several cancers, including colon cancer, is 
downregulated by other bioactive dietary agents such as resveratrol, docosahexanoic 
acid (DHA), retinoic acid and curcumin in several cancers, along with the upregulation 
of one of its targets, e.g., PTEN, a well-known tumor suppressor (175, 198, 401-403) 
(Figure 28). With respect to cell location within the colonic crypte, miR-21 was 
significantly reduced (P <0.05) in stem cells compared to differentiated cells (Figure 
27). Recent studies examining embryonic stem cells have reported similar findings, 
wherein miR-21 expression increased following induction of mouse embryonic stem cell 
differentiation (404, 405). Additionally, REST (RE1- silencing transcription factor), a 
key gene that maintains the self-renewal and pluripotency of mouse embryonic stem 
cells, inhibits the biogenesis of miR-21 in embryonic stem cells. Moreover, using gain 
and loss of function studies targeting pre-miR-21, miR-21 was shown to be one of the 
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regulators of self-renewal in mouse ES cells. Also, bioinformatics analyses showed that 
miR-21 is predicted to target Nanog and Sox2, which are markers of self-renewal (405). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. miR-21 is targeted by chemoprotective bioactive dietary agents. miR-21, a well-
defined oncogene is downregulated by several dietary agents such as resveratrol, oleic acid, 
DHA, retinoic acid and curcumin in different cancer cell types, resulting in the upregulation of 
one of its targets-PTEN, a well-known tumor suppressor. Colorectal cancer cells treated with 
curcumin decreased AP-1, a transcription factor which reduced mature miR-21 formation. This  
is associated with decreased cell proliferation, tumor growth, invasion and in vivo metastasis and 
repression of its downstream target-CSF1. DHA, docosahexanoic acid; AP-1, activator protein 1; 
PTEN, phosphatase and tensin homolog; CSF, colony stimulating factor 1. 
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Another interesting outcome of the study was that dietary bioactive agents could 
differently modulate miRNAs based on their location in the colonic crypt. In, stem cells, 
miR-19b, miR-27b, miR-26b and miR-203 were upregulated by CCA compared to FPA. 
However, in differentiated cells, miR-19b and miR-18a were significantly 
downregulated (P <0.05) in CCA fed mice, which was also observed in our previous 
study in which scraped mucosa (containing heterogeneous population of cells) from the 
rat colon was used  (151). The scrapped mucosa predominantly contains differentiated 
cells. Hence, these data suggest that stem cells respond uniquely to dietary agents. 
In order to elucidate the role of miRNAs in stem cells, it is important to 
determine the function of these miRNAs by identifying their targets. This can be 
determined by performing global mRNA profiling by RNA sequencing from the same 
samples that were used to determine the miRNA changes. An integrative analysis can be 
performed by combining mRNA expression and miRNA expression with the help of 
miRNA target prediction.  
In summary, our data indicate for the first time that select dietary cues can impact 
stem cell regulatory networks, in part, by modulating the steady-state levels of miRNAs 
such as miR-19b, miR-21, miR-26b and miR-203. To our knowledge, this is the first 
study to utilize Lgr5+ reporter mice to determine the impact of diet and carcinogen on 
miRNA expression in intestinal stem cells.  
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6. SUMMARY AND CONCLUSIONS 
 
 
6.1 Summary 
In rats injected with carcinogen, administration of fish oil + pectin (FPA) vs 
control (corn oil + cellulose (CCA)) diet upregulated miR-19b, miR-26b and miR-203, 
while downregulating the mRNA and the protein expression of their respective targets – 
PTK2B, PDE4B and TCF4 in colonic mucosa.  Upregulation of these miRNAs increased 
apoptosis and decreased cell proliferation. These data suggest that fish oil + pectin diet 
protects against carcinogen induced colon tumorigenesis, in part, by modulating the 
above mentioned miRNAs and their targets. Additionally, we demonstrated for the first 
time that miR-125a-5p, miR-190 and miR-191 are enriched in colon stem cells 
compared to differentiated cells. Moreover, FPA compared to CCA, specifically 
modulated the expression of miR-18a, miR-19b, miR-26b and miR-203 based on their 
location in the colonic crypt. Also, FPA decreased the expression of miR-21, an 
“oncomiR” specifically in the stem cells compared to CCA. The effect of fish oil + 
pectin combination on miRNA expression and their targets on mucosal physiology is 
summarized in Figures 29 and 30. 
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Figure 29. Fish oil and pectin combination alters expression of miRNAs in the colonic 
crypt. In AOM injected Sprague Dawely rats, the chemoprotective diet i.e., fish oil + pectin 
(FPA) feeding, increased the expression of miR-18a, miR-19b, miR-26b and miR-203 and 
decreased the expression of target genes, PTK2B, PDE4B and TCF4 in a mixed (heterogeneous) 
population of mucosal colonic cells. FPA as compared to CCA increased apoptosis and reduced 
cell proliferation. In AOM injected C57BL/6 mice, FPA also increased the expression of miR-
18a and miR-19b in differentiated cells, while decreasing their levels in stem cells. Solid arrows 
show observations, while dashed arrows indicate the predicted associations. PTK2B, protein 
tyrosine kinase 2 beta; PDE4B, phosphodiesterase 4B; TCF4, transcription factor 4.  
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Figure 30. Expression of miR-21 in rodents. Expression of miR-21 was higher in a mixed 
(heterogeneous) population of mucosal colonic cells from AOM injected rats compared to saline 
(control) injected Sprague Dawley rats. In C57BL/6 mice, expression of miR-21 was also higher 
in differentiated cells compared to stem cells. In AOM injected mice, fish + pectin diet decreased 
the expression of miR-21 specifically in the stem cells as compared to corn oil cellulose diet. 
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6.2 Conclusions 
miRNAs target critical genes known to regulate apoptosis, cell proliferation and 
differentiation (63-69, 73, 75-78, 406).  
The role for n-3 PUFA in prevention and treatment of colon cancer is well 
documented, but the efficacy of n-3 PUFA is still a matter of contention. Despite cogent 
scientific evidence indicating the protective effect of fish oil and fiber, there is a lack of 
data regarding the molecular mechanisms by which these dietary agents protect against 
colon tumorigenesis, especially with respect to the role of miRNAs. Hence, we 
determined whether the synergistic effects of chemoprotective dietary n-3 PUFA and 
fermentable fiber are mediated by impacting intestinal miRNA signatures.   
In the absence of comprehensive human data, the azoxymethane (AOM) 
chemical carcinogenesis model serves as one of the most definitive means of assessing 
human colon cancer risk (265, 281). Therefore, the first portion of the study was 
designed to determine the effects of cancer progression on miRNA expression in rats 
exposed to AOM. We observed that common global miRNA expression patterns (for 
example, miR-21) exist in human and rat colon tumors, confirming the utility of the 
model. In addition, n-3 PUFA-enriched chemoprotective diets suppressed the effects of 
AOM on let-7d, miR-15b, miR-107, miR-191 and miR-324-5p. We also demonstrated 
that BACE1 and PTEN are targets of miR-107 and miR-21, respectively (Section 2).  
To further elucidate the biological effects of diet and carcinogen on miRNAs, we 
integrated global miRNAs, total and polysomal gene expression datasets obtained from 
the above mentioned study. Four complementary computational approaches were 
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utilized, including gene set enrichment analysis (GSEA), coherent analysis, linear 
discriminant analysis (LDA) and pathway analysis in the context of three biological 
conditions: (a) tumor vs saline; (b) dietary fat effects in the presence of carcinogen (CA 
vs. FA); and (c) dietary fat x fiber interaction (CCA vs. FPA) in the presence of 
carcinogen (Section 3). miR-206 was significantly enriched with respect to both total 
and polysomal mRNA targets. These data suggest that polysome tracking of transcripts 
and miRNAs play an important role in experimental colon carcinogenesis. Using 
coherent expression analysis of miRNAs and their targets in the above mentioned 
comparisons, we identified several miRNAs, e.g. miR-15b, miR-103, and miR-107 
which were significantly altered in tumor vs saline comparisons along with their 
predicted targets. With respect to diet, miR-19b, miR-26b, miR-200c and miR-203 and 
their putative targets PTK2B, IGF1R, PDE4B and TCF4, respectively, were modulated. 
(Section 3).  These results demonstrate for the first time a novel role for fish oil/pectin 
feeding in protecting the colon from carcinogen–induced miRNAs dysregulation. 
Importantly, the data link dietary fish oil/pectin treatment with canonical pathways 
regulating intestinal stem cell fate. 
In complementary experiments (Section 4), we further elucidated the biological 
role of miR-19b, miR-26b and miR-203 in colon cancer. Using a series of loss and gain 
of function experiments along with luciferase reporter assays, we demonstrated that 
PDE4B and TCF4 are direct targets of miR-26b and miR-203, respectively. PTK2B was 
an indirect target of miR-19b. Also, phenotypic assays showed that these miRNAs 
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confer protection against colon cancer by increasing apoptosis and decreasing cell 
proliferation.  
Our data demonstrate that chemoprotective diets are capable of modulating key 
intestinal stem cell regulators. For example, TCF4, a key component of the Wnt 
signaling pathway which is essential for intestinal stem cells, was suppressed by the fish 
oil + pectin diet following exposure to AOM (Section 3). As described in Section 5, we 
demonstrated that based on the relative expression of miR-125a-5p, miR-190b and miR-
191, these miRNAs may be stem cell specific miRNAs.  With respect to the effect of 
dietary fat x fiber in presence of carcinogen (CCA vs. FPA) on miRNA expression in 
intestinal stem cells, we noted that miR-19b, miR-18a and miR-27b were altered in a 
manner similar to our previous studies, which utilized colonic scraped mucosa to assess 
miRNA expression. We also identified miR-21, a well-known “oncomiR” in colon 
cancer, to be significantly reduced in stem cells compared to differentiated cells.  
Interestingly, miR-21 was selectively upregulated by corn oil - cellulose feeding in only 
stem cells, but not in daughter or differentiated cells. This suggests that stem cells 
selectively respond to environmental factors. In order to understand the mechanism of 
action of these miRNAs, integration of miRNAs with mRNA expression datasets should 
be carried out as described above.  
The work described herein is noteworthy and elucidates mechanisms by which n-
3 PUFA inhibit colon carcinogenesis. Understanding the effect of bioactive dietary 
factors on miRNA expression and function may provide insight on prevention strategies 
to reduce the burden on cancer. In colon cancer, cancer stem cells play an important role 
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in cancer recurrence. Hence, in order to develop therapies to target these cells, it is 
important to identify the regulatory mechanisms and signaling pathways that impact the 
colon stem cell niche. Results from our study and the published literature point to the 
ability of bioactive food components to modify the self-renewal capabilities of cancer 
stem cells by modifying molecular targets (407, 408). 
 
6.3 Future directions 
 The research presented herein sets the groundwork for a number of future studies 
that could further explore the effects of omega-3 PUFA and fermentable fiber on 
intestinal miRNAs and their targets. 
6.3.1 Validation of in vivo results 
We determined that FPA treatment in mice increased the expression of miR-26b 
and miR-203, while decreasing the expression of their targets, PDE4B and TCF4, 
respectively. In vitro models are a powerful tool to determine the mechanism of action of 
dietary agents on modulation of miRNA expression (409). Hence, in order to determine 
how bioactive dietary agents modulate miRNA expression, the first step would be to 
recapitulate the results seen in vivo study (Section 2 and 3) by treating HCT116 cells 
with bioactive dietary agents such as DHA and EPA (main components of fish oil) and 
butyrate (fermented product of pectin) and assessing the mRNA and protein expression 
of miR-26b and miR-203 and their respective targets. HCT116 is a human colon cancer 
cell line, which has a mutation in serine at codon 45 of β-catenin. This is one of the 
amino acid residues typically mutated in several tumors (410, 411). This cell line also 
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has genetic mutations of K-RAS, MLH1, PIK3CA (412, 413) and the expression for 
dinucleotide-repeat (microsatellite instability) similar to human hereditary nonpolyposis 
colon cancers (414). Moreover, the HCT116 cell line has been utilized to probe the 
synergy between DHA and butyrate with respect to apoptosis (58). Future experiments 
should validate the in vivo results and also determine that HCT116 cell line can be 
utilized to evaluate the effects of nutritional bioactives on downstream mediators of 
PDE4B and TCF4.  
6.3.2 Determining downstream mediators of PDE4B in the colon  
In this study, FPA increased the expression of miR-26b while reducing the 
expression of its targets-PDE4B as compared to CCA. Moreover, we also demonstrated 
that induction of miR-26b induced apoptosis. Previous studies from the lab have 
demonstrated that fish oil + pectin combination enhances colonocyte apoptosis in colon 
cancer (58, 59, 247, 415). In order to determine how miR-26b induces apoptosis in 
colonic cells, it is necessary to probe the downstream mediators of one of its targets, 
PDE4B. In diffuse large B-cell lymphoma, it was shown that inhibition of PDE4B 
activated c-AMP induced apoptosis, which was associated with inhibition of the 
phosphatidylinositol 3- kinase (PI3K)/ AKT pathway (329). However, this mechanism 
of action has not been determined in colonic cells. Hence, one potential way to study this 
would be to treat HCT116 cells with rolipram, a PDE4B inhibitor (416) and measure the 
cellular cyclic-AMP levels. This will help to clarify the function of miR-26b in the 
intestine. 
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6.3.3 Determine methylation status of miR-203 promoter in colon cancer 
We have demonstrated that FPA increased miR-203 levels and decreased the 
expression of its target gene TCF4. There is evidence suggesting that in cancer, due to 
the hypermethylation of miR-203 promoter, transcription of miR-203 is reduced (351, 
417, 418). Therefore, it would be interesting to determine if bisulfite reactions indicate a 
differential methylation pattern at the mir-203 promoter locus. This would determine 
whether epigenetic modifications such as DNA methylation alterations are modulated by  
dietary n-3 PUFA and fiber in colonic cells and mediate miRNA expression.  
6.3.4  Role of miR-203 in invasion and migration in colon cancer 
miR-203 has been shown to inhibit tumor cell migration and invasiveness in 
prostate, breast and esophageal squamous cell cancers, partly by reducing the expression 
of several targets such as SNAI2 and LASP1 (351, 419-422). Moreover the target of 
miR-203, TCF4, was shown to promote invasion in breast cancer cells (422). However, 
the effect of miR-203 in invasion and migration is not yet known, hence, future studies 
should focus on determining the role of miR-203. One potential way to study this is to 
overexpress miR-203 in human colon cancer cells, followed by cell migration and 
wound healing assays. Also, tumorigenicity assays in vivo can be carried by 
transplanting HCT116 cells transfected with miR-203 mimics or inhibitors into 
xenograft nude mice.  Tumor growth can be assessed which will indicate the protective 
effect of miR-203 in colon cancer. This would provide a further understanding of the 
role of miR-203. 
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6.3.5 Determining downstream mediators of miRNAs enriched in stem cells 
We carried out a global miRNA profiling in mouse colonic stem cells, daughter 
stem cells and differentiated cells.  It was shown for the first time that miRNAs are 
differentially expressed in the three cell lineages. Also, the chemoprotective diet (fish oil 
+ pectin combination) in AOM injected mice (FPA) modulated expression of several 
miRNAs, such as miR-18a, miR-19b and miR-21 based on their location in the colonic 
crypt. There is evidence suggesting that miRNA-gene regulatory pathways establish 
stem cell identity (423, 424). However, to date the effect of these dietary agents on 
mRNA targets in stem cells during different stages (initiation, promotion and 
progression) of colon cancer development has not yet been elucidated. We hypothesized 
that FPA will suppress growth of colonocytes /crypts by regulating genes involved in 
stem cell signaling, in part through miRNA-mediated mechanisms. To elucidate the 
biological functions of these miRNAs, mRNA expression changes can be determined by 
performing global mRNA profiling by RNA sequencing from the same samples that 
were used to determine the miRNA changes. Hence, an integrative analysis can be 
performed by combining mRNA expression and miRNA expression with the help of 
miRNA target prediction. We predict that novel stem cell signaling networks and 
markers of intestinal stem cells will be identified (151, 375). 
6.3.6 Conditional expression of miR-21 in mouse colon stem cells 
One of the interesting observations from our study was the modulation of miR-21 
expression in stem cells. Specifically, we observed that miR-21 expression was higher in 
the differentiated cells compared to stem cells. Interestingly, the expression of miR-21 
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was significantly reduced by FPA vs control (CCA) treatment. This is noteworthy, 
because recent evidence has shown that miR-21 and its targets are modulated by several 
dietary agents in cancers of other tissue types (175, 198, 401-403). Hence, to elucidate 
the biological function of miR-21 in colon stem cells and to understand how 
chemoprotective diets modulate its expression, it is necessary to identify the targets of 
miR-21 and show that they are inversely correlated with miR-21 expression. One of the 
ways to determine the biological role of miR-21 is to use a mouse model that 
conditionally expresses miR-21 (425). The expression of miR-21 in this mouse model is 
Cre/loxP dependent and tetracycline-dependent at a Rosa26 locus. Hence, on crossing 
this mouse with Lgr5-EGFP, we can generate a mouse model that specifically 
overexpresses miR-21 in LGR5 positive stem cells. Dietary intervention studies in this 
model system, such as feeding with fish oil + pectin combination followed by 
assessment of changes in the expression of miR-21 and its downstream targets will help 
to elucidate the role of miR-21 in intestinal stem cell biology. 
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APPENDIX A 
 
LIST OF SEQUENCES OF MIRNA MIMICS, INHIBITORS & THEIR CONTROLS 
 
(1) miRNA inhibitors: 
 
 miR-19b: 5’ CAGTTTTGCATGGATTTGCAC 3’ 
miR-26b: 5’ ACCTATCCTGAATTACTTGA 3’ 
 miR-203: 5’ TAGTGGTCCTAAACATTTCA 3’ 
Scrambled control: 5’ GTGTAACACGTCTATACGCCA 3’ 
 
(2) miRNA mimics: 
miR-19b:5’ UGUGCAAAUCCAUGCAAAACUGA 3’ 
miR-26b: 5’ UUCAAGUAAUUCAGGAUAGGU 3’ 
miR-203: 5’ GUGAAAUGUUUAGGACCACUAG 3’ 
Scrambled control: 5’ UCACAACCUCCUAGAAAGAGUAGA 3’ 
 
(3) Morpholino sequence: 
 
PDE4B target protector:  5’ TCTGACTCCAAACTCAAGTAACTGA 3’ 
 
(4) Target 3’ UTR sequences 
 
PTK2B 3’ UTR sequence: 
 
Gene accession: NM_004103.4 
Insert size: 973bp 
 
5’ 
AAGAACCTGCTCGACGCTGTGGACCAGGCCAAGGTTCTGGCCAATCT
GGCCCACCCACCTGCAGAGTGACGGAGGGTGGGGGCCACCTGCCTG
CGTCTTCCGCCCCTGCCTGCCATGTACCTCCCCTGCCTTGCTGTTGGTC
ATGTGGGTCTTCCAGGGGGAAGGCCAAGGGGAGTCACCTTCCCTTGC
CACTTTGCACGACGCCCTCTCCCCACCCCTACCCCTGGCTGTACTGCT
CAGGCTGCAGCTGGACAGAGGGGACTCTGGGCTATGGACACAGGGT
GACGGTGACAAAGATGGCTCAGAGGGGGACTGCTGCTGCCTGGCCA
CTGCTCCCTAAGCCAGCCTGGTCCATGCAGGGGGCTCCTGGGGGTGG
GGAGGTGTCACATGGTGCCCCTAGCTTTATATATGGACATGCAGGCCG
ATTTGGGAACCAAGCTATTCCTTTCCCTTCCTCTTCGGCCCTCAGATGT
CCCTTGATGCACAGAGAAGCTGGGGAGGAGCTTTGTTTTGGGGGTCA
GGCAGCCAGTGAGATGAGGGATGGGCCTGGCATTCTTGTACAGTGTAT
ATTGAAATTTATTTAATGTGAGTTTGGTCTGGACTGACAGCATGTGCCC
 178 
 
TCCTGAGGGAGGACCTGGGGCACAGTCCAGGAACAAGCTAATTGGG
AGTCCAGGCACAGGATGCTGTGTTGTCAACAAACCAAGCATCAGGGG
GAAGAAGCAGAGAGATGCGGCCAAGATAGGACCTTGGGCCAAATCC
GCTCTCTTCCTGCCCCTCTTTCTCTTTCTTCCTTTACTTTCCCTTGCTTT
TCCCTCTTTTCTTACTCCTCCTCTTTCTCTCCCCAACCCCCATTCTCATC
TGCACCCTTCTTTTCTCATGTGTTTGCATAAACATTCTTTTAACTTCTTT
CTATTTGACTTGTGGTTGAATTAAAATTGTCCCATTTGCTTTGCGGTTT
GTTTTGTTTGTTTGACC 3’ 
 
Note: The underlined and bolded area is the predicted binding site for miR-19b. 
For details on PTK2B and miR-19b binding, please refer to Figure 13(A) 
 
Vector map: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector sequence:   pLightSwitch_3UTR  
Base pairs: 3910 
RPL10 Promoter: 33-307 
RenSP reporter gene (synthetic renilla luciferase; includes mODC PEST): 350-1408                                    
Multiple cloning region 2 (UTR region): 1409-1446 
SV40 late poly (A) region: 1455-1676  
ColE1-derived plasmid replication origin: 2001 
Synthetic Beta-lactamase (Ampr) coding region: 2792-3652 
Synthetic poly (A) signal/transcriptional pause site: 3757-3910   
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5’ 
GGCCTAACTGGCCGGTACCTGAGCTCACGCGTGTACCCGGTCACCTCTCTGA
TCTGCGCATGTGCTGGGCTACGCGCGGGCGCAAGCGCCAAGAGCGGCTGCG
TCTATGGTCATGACGTCTGACAGAGCGTCCACCCGTCTTCGACAGGACTCTA
TGGTTCTTACGCGCGCAGACAGACCGCCTATATAAGCCATGCGCAGGCGGA
GGAGCGCCTCTTTCCCTTCGGTGTGGGGAGCAAGCGCAGTTGTCGTCTCTTG
CGGTGCCGTCGCTGGTTCTCACACCTTTTAGGTCTGTTCTCGTCTTCCCGAGA
TCTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGCTTCCAAGGT
GTACGACCCGGAGCAGCGCAAGAGGATGATCACCGGCCCTCAGTGGTGGGC
TCGGTGCAAGCAGATGAACGTGCTCGACTCCTTCATCAACTACTACGACAGC
GAGAAACATGCGGAGAACGCCGTGATCTTCCTCCACGGCAACGCCGCTTCCT
CCTACCTGTGGCGCCACGTCGTGCCCCACATCGAGCCCGTCGCCCGGTGCAT
CATCCCTGATCTGATCGGGATGGGGAAGAGCGGGAAGAGCGGCAACGGCAG
CTACCGCCTGCTCGACCACTACAAGTACCTCACCGCCTGGTTCGAGCTGCTG
AACCTCCCCAAGAAGATCATCTTTGTGGGCCACGACTGGGGCGCTTGTCTCG
CTTTTCACTACTCCTACGAGCACCAGGATAAGATCAAGGCTATCGTGCATGC
TGAGAGCGTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCCGATATCGA
GGAGGATATTGCTCTGATCAAGTCCGAGGAGGGCGAGAAGATGGTCCTGGA
GAATAACTTCTTCGTGGAGACTATGCTGCCTAGCAAGATCATGCGCAAGCTG
GAGCCCGAGGAGTTCGCTGCTTACCTGGAGCCCTTCAAGGAGAAGGGCGAG
GTCAGAAGACCAACCCTCAGCTGGCCTCGGGAGATCCCTCTGGTCAAGGGC
GGGAAGCCGGACGTGGTGCAGATCGTCCGGAACTACAACGCCTACCTGCGC
GCCAGCGACGACCTGCCTAAGATGTTCATCGAGTCCGACCCCGGCTTCTTCA
GCAACGCTATCGTGGAGGGCGCCAAGAAGTTCCCCAACACCGAGTTCGTGA
AGGTGAAGGGCCTCCACTTCTCCCAAGAGGACGCCCCTGATGAGATGGGGA
AGTACATCAAGAGCTTCGTCGAGCGCGTCCTCAAGAACGAGCAGAATTCTCA
CGGCTTCCCTCCCGAGGTGGAGGAGCAGGCCGCCGGCACCCTGCCCATGAG
CTGCGCCCAGGAGAGCGGCATGGATAGACACCCTGCTGCTTGCGCCAGCGC
CAGGATCAACGTCTAATCTAGAGCTAGCCCTAGGGATATCCTCGAGGGCCGG
CCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACA
ACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTG
CTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTG
CATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGC
AAGTAAAACCTCTACAAATGTGGTAAAATCGATAAGGATCCGTCGACCGAT
GCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATG
ACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACA
GGTGCCGGCAGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTC
GTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTAT
CCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAG
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGG
CGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC
TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTT
 180 
 
CTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCA
GTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGT
TCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCG
GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGC
AGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACT
ACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGT
TACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCT
GGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAG
GATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAA
CGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTC
ACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATAT
ATGAGTAAACTTGGTCTGACAGCGGCCGCAAATGCTAAACCACTGCAGTGGT
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTC
ATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGC
TTACCATCTGGCCCCAGCGCTGCGATGATACCGCGAGAACCACGCTCACCGG
CTCCGGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA
GTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAA
GCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATCG
CTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCC
GGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAG
CGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGT
GTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCAT
CCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA
ATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAAT
ACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTT
CGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTA
ACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTT
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG
GCGACACGGAAATGTTGAATACTCATACTCGTCCTTTTTCAATATTATTGAA
GCATTTATCAGGGTTACTAGTACGTCTCTCAAGGATAAGTAAGTAATATTAA
GGTACGGGAGGTATTGGACAGGCCGCAATAAAATATCTTTATTTTCATTACA
TCTGTGTGTTGGTTTTTTGTGTGAATCGATAGTACTAACATACGCTCTCCATC
AAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAA
GTGCAGGTGCCAGAACATTTCTCT 3’ 
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PDE4B 3’ UTR sequence: 
 
Gene accession: NM_001037339.1 
Insert size: 1996 
 
5’ 
AAAACAGAGATTCCCTGGGAGAGACTGACATAGACATTGCAACAGAA
GACAAGTCCCCCGTGGATACATAATCCCCCTCTCCCTGTGGAGATGAA
CATTCTATCCTTGATGAGCATGCCAGCTATGTGGTAGGGCCAGCCCACC
ATGGGGGCCAAGACCTGCACAGGACAAGGGCCACCTGGCCTTTCAGT
TACTTGAGTTTGGAGTCAGAAAGCAAGACCAGGAAGCAAATAGCAGC
TCAGGAAATCCCACGGTTGACTTGCCTTGATGGCAAGCTTGGTGGAGA
GGGCTGAAGCTGTTGCTGGGGGCCGATTCTGATCAAGACACATGGCTT
GAAAATGGAAGACACAAAACTGAGAGATCATTCTGCACTAAGTTTCGG
GAACTTATCCCCGACAGTGACTGAACTCACTGACTAATAACTTCATTTA
TGAATCTTCTCACTTGTCCCTTTGTCTGCCAACCTGTGTGCCTTTTTTGT
AAAACATTTTCATGTCTTTAAAATGCCTGTTGAATACCTGGAGTTTAGT
ATCAACTTCTACACAGATAAGCTTTCAAAGTTGACAAACTTTTTTGACT
CTTTCTGGAAAAGGGAAAGAAAATAGTCTTCCTTCTTTCTTGGGCAATA
TCCTTCACTTTACTACAGTTACTTTTGCAAACAGACAGAAAGGATACA
CTTCTAACCACATTTTACTTCCTTCCCCTGTTGTCCAGTCCAACTCCAC
AGTCACTCTTAAAACTTCTCTCTGTTTGCCTGCCTCCAACAGTACTTTT
AACTTTTTGCTGTAAACAGAATAAAATTGAACAAATTAGGGGGTAGAA
AGGAGCAGTGGTGTCGTTCACCGTGAGAGTCTGCATAGAACTCAGCA
GTGTGCCCTGCTGTGTCTTGGACCCTGCCCCCCACAGGAGTTGTACAG
TCCCTGGCCCTGTTCCCTACCTCCTCTCTTCACCCCGTTAGGCTGTTTT
CAATGTAATGCTGCCGTCCTTCTCTTGCACTGCCTTCTGCGCTAACACC
TCCATTCCTGTTTATAACCGTGTATTTATTACTTAATGTATATAATGTAATG
TTTTGTAAGTTATTAATTTATATATCTAACATTGCCTGCCAATGGTGGTGT
TAAATTTGTGTAGAAAACTCTGCCTAAGAGTTACGACTTTTTCTTGTAA
TGTTTTGTATTGTGTATTATATAACCCAAACGTCACTTAGTAGAGACATA
TGGCCCCCTTGGCAGAGAGGACAGGGGTGGGCTTTTGTTCAAAGGGT
CTGCCCTTTCCCTGCCTGAGTTGCTACTTCTGCACAACCCCTTTATGAA
CCAGTTTTGGAAACAATATTCTCACATTAGATACTAAATGGTTTATACTG
AGCTTTTACTTTTGTATAGCTTGATAGGGGCAGGGGGCAATGGGATGTA
GTTTTTACCCAGGTTCTATCCAAATCTATGTGGGCATGAGTTGGGTTATA
ACTGGATCCTACTATCATTGTGGCTTTGGTTCAAAAGGAAACACTACAT
TTGCTCACAGATGATTCTTCTGAATGCTCCCGAACTACTGACTTTGAAG
AGGTAGCCTCCTGCCTGCCATTAAGCAGGAATGTCATGTTCCAGTTCAT
TACAAAAGAAAACAATAAAACAATGTGAATTTTTATAATAAAATGTGA
ACTGATGTAGCAAATTACGCAAATGTGAAGCCTCTTCTGATAACACTTG
TTAGGCCTCTTACTGATGTCAGTTTCAGTTTGTAAAATATGTTTCATGCT
TTCAGTTCAGCATTGTGACTCAGTAATTACAGAAAATGGCACAAATGT
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GCATGACCAATGTATGTCTATGAACACTGCATTGTTTCAGGTGGACATT
TTATCATTTTCAAATGTTTCTCACAATGTATGTTATAGTATTATTATTATAT
ATTGTGTTCAAATGCATTCTAAAGAGACTTTTATATGAGGTGAATAAAG
AAAAGCATGATTAGATTAGTCTGTAGGCCCACTTATTTCACA 3’ 
 
Note: The underlined and bolded area is the predicted binding site for miR-26b. 
For details on PDE4B and miR-26b binding, please refer to Figure 15(A) 
 
Vector map: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector sequence:   pLightSwitch_3UTR  
Base pairs: 3910 
RPL10 Promoter: 33-307 
RenSP reporter gene (synthetic renilla luciferase; includes mODC PEST): 350-1408                                    
Multiple cloning region 2 (UTR region): 1409-1446 
SV40 late poly (A) region: 1455-1676  
ColE1-derived plasmid replication origin: 2001 
Synthetic Beta-lactamase (Ampr) coding region: 2792-3652 
Synthetic poly (A) signal/transcriptional pause site: 3757-3910     
 
 
5’ 
GGCCTAACTGGCCGGTACCTGAGCTCACGCGTGTACCCGGTCACCTCTCTGA
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TCTGCGCATGTGCTGGGCTACGCGCGGGCGCAAGCGCCAAGAGCGGCTGCG
TCTATGGTCATGACGTCTGACAGAGCGTCCACCCGTCTTCGACAGGACTCTA
TGGTTCTTACGCGCGCAGACAGACCGCCTATATAAGCCATGCGCAGGCGGA
GGAGCGCCTCTTTCCCTTCGGTGTGGGGAGCAAGCGCAGTTGTCGTCTCTTG
CGGTGCCGTCGCTGGTTCTCACACCTTTTAGGTCTGTTCTCGTCTTCCCGAGA
TCTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGCTTCCAAGGT
GTACGACCCGGAGCAGCGCAAGAGGATGATCACCGGCCCTCAGTGGTGGGC
TCGGTGCAAGCAGATGAACGTGCTCGACTCCTTCATCAACTACTACGACAGC
GAGAAACATGCGGAGAACGCCGTGATCTTCCTCCACGGCAACGCCGCTTCCT
CCTACCTGTGGCGCCACGTCGTGCCCCACATCGAGCCCGTCGCCCGGTGCAT
CATCCCTGATCTGATCGGGATGGGGAAGAGCGGGAAGAGCGGCAACGGCAG
CTACCGCCTGCTCGACCACTACAAGTACCTCACCGCCTGGTTCGAGCTGCTG
AACCTCCCCAAGAAGATCATCTTTGTGGGCCACGACTGGGGCGCTTGTCTCG
CTTTTCACTACTCCTACGAGCACCAGGATAAGATCAAGGCTATCGTGCATGC
TGAGAGCGTCGTGGACGTGATCGAGTCCTGGGACGAGTGGCCCGATATCGA
GGAGGATATTGCTCTGATCAAGTCCGAGGAGGGCGAGAAGATGGTCCTGGA
GAATAACTTCTTCGTGGAGACTATGCTGCCTAGCAAGATCATGCGCAAGCTG
GAGCCCGAGGAGTTCGCTGCTTACCTGGAGCCCTTCAAGGAGAAGGGCGAG
GTCAGAAGACCAACCCTCAGCTGGCCTCGGGAGATCCCTCTGGTCAAGGGC
GGGAAGCCGGACGTGGTGCAGATCGTCCGGAACTACAACGCCTACCTGCGC
GCCAGCGACGACCTGCCTAAGATGTTCATCGAGTCCGACCCCGGCTTCTTCA
GCAACGCTATCGTGGAGGGCGCCAAGAAGTTCCCCAACACCGAGTTCGTGA
AGGTGAAGGGCCTCCACTTCTCCCAAGAGGACGCCCCTGATGAGATGGGGA
AGTACATCAAGAGCTTCGTCGAGCGCGTCCTCAAGAACGAGCAGAATTCTCA
CGGCTTCCCTCCCGAGGTGGAGGAGCAGGCCGCCGGCACCCTGCCCATGAG
CTGCGCCCAGGAGAGCGGCATGGATAGACACCCTGCTGCTTGCGCCAGCGC
CAGGATCAACGTCTAATCTAGAGCTAGCCCTAGGGATATCCTCGAGGGCCGG
CCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACA
ACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTG
CTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTG
CATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGC
AAGTAAAACCTCTACAAATGTGGTAAAATCGATAAGGATCCGTCGACCGAT
GCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATG
ACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACA
GGTGCCGGCAGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTC
GTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTAT
CCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAG
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGG
CGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC
TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTT
CTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCA
GTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGT
TCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCG
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GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGC
AGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACT
ACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGT
TACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCT
GGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAG
GATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAA
CGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTC
ACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATAT
ATGAGTAAACTTGGTCTGACAGCGGCCGCAAATGCTAAACCACTGCAGTGGT
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTC
ATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGC
TTACCATCTGGCCCCAGCGCTGCGATGATACCGCGAGAACCACGCTCACCGG
CTCCGGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA
GTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAA
GCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATCG
CTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCC
GGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAG
CGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGT
GTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCAT
CCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA
ATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAAT
ACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTT
CGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTA
ACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTT
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG
GCGACACGGAAATGTTGAATACTCATACTCGTCCTTTTTCAATATTATTGAA
GCATTTATCAGGGTTACTAGTACGTCTCTCAAGGATAAGTAAGTAATATTAA
GGTACGGGAGGTATTGGACAGGCCGCAATAAAATATCTTTATTTTCATTACA
TCTGTGTGTTGGTTTTTTGTGTGAATCGATAGTACTAACATACGCTCTCCATC
AAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAA
GTGCAGGTGCCAGAACATTTCTCT 3’ 
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             Scrambled 3’ UTR plasmid (Switchgear genomics) 
This is a scrambled sequence pLightSwitch 3’ UTR plasmid which is used as a 
negative control. 
 
Insert size: 2538 bp 
 
5’ 
TTTGCAAAAATTCAGTTCTCCAATAGTACATGCCGCATTTAAACTTGAA
CAAACAAACCCAATCTTCTGATATTTGATAATAGCGCCTTTTAAAAACC
ATAATCATTAGTTTTAAAGCTCTTTGGAACATGACGGATTTAAGCACAA
TATGGATATTTTCTTTTTTTTTTCAAATAGAGATATCCATTTGAAAAGAA
GATATTAATTCAGGATAGTAAAGCAGTATCTTCAGCTACAGTTAAGAAA
AACATGTATTTATACCTACAATATCTAAGAGTTTCTAAAGGTAATTTTCA
AAGTTATTTTCCTCATCTATGTGTTTATAGCACAGTAAAGTTCAGATAAC
TTCCTACTGAAAAAGTTTAACAGAAAAAGCTAAGGTTAAAATGTAGCT
TCAAAAACACCAGGAATACTAAACATAATTGTCTGATTTA 
AAAAAGCAGCCATAATTGGGGGTCTAAAAACTAGGAGTGGTTGCACA
GAATAAATATACAAATCCTTAAAAATACAATCAGAAAACACAAACAGA
AATTTGCAAAATAATAAAATAGGATTTTTTTTTTGGCAAGATTAAGAAC
CAGACATTTCTAGGCAGTAAGTAAAGCATTATATCATTCAGGGATAAAT
AAAGCCCATAAATCAAATCACTCCCACAGAGGTTATGAACTGAAGGTC
TTAAATACCTAAATGTGTCTGCCATGGCACTCTCCTTTCTCATTTGTCAA
TAGCTTCCACAGTAATCCATGGATATTCAGACTACTGGCTTTCCCTAAG
GGTCAATTATTATGAGCATATTATTGCATAATGCACGTGTAAAAAATGTT
GTACCTGACTCTCTTCTTATCAATATTCTGATAAATGTTTTGACTTTCAG
GGAAAAATTTTAAAAAATGCCTTATATAGCAGTGTTTTTAGCTGTTTTC
CAATATAACCAAGCTAAAATGTACATGATTTTTGTAGCATCATCCTTTCA
AAGTCATTATGTGTGTAAAGAAAAGAATCAATACTTTTCAAGTATATGT
AAAATATATAAGCATGTTCAACTTTATCCAAACATTAAAAATGAGACCT
TTTTAATAGATAGACAAAATATATTGGATATATTAAAATTATGAAAACAA
AATAACTGTGCTTTTAATTACATCATAATTTTGTTTTATTATTAATAAGGT
AATATGGTAAATTCTAAGCAATTGTTCATAAATGATAACAATTTCATCTT
CCTATATTGTCCAGCAAATTTTCCCCCTCTAGTGTAAAGTGGTTCAGTG
TATCTATGCCTTCTGAATGGACTCTGTCTTT 
CTTGTTGTGAATCACACTCAGAAGCTATACTGGTATTATAACTCTCGTAC
ATATTAATATTGCCTCATCATTAATCTTCTTGTCTTATCCTTGGCTTGTCA
CCATTGACTTGCATACTTTGAGGTAGTCTCCAAATAAATCCTGTTTTCAT
GTTCTAGGTAGATAAGGTCCTCTACCCTAAACCACTTGATAACCTTCAT
TCTGCTTTAGGCCTGGTGAACCTGATAACATAACCCCTGAGTTACTGTG
CTTAGCCTTGAGCTCCCTTTAAATTATCCAACCAATCCTCTCAGAGGAA
ACCCATCTCTATGATGCCTTAGACCCCAATAGTCTTTTGCCCACAGGTA
CCCATCTCTCCCTCTTGCTTCCCACATACTCGTTAAGCTCCTTTATCCTA
GATATCCCCCACCTCCCTTCCTGTGGGCCTTATGACA 
CAGCCTGTCCTCTTCTCTCAGATATTTGTGTGTAATAAACCTAATCTTTC
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TGCCATTCTGGCTTGAGTACTTCTCATTATGCTATACTTTACTACGCTGA
CCTTAACTTACAAACTTCACTTAAAAAGTCACCAGTGAAAAGTTCCAA
AGTCCTAGATATCTGGGCACTGGGATTGATGGAATTTTTTGTCCTTGAA
ATACAGCTTGGAATACAATTTTTACTTTCTTTCCCATTGGCTCATACTAT
GACTTGAGGGGAAACTAACCTATATTCTGAAAGGTTTCTGAAATTTTCT
ATTTGGTTGTTACAAGAGTTGCCTAACTTAAGAAAAATAATAAATCAAA
TTTGGGTGCTGCCAAGCAAAAACCCCAATATATATGCCACTCAACAGTT
GAAAAGATAACTGCCATCAGAGGTCAGAAAGCAACAGATTGGTGTTAT
TGAGGAAGCCCAACGAGAACTTTCCAACAGACTTGCCTTATTTTGCAC
TAGCAACTTTTTCCCAGCTGGTGAGAAAAGCTGAGATAGACTGCTGAA
TAATGAGACACATTTAGCCATTGCCCCAATTGACACAGTTAATCACAAG
ATATGTGAATAAAGTTTTTCCCTCACACCAACCAGGCTGCCTATCCCAG
ATAGTTGAATGAGGCCACTTGGGACCATCCGGCCCCAGCTGAACCAGC
CCACATCAGAAAACAGGCTCTGACAACGTGTGGAGCTATGAGAATCAA
TTCATAATTTTTTTAAGCCAGCAAAACAAAAATGTAAACCACCTGTGTT
TGGCTGGAACCATGTAGAAGC 3’ 
 
 
 
Note: The vector map and the sequence are similar to PTK2B and PDE4B 
plasmids. 
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TCF4 3’ UTR 
 
Gene accession: NM_003199.2 
Insert size: 2857bp 
 
5’ 
GCGATCGCGAATTCCGTACCTGGAGAAACATAATCTGCACCTATCCAT
ATTAATTGGGTTGTATCCCCATTAAAAAAGAAAAAAAGGGAATGTGG
CCTTTTTAGTGTGTTTTTTATTGTTGTTGTTTTGTAATTATCAAACCCA
GGTAAGATATTGGTATCCTGCACTGGATTTTCAAATGAAGTTCAGCAG
AAGACAGTTAAGATTAAAGTACTATACAAAAATTTCAAAAGGGTCCA
TACTACGCTATCTGTATGACGACACTTAGGCTGGGGATCTCTTTCAGA
AACTCGGACTTTAAAAGCAACTTGGAGCAGTTGATCCACCTCCACATT
CAAGTAATTTATGAATATGCAGAATAGGGATCTGTTCATCTAGAAATT
TTTACCATTTGTCTTCTGTGTAGCTGCAAGGAACACTAATGTTTATAC
AACTGTCAGTCCACCCAGTGGTGCAACTGGTTCTGATTCAGTCTTCCG
ATTCCTTTTATTTTTCACTTTTTCCTATTTCTGAATTTTTTTTTTTATTTG
TGATCTTGATTTTGATGAGGGGTTGGGGAGTGGGGAGGGAGTCGAAC
CAAGACTTGGAGTTAAGAGGATTTTCATCTTTTGCATCCAACAGGCAG
AATATGATCTGTGTCCAAAAGTGAACTTGAGTCAGGAATGAATCAAT
TTCAGCATAAACAAGCACAAAAATTTAGTCTGCTGGCTGACTGGAAG
CAAAAAAGTCAAGATGGAATATGATGAATTCCAACACAATGGGGCAC
CAAGGCCTTTAGGCCTCTCTTTTTATTTTGCTTTGGTTTTGTTTGTTTTT
CTTTAGAGACATGCTCTTTCTCATGGGACTTGAAGTGGACTCATCTTT
GTGCAGTGCTGGTTTTGCCATACTCATTTCAAGTATTATAGACATATG
TAATGGTGAAAATATATGAACTGTGGCCTTTTTCATTCTTGTTACTTGT
GATGCAATTAAGTGAAGATAAGAAAAAAAAAAAAAAAGCAGAGATT
TACCATGTATCAGTGCCTGGCTTTTTGTTATAAAGCTTTGTTTGTCTAG
TGCTCTTTTGCTATAAAATAGACTGTAGTACACCCTAGTAGGAAAAAA
AAAAAACTAAATTTAAAAATAAAAAATATATTTGGCTTATTTTTCGCA
GGAGCAATCCTTTTATACCATGAATATTACAAAAAAATTGTCAGATTC
TGAATATTTCTTCTTTGTAGATTTTTGGAATCATTATGAGTAAAAGTTT
GTTACTTTATTTTACTATTTAAAAGATGTTATTTTACCATGTGTTACCA
AGATGAAACTGTATGGGTAGCTTTTTTGTTTGTTTTTTGTTTTGTTTTT
GTTTTTGTTTTTGTTTTTAGTTGTAGGTCGCAGCGGGGAAATTTTTTGC
GACTGTACACATAGCTGCAGCATTAAAAACTTAAAAAAATTGTTAAA
AAAAAAAAAAGGGAAAACATTTCAAAAAAAAAAAAAAAGATAAAC
AGTTACACCTTGTTTTCAATGTGTGGCTGAGTGCCTCGATTTTTTCATG
TTTTTGGTGTATTTCTGATTTGTAGAAGTGTCCAAACAGGTTGTGTGCT
GGAGTTCCTTCAAGACAAAAACAAACCCAGCTTGGTCAAGGCCATTA
CCTGTTTCCCATCTGTAGTTATTCGATGAAGTCATGTACATGACCGTT
CTGTAGCAATAAATGTGCCATTTTTATAAACTGTTTCTGACACTTGTTT
CATTTCATTTTGCATTGTCCATATAGCTATGATTCTCTTCTGTAAGTAA
AACGCATCTATATTTCATTTTCCAAGTGTTGGAGGTATTGACAGCTTA
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ACAAACAAAACATACAAAAAAAATCACAAAAACAAATTGAAAAGCA
AAGCACATGATTGATCAAGGAAGAGATGCCCTTAATGAAAATGGAAC
GGGATGCATGCAAAACAAAAAGAAAACTGTCTAGAGGATTAACTAAT
TGAAGGAATATAATTAATGTGTGTGTAACACTGAAGCTATGCATTTGA
AGAGCTCTGAACTGCACCAGTGTTTTCGGTTGTGCTGCAGGTTGCTAA
GTCAAGTCAGCCTTAACCTTTTGCACCAGTTGGTCGGCTGTTTGGCAG
AACATTCTCAGATCTTTTCAGTCAAAAATCTAAGATGATTTATTTTGT
ATCACTTTGTTAAAAGCTGAATATTGTTAACTACAGTTAATATTAACA
CTGTATTTATACTTTCTCAAACTACATCCGCCCCACCACTTCTGGTTGC
CTCTGTTGACTATTAATCCAGATGTAAACAACCAGATGTTTTTTTCTA
ACTTGTACAAACTGACGTGTGTCAACTATCATGGAAGGAAAAAAATG
TACAGATTAAAATTATTCAGTGTTATGTACTGTAAGTTAATATTTTTGT
AGAATGGACATCAATCTACTTTGCAAAATTTGGAGGCTATTTCAACAT
TGCACTGTAGAAATGTAAAGTAATGTATGCAATGTAAAGGAAAGCCC
GCGGTAGCTGAGCGCTTCATAACAGAATGTTCTAATCAAGTACGTGG
TATTTGGGGATGTCTCCAATATTGCTCTTGTATTCTTTCTAATTGGGTT
TAGTGACTAGTTGAAGGAAAATGTTATAACGCCATTTGGTTCACATGT
GAAGTGCCCTCCATAGCCAAATGTTGGGATTTTTTTTTTTTTCGTTTTT
GGTTGGACTGTTTGCAGATATTTAAATTTTATGAAATTTCCAAAGATT
TTGGTTGATAACCCCCTTTTACCTTCTAAATGATTTGAGATGTTCTTAT
GTTCTTACTGTGTGTTTTAAATATATATAAAAGAGCCACAAGCATTTA
GTCTTTTAGTATTCTCGAGACTAGT 3’ 
Note: The underlined and bolded areas are the predicted binding sites for miR-
203. For details on TCF4 and miR-203 binding, please refer to Figure 17(A) 
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Vector map: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information about the vector: 
 
Whole Plasmid Size:  10232 bp  
Antibiotic:   Kanamycin 
Stable Selection Marker :    Neomycin  
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APPENDIX B 
 
HCT116 CELL CULTURE 
 
 
Purpose: To grow  HCT116 p53
+/+ 
 cells. 
 
Day 1: 
 
Protocol # 1: Preparation of Complete McCoy’s 5A modified media for HCT116 
cells 
 
Preparation of Media: 
Purpose: To prepare complete McCoy’s 5A media for HCT116 cell culture p53+/+ and 
p53-/- cells 
Reagents: (supplier, catalog number) 
  McCoy’s 5A (Gibco 16600-082) w/o HEPES 
10% FBS (Hyclone AJA9530) (55ml to obtain a final concentration of 
10%) 
1% Glutamax (Gibco 3505-061)(5.5ml to obtain a final concentration of 
1%) 
 
Materials: Take the glass tube which should be autoclaved and unopened. After you 
open and use, then close it back and put it in the drawer in cell culture room.  
 
Procedure  
(1)Thaw 5.5 ml of Glutamax (horizontal freezer behind Laurie’s general desk) and 56 ml 
FBS (1 tube has 27.5 ml of FBS, hence take 2 tubes*) at 4°C overnight. 
(2) Add Glutamax, FBS into 500 ml of McCoy’s 5A modified medium without HEPES.. 
(3) Gently tilt the bottle to mix (upside down) 
(4) Label as sterile, complete (after adding FBS and glutamax, the media is now called 
complete), your initials and the date and store at 4°C.  
Final concentration: 10% FBS, 1% Glutamax 
 
* When there are only 3 conical tubes in the freezer, then aliquot a bottle and put back 
some tubes in the horizontal freezer at the back behind the Laurie’s general desk in the 
Styrofoam rack) 
Protocol # 2, Preparation of HCT-116 Cell Culture 
 
Purpose: To start HCT 116 culture by growing cells in separate T-75 flasks. 
 
Preparation 
-Turn on the UV in the hood for at least15 min prior to keep it sterile for culture. 
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Procedure 
* After making media, aliquot PBS and then take out the vial (which has the HCT116 
cells) 
1. Warm complete McCoy’s 5A media to room temperature. 
2. Aliquot 9 ml PBS (w/o Ca2+ and Mg2+) in a 15 ml conical tube (to spin down 
frozen cells). 
3. Take a vial of p53+/+ cells from the liquid nitrogen storage system (located 
behind Jennifer’s desk-white nitrogen tank-rack 5, box 4) thaw rapidly at 37oC 
with gentle agitation. 
4. Add 1 ml of PBS (w/o Ca2+ and Mg2+) in the thawed cells and then into the PBS 
in the conical tube. (Slowly introduce cells to new environment by adding a few 
drops of PBS to cryovial before transferring to tube of PBS).  
5. Add  9ml of the PBS and wash cells in 10 mL PBS (w/o Ca2+ and Mg2+) by 
(pipetting up and down ) 
6. Centrifuge at 150 x g for 5 min at room temperature. Remove the supernatant by 
attaching the glass pipette to the vacuum and sucking the supernatant out). 
7. Add 13 ml of the McCoy’s medium in T-75 flask. 
8. Resuspend the cell pellet in 3 ml McCoy’s 5A complete medium.  
9. Add resuspended cells (3ml) into a T-75 flask with 13 ml McCoy’s  
10. Gently rotate the flask to distribute the cells evenly 
11. Label the flask - specify the cell type,  passage number, date and initials  
12. Incubate at 37oC; under 5% CO2 atmospheric pressure 
13. Check daily until 70-90% confluent, usually 3 days. 
14. If cells are not passaged, re-feed cells. 
15. Repeat the same procedure for p53-/- cells. Take care not to culture both wild 
type and knock out cells at the same time.  
 
[Feeding cells 
Check of cell confluence every day. 
Feed cells every 48 h (maximum 72 h). 
 
Procedure 
1. Aspirate old media from the flask using sterile technique and replenish with fresh 
complete McCoy’s 5A media. 
2. When culture reaches 70-90% confluence, trypsinize the cells and passage them. 
Day 2: 
Protocol # 3, HCT-116 Cell Culture: Seeding, Passing or Freezing 
 
Purpose: To pass and to seed or freeze p53+/+ and p53-/- cell culture. 
 
Preparation 
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- Use sterile hood conditions for the procedure. 
-Warm complete McCoy’s 5A media and trypsin-EDTA (Gibco, #25300-054) to room 
temperature. 
 
Procedure  
For any 70% confluent cell culture in a T-75 flask: 
1. Remove all media. 
2. Wash cells once with PBS (w/o Ca2+ and Mg2+), aspirate gently without 
disturbing the cell monolayer. 
3. Add 5 ml Trypsin/b EDTA, incubate 3 min at 37oC in CO2 incubator until > 90% 
cells detach. Tap the flask from the side and bottom. 
4. Add 5 ml complete medium to trypsinized cells which are then pipetted from the 
flask into a 50 ml conical tube. 
5. Spin cells down at 150 x g, 5 min.   
6. Vacuum aspirate supernatant (media with trypsin), taking care not to disturb the 
pellet. 
7. Resuspend pellet in complete McCoy’s 5A media. 
8. Incubate flasks in a humidified, 37oC, 5% CO2 incubator. Look at cells before 
incubating. 
9. Repeat the same for p53-/- cells. 
 
A. Procedure to count cells and seed cells (similar to YAMC cells):   
  
1. Take Hemacytometer and the coverslip and spray it with alcohol. 
2.  Wipe it with kim-wipe 
3. Put coverslip on the Hemacytometer (place the Hemacytometer in the hood on a 
flat surface).  
4. Take 10 ul cells and put it them in the notch in the Hemacytometer with the 
coverslip. 
5. Open Nikon microscope and place the Hemacytometer. 
6. Count the no of cells  in at least 4 squares on one side of Hemacytometer. 
 
Calculations:  (say need 25,000 cells/ml and you have to add 1.5 ml per well for a 6 well 
plate) 
 Total no. of cells in all the counted squares  = 67 
 Number of squares counted = 4 
 
 Cell density (cells count per ml) = 67 x 10,000  = 167500  cells/ml 
                                                                    4 
 
 
 Now, for a one 6 well plate , need 25,000 cells in 1.5ml. Hence the required cell 
density = 16666.66 cells/ml 
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 ViCi=VfCf 
 
             Vi= 16666.66  cells/ml x 1.5ml =0.149 ml 
                             167500 cells/ml 
 
 
 Therefore, 1.5ml- 0.149 ml = z ml media. Therefore, add 1.359 ml media and 
0.149 ml of cell suspension. Then dispense 1.5 ml into the well.  
 
 Seed cell according to desired density.  
 
 
B. Procedure for cell freezing (to store cells in liquid nitrogen) 
Freezing Medium:  Cell Culture Freezing Medium with DMSO (Specialty Media 
S-002-D). 
1. Label cryovials with cell type, passage number, date and initials. 
2. Defrost freezing medium, place cryovials and freezing medium both 
on ice 
3. To collect cells, follow Steps 1 - 6 of Procedure: Passage Cells  
4. Resuspend pellet from T-175 flask in freezing medium to give 5 x 106 cells / 
ml 
5. Keep vials in Mr. Frosty (Nalgene, #5100-0001) at –80˚C for a day 
(not more than 48 h).  
6. Transfer vials into liquid nitrogen for storage 
7. Enter the rack, box # and vial position into cell culture log book 
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APPENDIX C 
TRANSFECTION OF MIRNA INHIBITORS-24 WELL 
 
Purpose: Transfection of miRNA inhibitors (anti-miR-19b, miR-26b and miR-203) in 
HCT116 cell line using Lipofectamine2000 transfection reagent-24 well format 
 
Objective: To determine if the miRNA knockdown is successful by checking out the 
miRNA expression utilizing Real Time PCR after transfection. The Real Time PCR 
protocol that can be used is “Protocols for RTPCR and Real time PCR of miRNA and 
gene” by MSS. 
 
Material required: 
(1) Pipette and pipette tips 
(2) DPBS (Gibco-Cat #14190) 
(3) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(4) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(5) Sterile 0.6ml RNase free tubes 
(6) Ice bucket 
(8) Lyophilized fluorescent miRNA inhibitors (Exiqon: 5’ FITC labeled miR-19b 
inhibitor-Cat # 410119-04; 5’ FITC labeled miR-26b inhibitor-Cat #411928-04; 5’ FITC 
labeled miR-203 inhibitor-Cat #410129-04) 
(9) 24 well plate (Costar –Cat # 3524) 
(10) Glass pipettes 
(11) McCoy’s 5A modified complete medium (instructions for making up the complete 
medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(12) RNase free water 
 
Resuspension of lyophilized miRNA inhibitors (under sterile hood): 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make sure 
that all material is collected at the bottom of the tube before removing the cap in step 2. 
2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve the 
desired concentration. Adding 250 μl water to 5 nmole microRNA Inhibitor vial which 
will make a 20 μM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
6. Repeat steps 4 and 5. 
7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
8. Store at –200C 
Procedure: 
Day 1: 
(1) Seed 2x105 cells in 24 well tissue culture plate in 500 µl of complete medium 
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Day 2: 
Note: The volumes mentioned are for one well in a 24-well plate. 
(2) For each well, use one 0.6 ml sterile RNase free tube. 
(3) Add 47.5 µl of Opti-mem medium and 2.5 µl of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the required amount of miRNA inhibitor (from the stock solution –made 
above) in 50 µl of opti-mem medium. The concentration of inhibitor is 20 µM in 
the stock solution. See MSS’s dilution of mimcs and inhibitors page for 
calculations) 
(6) Add the 50 ul of the diluted miRNA inhibitor from step 5 into the 0.6 ml tube 
containing 50 µL  from step 3 diluted Lipofectamine solution. 
(7) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(8) During this 20 min incubation time, take out the 24-well plate in which the cells 
were seeded the day earlier. 
(9) Using a glass pipette, suck out the old media and add 400 µl of complete 
McCoy’s 5A median in each well. 
(10) After 20 minutes, add the total 100 µl solution drop-wise from each 0.6 ml tube 
(from step 6) to the corresponding well in the 24-well plate. 
       (11) Gently swirl the plate around and put the plate back in the incubator for 24 
hours. 
(12)After 6-8 hours of the transfection, take the plate out and look under the 
microscope to see whether the transfection has successfully happened by observing 
the fluorescent cells. 
        (13)Based on the end point of this experiment, several options are possible. One of 
them is below: 
 
For RNA isolation from transfected cells: 
(14) After 24 hours, take out the plate and suck off the old media. Add PBS to the 
wells and swirl the plate. Suck off the PBS.  
(15)Repeat Step 14 twice. 
(16)After the last PBS wash, take the plate and put it on ice. Add 500 ul of 
miRVana lysis buffer (from miRVana miRNA isolation kit). Scrape off the cells 
and transfer the lysate to a 2 ml RNase free tube. Pipette up and down. Vortex the 
tube and carry it forward for miRNA isolation utilizing “MSS’s miRNA 
isolation-using miRVana kit” protocol 
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APPENDIX D 
 
TRANSFECTION OF MIRNA INHIBITORS-100MM PLATE 
 
 
Purpose: Transfection of miRNA inhibitors (anti-miR-19b, miR-26b and miR-203) in 
HCT116 cell line using Lipofectamine2000 transfection reagent-100 mm plate format 
 
Objective: To determine if the protein expression of the predicted targets of the 
miRNAs are changed by inhibition of miRNA, HCT116 cells are transfected with 
miRNA inhibitors and total cell lysates are obtained. 
 
Material required: 
(1)Pipette and pipette tips 
(2) DPBS (Gibco-Cat #14190) 
(3) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(4) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(5) Sterile 0.6 ml RNAse free tubes 
(6) Ice bucket 
(8) Lyophilized fluorescent miRNA inhibitors (Exiqon: 5’ FITC labeled miR-19b 
inhibitor-Cat # 410119-04; 5’ FITC labeled miR-26b inhibitor-Cat #411928-04; 5’ FITC 
labeled miR-203 inhibitor-Cat #410129-04) 
(9) 100mm tissue culture plate (BD falcon –Ref 353803) 
(10) Glass pipettes 
(11) McCoy’s 5A modified complete medium (instructions for making up the complete 
medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(12) RNase free water 
 
Resuspension of lyophiolized miRNA inhibitors (under sterile hood): 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make sure 
that all material is collected at the bottom of the tube before removing the cap in step 2. 
2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve the 
desired concentration. Adding 250 μl water to 5 nmole microRNA Inhibitor vial which 
will make a 20 μM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
6. Repeat steps 4 and 5. 
7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
8. Store at –200C 
Procedure: 
Day 1: 
(1) Seed 1x106 cells in 100mm tissue culture plate in 7000 µl of McCoy’s 5A 
complete medium 
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Day 2: 
Note: The volumes mentioned are for one 100mm plate. 
(2) For each well, use one 15 ml sterile conical tube. 
(3) Add 1485 µl of Opti-mem medium and 15 µl of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the miRNA inhibitor in 1000 µl of Opti-mem medium from the stock 
solution (Refer to MSS’s dilution of inhibitor and mimics protocol). 
(6) Add the diluted miRNA inhibitor into the 15 ml conical tube containing diluted 
lipofectamine solution (from step 3). 
(7) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(8) During this 20 min incubation time, take out the 100 mm plate in which the cells 
were seeded the day earlier. 
(9) Using a glass pipette, suck out the old media and add 4500 µl of complete 
McCoy’s 5A median in each well. 
(10) After 20 minutes, add the total 2500 µl solution from each 15ml tube to the 
corresponding 100 mm plate. 
(11) Gently swirl the plate around and put the plate back in the incubator for 24 
hours. 
(12) After 6-8 hours, of the transfection, take the plate out and look under the 
microscope to see whether the transfection has successfully happened by 
observing the fluorescent cells. 
(13) Based on the end point of this experiment, several options are possible. One of 
them is below: 
 
For total cell lysate from transfected cells: 
(14) After 24 and 48 hrs of transfection, take out the plate and suck off the old 
media. Add PBS to the wells and swirl the plate. Suck off the PBS.  
(15) Repeat Step 14 twice. 
(16) After the last PBS wash, take the plate and put it on ice.  
(17) Add 200 µl of lysis buffer and use a scraper to scrape the cells from the plate 
and follow “MSS- Total cell lysate protocol.” 
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APPENDIX E 
TRANSFECTION OF MIRNA MIMICS -24 WELL 
 
Purpose: Transfection of miRNA mimics (miR-19b, miR-26b and miR-203) in 
HCT116 cell line using Lipofectamine2000 transfection reagent-24 well format 
 
Objective: To determine whether the miRNA mimics are successfully transfected, 
miRNA expression will be determined by utilizing Real time PCR. The Real time PCR 
protocol that can be used is “Protocols for RTPCR and Real time PCR of miRNA and 
gene” by MSS. 
 
Material required: 
(1) Pipette and pipette tips 
(2) DPBS (Gibco-Cat #14190) 
(3) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(4) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(5) Sterile 0.6 ml RNAse free tubes 
(6) Ice bucket 
(8) Lyophilized miRNA mimics (Thermoscientific -Dharmacon: miRIDIAN mimic-
miR-19b-Cat # C-300489-03; miR-26 mimic-Cat # C-300501-07; miR-203 mimic-Cat 
#C-300562-03; control mimic-Cat # CN-0010000-01-05) 
(9) 24 well plate (Costar –Cat # 3524) 
(10) Glass pipettes 
(11) McCoy’s 5A modified complete medium (instructions for making up the complete 
medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(12) RNase free water 
 
Resuspension of lyophiolized miRNA mimics (under sterile hood): 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make sure 
that all material is collected at the bottom of the tube before removing the cap in step 2. 
2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve the 
desired concentration. Adding 250 µl water to 5 nmole microRNA Inhibitor vial which 
will make a 20 µM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
6. Repeat steps 4 and 5. 
7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
8. Store at –200C 
Procedure: 
Day 1: 
(1) Seed 2x105 cells in 24 well tissue culture plate in 500 µl of complete medium 
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Day 2: 
Note: The volumes mentioned are for one well in a 24-well plate. 
(2) For each well, use one 0.6 ml sterile RNase free tube. 
(3) Add 47.5 µl of Opti-mem medium and 2.5 ul of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the required amount of miRNA mimics (from the stock solution –made 
above) (Also,refer to MSS’s dilution of inhibitor and mimics protocol) in 50 µl of 
Opti-mem medium. The concentration of inhibitor is 20 µM in the stock solution. 
(6) Add the 50 µl of diluted miRNA mimic into the 0.6 ml tube containing (50 µl 
from step 3) diluted lipofectamine solution. 
(7) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(8) During this 20 min incubation time, take out the 24-well plate in which the cells 
were seeded the day earlier. 
(9) Using a glass pipette, suck out the old media and add 400 µl of complete 
McCoy’s 5A median in each well. 
(10) After 20 minutes, add the total 100 µl solution from each 0.6 ml tube to the 
corresponding well in the 24-well plate. 
(11) Gently swirl the plate around and put the plate back in the incubator for 24 
hours. 
(12) Based on the end point of this experiment, several options are possible. One of 
them is below: 
 
For RNA isolation from transfected cells: 
(13) After 24 hours, take out the plate and suck off the old media. Add PBS to the 
wells and swirl the plate. Suck off the PBS.  
(14) Repeat Step 14 twice. 
(15) After the last PBS wash, take the plate and put it on ice. Add 500 µl of 
miRVana lysis buffer (from miRvana miRNA isolation kit). Scrape off the cells 
and transfer the lysate in a 2 ml RNase free tube. Pipette up and down. Vortex the 
tube and carry it forward for miRNA isolation utilizing “MSS’s miRNA 
isolation-using miRVana kit” protocol 
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APPENDIX F 
TRANSFECTION OF MIRNA MIMCS -100MM PLATE 
 
 
Purpose: Transfection of miRNA mimics (miR-19b, miR-26b and miR-203) in 
HCT116 cell line using Lipofectamine2000 transfection reagent- for 100mm dish  
 
Objective: To determine if the miRNA mimics are successfully transfected, miRNA 
expression will be determined by utilizing Real Time PCR. The Real Time PCR protocol 
that can be used is “Protocols for RTPCR and Real time PCR of miRNA and gene” by 
MSS. 
 
Material required: 
(1)Pipette and pipette tips 
(2) DPBS (Gibco-Cat #14190) 
(3) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(4) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(5) Sterile 15 ml conical tubes (BD Falcon) 
(6) Ice bucket 
(8) Lyophilized miRNA mimics (Thermoscientific -Dharmacon: miRIDIAN mimic-
miR-19b-Cat # C-300489-03; miR-26 mimic-Cat # C-300501-07; miR-203 mimic-Cat 
#C-300562-03; control mimic-Cat # CN-0010000-01-05) 
(9) 100 mm tissue culture plate (BD falcon –Ref 353803) 
(10) Glass pipettes 
(11) McCoy’s 5A modified complete medium (instructions for making up the complete 
medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(12) RNase free water 
 
Resuspension of lyophiolized miRNA mimics (under sterile hood): 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make sure 
that all material is collected at the bottom of the tube before removing the cap in step 2. 
2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve the 
desired concentration. Adding 250 µl water to 5 nanomole microRNA Inhibitor vial 
which will make a 20 μM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
6. Repeat steps 4 and 5. 
7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
8. Store at –200C 
Procedure: 
Day 1: 
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(1) Seed 1x106 cells in 100 mm tissue culture plate in 7000 µl of McCoy’s 5A 
complete medium 
Day 2: 
Note: The volumes mentioned are for one 100mm plate. 
(2) For each well, use one 15 ml sterile conical tube. 
(3) Add 1485 µl of Opti-mem medium and 15 µl of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the miRNA mimic in 1000 µl l of Opti-mem medium from the stock 
solution (made above in step 3 of resuspension protocol) (Also, refer to MSS’s 
dilution of inhibitor and mimics protocol). 
(6) Add the diluted miRNA mimic into the 15 ml conical tube containing diluted 
lipofectamine solution (from step 3). 
(7) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(8) During this 20 min incubation time, take out the 100 mm plate in which the cells 
were seeded the day earlier. 
(9) Using a glass pipette, suck out the old media and add 4500 µl of complete 
McCoy’s 5A median in each well. 
(10) After 20 minutes, add the total 2500 µl solution from each conical tube to 
the corresponding 100 mm plate. 
(11) Gently swirl the plate around and put the plate back in the incubator for 
24 hours. 
(12) Based on the end point of this experiment, several options are possible. 
One of them is below: 
 
For total cell lysate from transfected cells: 
(13) After 24 and 48 hours of transfection, take out the plate and suck off the old 
media. Add PBS to the wells and swirl the plate. Suck off the PBS.  
(14) Repeat Step 14 twice. 
(15) After the last PBS wash, take the plate and put it on ice.  
(16) Add 200 µl of lysis buffer and use a scrapper to scrap the cells from the plate 
and follow “MSS- Total cell lysate protocol.” 
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APPENDIX G 
DUAL –GLO LUCIFERASE ASSAY  
 
Purpose: To determine the luciferase activity after transfecting HCT116 cells with 
3’UTR plasmids (containing Firefly and Renilla luciferase genes) 
Objective: HCT116 cell line is co-transfected with 3’ UTR TCF4 and miRNA mimic (as 
per MSS:” Co-transfection/Transfection of miRNA mimics/inhibitors in HCT116 cell 
line using lipofectamine 2000” protocol). 24 hours after the transfection, to determine 
the luciferase activities, Promega Dual-glo luciferase assay is carried out. 
Materials: 
(1) Multichannel pipette (100-300 µl) 
(2) Multichannel 300 µl pipette tips 
(3) Pipette Basin (13681500) 
(4) Foil 
(5) Luminometer. (Molecular devices: SpectraMaxL-located at back of Rm 323) 
(6) 96 well plate which has the cells growing (details from MSS:” Co-
trasnfection/Transfection of miRNA mimics/inhibitors in HCT116 cell line using 
lipofectamine 2000” protocol)   
(7) Dual-Glo Luciferase Assay system (Promega: E2920) 
(8) 15 ml conical tube 
Notes: 
1. Assay reagents are stable at room temperature for several hours. Freezing the reagent 
can reduce the loss of activity of the Dual-Glo® Luciferase Reagent. Do not thaw the 
reconstituted reagent at temperatures above 25°C. Mix well after thawing. To thaw the 
reagent, place the reagent in a 250C temperature water bath (just thaw on room temp 
bench). Prepare only the amount of Dual-Glo® Stop & Glo® Reagent required. For best 
results; prepare the Dual-Glo® Stop & Glo® Reagent immediately before use. 
 
2. Dual-Glo® Luciferase Reagent Stability: Liquid reagent has approximately a 10% 
loss of firefly RLU after 8 hours at room temperature and after 48 hours at 4°C. Frozen 
reagent has approximately a 10% loss of firefly RLU after 1 week at –20°C and after 6 
months at –70°C. Do not store the reagent at –20°C for longer than 1 week. The reagent 
can be exposed to 5 freeze-thaw cycles with approximately a 15% loss in firefly RLU. 
Holding or storing the reconstituted reagent may cause Renilla RLU to rise. 
 
3. Approximate stability of Dual-Glo® Stop & Glo® Reagent after reconstitution: 8.1% 
loss after 8 hours at room temperature, 8.5% loss after 24 hours at 4°C. Hence, always 
prepare the Dual-Glo® Stop & Glo® Reagent immediately before use. 
 
4. The temperature optimum for the activity of both luciferases is approximately room 
temperature (20–25°C), so it is important that the reagents be equilibrated to room 
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temperature before beginning measurements. To avoid the need to temperature 
equilibrate reagents before use, store the Dual-Glo® Luciferase Buffer and the Dual-
Glo® Stop & Glo® Buffer at room temperature. If reagents are colder than room 
temperature, place them in a room temperature water bath to equilibrate before use. 
 
5. To achieve maximum reproducibility, equilibrate cells in media to room temperature 
before performing luciferase measurements 
 
Procedure: 
Reagent preparation: 
(1) Transfer the contents of one bottle of Dual-Glo Luciferase Buffer to one bottle of 
Dual-Glo luciferase substrate to create the Dual-Glo Luciferase reagent. Mix by 
inversion until the substrate is thoroughly dissolved. 
(2) Calculate the amount of Dual-Glo Stop & Glo Reagent (100 µl per well) needed 
to perform the experiment. Dilute the Dual-Glo Stop & Glo substrate 1:100 into 
an appropriate volume of Dual Glo Stop and Glo buffer in a 15 ml conical tube. 
Eg: If 6 ml of Dual Glo Stop & Glo Reagent is needed, dilute 60 µl of Dual-Glo 
Stop & Glo substrate into 6 ml of Dual-Glo Stop & Glo buffer. 
Assay Procedure: 
(1) Remove 96 well plates containing mammalian cells from the incubator. Make 
certain that the plates are compatible with the type of luminometer being used 
(i.e white tissue culture treated 96 well plates). 
(2) Measuring firefly luciferase activity: Add 100 µl of Dual-Glo® Luciferase 
Reagent equal to the culture medium volume (i.e.100 µl) to each well and mix. 
Do not remove the cell culture medium from the wells. 
(3) Wait at least 10 minutes, and then measure the firefly luminescence at 470 nm. 
Optimal results will be generated if the luminescence is measured within 2 hours 
of addition of Dual-Glo® Luciferase Reagent. 
(4) Measuring Renilla luciferase activity: Add 100 ul of Dual-Glo® Stop & Glo® 
Reagent to each well and mix.  
Note: Dual-Glo® Stop & Glo® Reagent should be added to plate wells within 4 
hours of addition of Dual-Glo® Luciferase Reagent.  
 
(5) Wait at least 10 minutes, and then measure luminescence at 540 nm. Renilla 
luminescence should be measured in the same plate order as the firefly 
luminescence was measured. 
(6) Optimal results will be generated if the luminescence is measured within 2 hours 
of addition of Dual-Glo® Stop & Glo® Reagent. 
(7)  Calculate the ratio of luminescence from the experimental reporter to 
luminescence from the control reporter 
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APPENDIX H 
LIGHTSWITCH LUCIFERASE ASSAY (SWITCHGEAR GENOMICS) 
 
Purpose: To determine the luciferase activity after transfecting cells with plasmids 
w/wo miRNA mimics. 
Note: This assay is to be carried out after transfecting cells with plasmids from 
Switchgear Genomics Company. 
Materials required: 
(1) 3’ UTR PDE4B plasmid (Switch gear genomics: S810648) 
(2) 3’UTR pTK2B plasmid (Switchgear genomics: S806790) 
Control 3’UTR (Switchgear genomics: S806790) 
(3) Light switch Luciferase assay reagent kit (Switchgear genomics-LS010) 
(4) Multichannel pipette (100-300 µl) 
(5) Multichannel 300 µl pipette tips 
(6) Pipette Basin (Fisherbrand:13681500) 
(7) Foil 
(8) Luminometer. (Molecular devices: SpectraMaxL-located at back of Rm 323) 
(9) 96 well white plate (Costar-3912)-optional 
(10) 96 well plate which has the cells growing (details from MSS:” Cotransfection 
/Transfection of miRNA mimics/inhibitors in HCT116 cell line using 
Lipofectamine 2000” protocol) 
Procedure: 
(1) Thaw the Assay buffer for at least one hour before the assay is carried out. If 
there is shortage of time, thaw it in a 37C water bath 
(2) For reconstitution of 100X substrate, add 100 µl of substrate solvent to tube 
of lyophilized Assay substrate. Dissolve completely, Protect from light and 
minimize time at room temperature. The 100x substrate can be stored at -20C 
and protected from light for 2-3 weeks. 
(3) For preparation of Assay solution (for e.g.: for a full 96 well plate), take the 
thawed assay buffer and add 100 µl of reconstituted 100x substrate just prior 
to use. Prepare assay solution (buffer+substarte mix) fresh for each use and 
use within 2-3 hours. To assay fewer wells, make up only what you need and 
store remaining substrate and buffer separately at -200C. For better results, 
avoid additional freeze thaw cycles. To re-thaw re-frozen buffer, incubate in a 
warm 370C water bath for at least 1 hour and mix well to ensure that all the 
components go back in the solution. 
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(4) Take out the 96 well plate from the incubator. Do not wash the cells or 
remove the cell culture medium.  The solutions in the next step will be 
directly added to  
 
(5) Pour the assay solution (buffer + substrate) in a pipette basin and using a 
multichannel pipette, pipette 100ul directly to each sample well, which 
already has 100 µl of cell culture medium. 
(6) If the cells were grown in a plate that is not compatible with the luminometer, 
then transfer the entire volume of samples to a white 96 well plate (i.e. total 
200 µl). This can be done since the assay solution has lysis buffer which will 
lyse the cells. 
(7) Cover the plate with foil and incubate for 30 minutes at room temperature. 
(8) Read each well for 2 seconds in a plate luminometer at 470 nm and then 
second time with 570 nm.  
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APPENDIX I 
DILUTION OF MIRNA INHIBITORS, MIRNA MIMICS AND PLASMIDS 
 
 
 Purpose:To dilute miRNA inhibitors, mimics and plasmids. 
 
I. miRNA inhibitors and miRNA mimics: 
---Concentration of Stock solution: 20 µM  
---Total volume of stock solution= 250 µl 
 
For one well of  24 well plate: 
Required amount: 30 nM in 600 µl. 
Volume of diluted  miRNA= 50 µl. 
Therefore, take 0.9 µl of 20 µM stock solution and add 49.1 µl of Opti-mem medium. 
Add this 50 µl to 550 µl, so the final concentration is 30 nM in 600 µl. 
 
For one well of 96 well plate: 
Required amount: 30 nM in 100 ul. 
Volume of diluted  miRNA = 12.5 ul. 
Therefore, take 0.15 ul of 20 uM stock solution and add 12.35 ul of Opti-mem medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 30 nM in 100 µl. 
 
 
For one 100mm plate: 
Required amount: 30nM in 7000 µl. 
Volume of diluted  miRNA = 1000 µl. 
Therefore, take 10.5 µl of 20 uM stock solution and add 989.5 µl of Opti-mem medium. 
Add this 1000 µl to 6000 µl, so the final concentration is 30 nM in 7000 µl. 
 
 
II. 3’ UTR plasmid: 
For one well of 96 well plate: 
 
PDE4B plasmid: 
Original concentration: 1136.3 ng/ µl 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.08 µl of original concentration and add 12.42 µl of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
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Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 0.8 µl of original concentration and add 124.2 µl of 
optimum medium. 
 
PTK2B plasmid:  
Original concentration: 933.11 ng/ µl 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.10 µl of original concentration and add 12.40 µl of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 1.0 µl of original concentration and add 124.0 µl of 
optimum medium. 
 
Scrambled 3’ UTR (Switchgear genomics) 
Original concentration:1146.85 ng/ul 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.09 µl of original concentration and add 12.41ul of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 0.9 µl of original concentration and add 124.1 µl of 
optimum medium. 
 
TCF4 plasmid 
Original concentration: 852.70 ng/ul 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.12 µl of original concentration and add 12.38 µl of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 1.2 µl of original concentration and add 123.8 µl of 
optimum medium. 
 
Mutant TCF4 plasmid 
Original concentration:235 ng/ul 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.42 µl of original concentration and add 12.08 µl of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 4.2 µl of original concentration and add 120.8 µl of 
optimum medium. 
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Scrambled 3’UTR (Genecopiea) 
Original concentration: 1903.2 ng/ul 
Need 100 ng in 100 µl 
Volume of dilution: 12.5 µl 
Therefore, take 0.05 µl of original concentration and add 12.45 µl of optimum medium. 
Add this 12.5 µl to 87.5 µl, so the final concentration is 100 ng in 100 µl. 
Since the volume to be taken is small, you can scale up the dilution. i.e If you are going 
to add this to 10 wells, then take 0.5 µl of original concentration and add 124.5 µl of 
optimum medium. 
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APPENDIX J 
CO-TRASNFECTION OT MIRNA MIMCS, PLASMIDS AND TARGET 
PROTECTORS 
 
Purpose: To cotransfect 3’ UTR plasmids miRNA mimics and target protectors in 
HCT116 cells to determine if the mRNA is a direct target of miRNA. (i.e. Co-
transfection of morpholinos (target protectors), miR-26b mimic and 3’UTR plasmids in 
HCT116 cell line using Endoporter reagent) 
 
Materials: 
(1) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(2) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(3) Sterile 0.6 ml RNase free tubes 
(4) Ice bucket 
(5) Lyophilized miRNA mimics (miR-26 mimic-Cat # C-300501-07; control mimic-
Cat # CN-0010000-01-05) 
(6) 3’ UTR PDE4B plasmid (Switch gear genomics: S810648) 
(7) Firefly normalization plasmid - Cypridina TK control construct (Switchgear 
genomics: SN0322S) 
(8) Control 3’UTR (Switchgear genomics: S806790) 
(9) 3’ UTR PDE4B Target protector (TP) (Gene tools)(stored at RT) 
(Sequence: TCTGACTCCAAACTCAAGTAACTGA) 
(10) Random control target protector 25-N, 100 nmol (Gene tools) (stored at RT) 
(11) Endo-Porter Aqueous, 1 ml (Gene Tools) (stored at 4C) 
(12) Glass pipettes 
(13) McCoy’s 5A modified complete medium (instructions for making up the 
complete medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(14) 96-well white tissue culture treated plate (BD Falcon- Cat # 353296)  
 
Notes: 
 
(1) Make sure to do the experiment in triplicates. 
(2) Make table as shown on page 212 to prevent mistakes and confusion while 
transfecting. 
 
Resuspension of lyophiolized miRNA mimics: (under sterile hood): 
 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make 
sure that all material is collected at the bottom of the tube before removing the 
cap in step 2. 
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2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve 
the desired concentration. Adding 250 μl water to 5 nmole microRNA Inhibitor 
vials which will make a 20 μM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
     6. Repeat steps 4 and 5. 
     7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
 
8. Store at –200C 
Resuspension of lyophilized target protectors (under sterile hood): 
1, The target protector is sent as a sterile freeze dried morpholino oligo that is custom 
made. 300 nanomoles is provided. 
2. Carefully open the glass vial and add 0.3 ml of sterile water to give 0.3 ml of a 1mM 
oligo stock solution. 
3. The target protector control vial contains 100 nanomoles of freeze dried standard 
control morpholino oligo. Add 0.1 ml of sterile water to give 1 mM oligo stock solution. 
4. Wrap Parafilm tightly around the vial closure to prevent evaporation. Keep it in a dark 
box at RT.  
Procedure: 
Day 1: 
(1) Seed 2.5x 105 cells in 96 well plate in 100 µl of complete medium. 
Day 2: 
Note: The volumes mentioned are for one well in a 96-well plate. 
Look at table on page 212 to determine the volume of reagents to be added in each well 
 
(2) For each well, use a 0.6 ml sterile RNase free tube.(i.e. if transfection will be 
carried out in 10 wells, take 10 tubes). 
(3) Add 24.45 µl of Opti-mem medium and 0.55 µl of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the miRNA mimic in 12.5 µl of opti-mem medium (see MSS’s“Dilution of 
miRNA inhibitors/mimics or plasmids” protocol). 
(6) Dilute the PDE4B plasmids in 6.5 µl of opti-mem medium  (see MSS’s “Dilution 
of miRNA inhibitors and mimics” protocol) 
(7) For control wells, dilute the scrambled control plasmid in 6.5 µl of opti-mem 
medium 
(8) Also dilute normalization plasmid (called the transfection control) in 6.5 ul of 
optimum medium. This is added in every well where PDE4B plasmid is added. 
(9) Add the diluted miRNA mimic (step 5) and diluted plasmids (Step 6) into the 0.6 
ml tube containing diluted lipofectamine solution (Step 3). 
(10) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(11) During this 20 minute incubation time, take two 0.6 µl sterile RNAse free tubes. 
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(12) In one tube, dilute morpholinos (target protector) in 6.5 µl of sterile RNAse 
free water. Similarly, also dilute the target protector control in 6.5 µl of sterile 
RNAse free water. 
(13) In the other tube, add 19.5 µl of Opti-mem medium and 1.8 µl of Endoporter 
reagent (For one well, need 7.1 µl. For three wells, need 21.3 µl).  
(14) Now, take 7.1 µl from Step 13 and add it in the tube made in Step 12 
containing the diluted morpholino. Mix well by pipetting up and down. The final 
solution in this tube should be 13.6 µl (i.e 6.5 µl of diluted morpholino+7.1 µl of 
endoporter solution) 
(15) Take out the 96 well plate in which the cells were seeded the previous day. 
(16) Using a glass pipette, suck out the old media and appropriate amount  of 
complete McCoy’s 5A median in each well based on the table on 4th page of this 
protocol. 
(The total volume should be 100 µl. We have 25 µl of lipofectamine solution 
+12.5 µl of miRNA mimic+12.5 µl of PDE4B 3’ UTR+13.6 µl of morpholino. 
These add up to 62.5 µl and 36.4 µl remain). See the table n page 4 for more 
clear details. 
(17) Add the total 50 µl solution (from step 9) containing the plasmid-miRNA-
lipofectamine complex from each 0.6 ml tube to the corresponding well in the 96 
well plate 
(18) Gently swirl the plate around. 
(19) Add the total 13.6 µl from step 14. 
(20) Gently swirl the plate around. 
(21) Put the plate back in the incubator for 24 hours. 
(22) Carry out luciferase activity using either MSS’s “Lightswitch luciferase assay 
(used with Switchgear genomics plasmids) 
 
 
 The table below shows what would be added for each combination that is tested. 
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Combinations Amount 
of 
media 
(optimu
m 
medium
) 
( µl) 
Lipof
ecta
mine 
soluti
on 
200+
opti-
mem 
( µl) 
PDE
4B 
plas
mid 
( µl) 
miR-
26b 
mimic 
( µl) 
Nor
maliz
ation 
plas
mid 
( µl) 
PDE4
B 
Target 
protect
or 
(with 
Endop
orter 
sol. 
( µl) 
Target 
protector 
control 
(with 
Eendopo
rter sol.) 
( µl) 
Scram
bled 
plasmi
d 
( µl) 
Scrambled 
mimic 
( µl) 
PDE4B plasmid 
+miR-26b+ 
normalization 
plasmid 
 
49.5 25 6.5 12.5 6.5 - - - - 
3’ UTR 
scrambled 
plasmid + 
miR-26b+ 
normalization 
plasmid 
 
49.5 25 - 12.5.5 6.5 - - 6.5 - 
PDE4B plasmid 
+scrambled 
mimic+ 
normalization 
plasmid 
 
49.5 25 6.5 - 6.5 - - - 12.5 
3’ UTR 
scrambled 
plasmid 
+scrambled 
mimic+ 
normalization 
plasmid 
49.5 25 
 
 
 
 
 
- 
 
 
 
- 6.5 - - 6.5 12.5 
PDE4B plasmid 
+Target protector 
+normalization 
plasmid 
48.4 25 6.5 - 6.5 13.6 - - - 
PDE4B plasmid 
+Target protector 
control + 
Normalization 
plasmid 
 
48.4 25 6.5 - 6.5  13.6   
PDE4B plasmid 
+Target 
protector+ miR-
26b mimic 
 
35.9 25 6.5 12.5 6.5 13.6 - - - 
PDE4B plasmid+ 
Target protector  
+ scrambled 
control mimic 
35.9 25 6.5 - 6.5 13.6 - - 12.5 
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APPENDIX K 
 
CO-TRASNFECTION OT MIRNA MIMCS AND  PLASMIDS  
  
 
Purpose: To cotransfect 3’ UTR plasmids with miRNA mimics in HCT116 cells to 
determine if the mRNA is a direct target of miRNA (i.e. Cotransfection of 3’ UTR 
plasmids with miRNA mimics in HCT116 cells using Lipofectamine 2000 
transfection reagent 
 
Materials: 
(1) Lipofectamine 2000 transfection reagent (Invitrogen-Cat # 52887 for 1.5 ml) 
(2) Opti-mem-I medium (reduced serum)-(Gibco-Cat # 11058) 
(3) Sterile 0.6 ml RNase free tubes 
(4) Ice bucket 
(5) Lyophilized miRNA mimics (Thermoscientific -Dharmacon: miRIDIAN mimic-
miR-19b-Cat # C-300489-03; miR-26 mimic-Cat # C-300501-07; miR-203 
mimic-Cat #C-300562-03; control mimic-Cat # CN-0010000-01-05) 
(6) 3’ UTR TCF4 plasmid (Genecopoeia: HmiT017951-MT01) (This plasmid had 
both Renilla and Firefly luciferase genes) 
(7) 3’UTR control plasmid (Genecopoeia: CmiT000001-MT01) 
(8) 3’ UTR PDE4B plasmid (Switchgear Genomics: S810648) 
(9) 3’UTR pTK2B plasmid (Switchgear Genomics: S806790) 
(10) Control 3’UTR (Switchgear Genomics: S806790) 
(11) Glass pipettes 
(12) McCoy’s 5A modified complete medium (instructions for making up the 
complete medium are in HCT116 cell culture protocol) (Gibco-Cat # 16600-108) 
(13) 96-well white tissue culture treated plate (BD Falcon- Cat # 353296)  
 
Resuspension of lyophiolized miRNA mimics: (under sterile hood) 
1. Briefly centrifuge the screw cap tube at low speed (maximum 4000 x g) to make sure 
that all material is collected at the bottom of the tube before removing the cap in step 2. 
2. Remove screw cap carefully. 
3. Add nuclease-free, sterile water using a pipette with a sterile filter tip to achieve the 
desired concentration. Adding 250 μl water to 5 nmole microRNA Inhibitor vials which 
will make a 20 μM solution. 
4. Let the tube stand for a few minutes at ambient temperature. 
5. Gently pipette up and down 5 times to resuspend. 
6. Repeat steps 4 and 5. 
7. Aliquot the inhibitor in several tubes to limit the number of thaw-freeze cycles. 
8. Store at –200C 
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Procedure: 
Day 1: 
(1) Seed 2.5x 105 cells in 96 well plate in 100ul of complete medium. 
Day 2: 
Note: The volumes mentioned are for one well in a 96-well plate. 
(2) For each well, use one 0.6 ml sterile RNase free tube. 
(3) Add 24.45 µl of Opti-mem medium and 0.55 µl of Lipofectamine in the tube. 
Finger-flick to mix and spin down. 
(4) Incubate for 5 min at RT. 
(5) Dilute the miRNA mimic in 12. 5 µl of opti-mem medium (see MSS’s“Dilution 
of miRNA inhibitors/mimics or plasmids” protocol) 
(6) Dilute the plasmids in 12.5 µl of Opti-mem medium  (see MSS’s “Dilution of 
miRNA inhibitors/mimics or plasmids” protocol) 
(7) Add the diluted miRNA mimic and diluted plasmids into the 0.6 ml tube 
containing diluted lipofectamine solution. 
(8) Finger flick the tube and spin down. Incubate for 20 min at RT for the complex 
formation to occur. 
(9) During this 20 minute incubation time, take out the 96 well plate in which the 
cells were seeded the previous day. 
(10) Using a glass pipette, suck out the old media and add 50 µl of complete 
McCoy’s 5A media in each well. 
(11) After 20 minutes, add the total 50 µl solution containing the DNA-miRNA-
lipofectamine complex from each 0.6 ml tube to the corresponding well in the 96 
well plate 
(12) Gently swirl the plate around and put the plate back in the incubator for 24 
hours. 
(13) Carry out luciferase activity using either MSS’s “Lightswitch luciferase assay 
(used with Switchgear genomics plasmids)” or Dual-glo luciferase assay (used 
with Genecopeia plasmids)” protocols based on the type of plasmid used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 215 
 
APPENDIX L 
 
ISOLATION OF MIRNA 
 
Purpose: To isolate microRNA from tissues, adherent cell lines or single cells. 
  
Materials: 
(1) mirVana miRNA isolation kit (Ambion, Cat #1560/1561) 
(2) Acid-phenol chloroform (part of miRNA isolation kit) 
(3) RNase-free 2 ml / 0.6 ml polypropylene microfuge tubes 
(4) pipettors 
(5) RNase free tips 
(6) 100% ethanol 
(7) microcentrifuge. 
(8) optional–vacuum manifold. 
(9) cell scraper 
 
Note: USE RNAse FREE TIPS!!! 
Prepare the Wash Solutions: 
Once ethanol has been added, cap the Wash Solution bottles tightly to prevent 
evaporation. 
 
_____(1) Add 21 ml 100% ethanol to miRNA Wash Solution 1. Mix well. Place a 
check mark in the empty box on the label to indicate that the ethanol has been added. 
 
____(2) Add 40 ml 100% ethanol to Wash Solution 2/3. Mix well. Place a check mark 
in the empty box on the label to indicate that the ethanol has been added. 
 
NOTE : A precipitate may form in the Wash Solution 2/3 bottle over the next several 
days as excess EDTA falls out of solution. Simply leave these crystals in the bottle when 
removing Wash Solution for use. 
 
 
Sample amount 
Samples of 102–107 cultured eukaryotic cells can be processed per prep. However, if the 
initial lysate volume exceeds 300 µl, the samples will need to be processed in multiple 
loads due to limitations of filter capacity.  Note:  one nearly confluent T-175 flask will 
contain approximately 0.8 x 107 cells. This is not a problem as I use flasks which have 
around 60-65% confluency. 
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Procedure: 
 
        For Adherent cells: 
 
1. Aspirate the culture medium, and rinse 2-3 times with PBS to remove the 
medium.  Place the flask on ice. 
 
2. Disrupt samples in 300–600 μl Lysis/Binding Buffer 
Remove the PBS wash, and add 300–600 µl Lysis/Binding Solution for 102–107cells. 
low end of the range (~300 µl) for small numbers of cells (hundreds), and use closer 
to 600 µl when isolating RNA from larger numbers of cells (thousands–millions). 
For adherent cells lysed directly in the culture plate, collect the lysate with a cell 
scraper, and pipet it into a 2 ml tube. 
 
 
 
3. Vortex or pipet vigorously to completely lyse the cells and to obtain a 
homogenous lysate.  
 
RECORD STARTING VOLUME OF SAMPLE. Sample can be stored at -80°C 
for later isolation. 
 
4.  Add 1/10 volume of miRNA Homogenate Additive to the cell lysate and mix 
well by vortexing or inverting the tube several times. (For example, if the lysate 
volume is 300 µl, add 30 µl miRNA Homogenate Additive.) 
 
5.  Leave the mixture on ice for 10 min. 
 
6. Add a starting volume of Acid-Phenol:Chloroform that is equal to the lysate 
volume before addition of the miRNA Homogenate Additive. (For example, if 
the original lysate volume was 300 µl, add 300 µl Acid-Phenol:Chloroform.) 
 
IMPORTANT: Be sure to withdraw from the bottom phase in the bottle of Acid-
Phenol:Chloroform, because the upper phase consists of an aqueous  buffer. 
 
7.  Vortex for 30–60 sec to mix. 
 
8. Centrifuge for 5 min at 10,000 x g at room temperature to separate the aqueous 
and organic phases. After centrifugation, the interphase should be compact; if it is 
not, repeat the centrifugation. Do not place tubes on ice  
 
9. Carefully remove the aqueous (upper) phase without disturbing the interphase, 
and transfer to a fresh tube. Note the volume removed. 
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10. Pre-heat elution solution from kit to 95°C (100 ul per sample) for use in 
eluting the RNA from the filter at the end of the procedure. 
 
11. Add 1.25 volumes of room temperature 100% ethanol to the aqueous phase. 
     (e.g. if 300 µl was recovered in step E.3, add 375 µl ethanol). Mix thoroughly. 
 
12. For each sample, place a Filter Cartridge into one of the Collection Tubes 
supplied. 
 
13. Pipette the lysate (from the previous step) onto the Filter Cartridge (700 µl at a 
time). For sample volumes greater than 700 µl, apply the mixture in successive 
applications to the same filter. 
 
14. Centrifuge for ~15 sec at 10,000 x g (typically 10,000 rpm). (Spinning harder 
than this may damage the filters). Repeat application until all sample has been 
applied, discarding flow through. 
              
15. Apply 700 µl miRNA Wash Solution 1 to the Filter. 
 
16. Centrifuge for ~5–10 sec at 10,000 x g . Discard the flow-through from the 
Collection Tube, and replace the Filter Cartridge into the same Collection Tube. 
 
17. Wash the filter with 500 µl Wash Solution 2/3. Centrifuge for 5-10 sec at 
10,000xg. Discard flow through. 
 
18. Repeat this step. Discard flow through. 
   
19. Replace the Filter Cartridge in the same Collection Tube and spin the assembly 
for 1 min to remove residual fluid from the filter. 
 
20. Transfer the Filter Cartridge into a fresh Collection Tube (provided with the kit).  
 
21. Apply 100 µl of pre-heated (95°C) Elution Solution to the center of the filter, and 
close the cap.  
 
22. Spin for ~20–30 sec at 10,000xg to recover the RNA. 
 
23. Collect the eluent (which contains the RNA). (About 80ul of eluent will be 
recovered). 
 
     DNase Treatment: 
 
24. To eluted RNA, add 8 µl (0.1 vol) 10x DNase I buffer (Ambion DNA free kit) 
and 2ul DNase. Mix gently and incubate at 37°C for 20-30 minutes. 
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25.  Add 8 µl DNase inactivation reagent (after resuspending it). Incubate for 2 min, 
flicking a few times during incubation. 
 
26. Centrifuge tube for 1 min, 10,000 x g. Remove supernatant to new tube, leaving 
reagent behind. 
 
   RNA quantitation: by Nano Drop (no dilution necessary) 
   RNA quality assessment: by Agilent Bioanalyzer on a Nano chip.  
  (Note:  if you won’t be doing the Nano Drop and Agilent the same day, save a 5 µl 
aliquot in a separate tube so you don’t have to thaw your entire sample.   
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APPENDIX M 
 
WESTERN BLOTTING 
 
 
Purpose:  To measure the amount of total proteins. 
 
Preparation: 
-Thaw samples on ice 
-Label 0.6 mL eppy tubes 
-Turn heating block on and set temperature to 98C 
-Prepare the western template sheet  
- Cut PVDF membrane and filter papers ready 
  
Procedure: 
Sample preparation 
1.  Thaw the samples on ice while you turn on the heating block and set the temperature 
to 98°C (takes about 15 min).  
2.  Dye used for the sample dilution is 5X Pyronin. Use 1X of the dye based on the total 
volume of sample required (usually 25 mL total).  
3.  With the aid of western template sheet make the necessary dilution (if required) and 
add the calculated amount of dye and water to the samples and standard. 
4.  Quick spin. 
5.  Boil the samples for 5-10 min depending on the volume of the samples (25 mL 
volume boil for 10 min). Do not boil the marker. 
6.  Quick- spin of the samples on the tabletop. 
 
Gel unit set up  
7.  Take the pre-made gel (usually 4-20%) and carefully rip off and discard the white 
tape and the comb.  Mark the lanes on the plate. 
8.  Attach the gel to the gel rack align 3rd with the lower gasket and clamp the unit. 
(Note that the red clip should have the broad end facing you, broad ends face outside on 
all 4 clips).  Either run a gel on each side or attach the white space holder on the empty 
side. 
9.  Pour running buffer to fill the stand and the trough up to the top mark. 
10.  Use gel-loading tips (or 10 mL XL tips) and load the complete sample volume. 
11.  Close the unit with the lid and check the leads and make sure black-to-black and 
red-to-red. 
12.  In the cold room run the gel at 125 V for as long as needed.  Check after 10 minutes 
to make sure it is running. 
13.  After about 1 h check every 15 min. 
14.  Stop the gel when it has run as far as needed. 
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Gel transfer 
15.  Crack open the plate with a scalpel between the markings on the plate all around by 
keeping the large side of the gel down. 
16.  Cut the gel just above the bottom. 
17.  Carefully separate the gel from the plate and cut the gel at lane one to identify the 
side (left end). 
18.  Take the gel transfer unit in a staining tray and pour transfer buffer into it and the 
trough.  Allow gel to equilibrate in transfer buffer for 15-30 min.  Wet membrane with 
methanol then equilibrate in transfer buffer for ~5 min. 
19.  Take the cassette and lay it open. 
20.  Put a sponge on the black side of the cassette and place a filter paper on top of it. 
21.  Pour transfer buffer to keep it wet. 
22.  Take the gel plate out of the running trough and transfer the running buffer into the 
bottle for reuse. 
23.  Place the gel on the filter paper with lane one on the right (protein side facing the 
membrane. 
24.  Cut the right hand top corner of the membrane to identify the side. 
25.  Place the membrane on the gel and place the other filter paper on the membrane. 
Now, use a roller on the filter paper to eliminate any air bubbles in between. 
26.  Place the sponge and close the white side of the cassette and clip it.  
27.  Place the cassette in the transfer unit with the hinges facing the top and black side 
facing back. 
28.  Put a stir bar into the transfer trough. 
29.  Fill the trough with transfer buffer just enough to cover the hinges of the cassette. 
Check the terminals black to black correspond. 
30.  Place it on the cold room stir plate. 
31.  Connect black-to-black and red-to-red and set current to 400 milliamps and let it 
transfer for at least 90 min. 
 
Blocking 
32.  At the end of 90 min- make 4% nonfat dry milk/ PBS/ Tween in a 50 mL tube (to 30 
mL of PBS –Tween and add 1.2 gm of pre-weighted milk powder). Mix gently by 
inverting.  If 5% BSA is required, add 1.5 g IgG free BSA to 30 mL PBS-T. 
33.  Pour the milk into a dish and keep ready to transfer the membrane into it. 
34.  After the transfer is complete- open the gel unit and transfer the transfer buffer into 
the bottle. 
35.  Use a pair of forceps to take the membrane and place the membrane into the milk 
dish (with the side facing gel-protein side now facing top) 
36.  Place it on the shaker for 1 hr at room temperature. 
 
Primary antibody 
37.  Take a dish with 1.2 gm dry milk powder and 30 mL PBS- Tween. Mix and pour 
into a new dish. 
38.  Transfer the membrane from the blocking buffer into the dish with fresh milk.  
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39.  Now, add the appropriate volume of the primary antibody (based on the dilution and 
add it into the dish). 
40.  Close the lid of the dish and shake it gently on the cold room shaker overnight. 
 
Washing 
41.  The next day take the membrane and give a quick wash with PBS –Tween. 
42.  Then replace the membrane in fresh PBS- Tween in the dish and keep on the shaker 
at room temp for 10 min. Let it shake vigorously. 
43.  Repeat the wash 2 times at 5-10 min interval. 
 
Secondary antibody 
44.  Make 30 mL milk/ PBS/ Tween and pour into the dish after the second wash. 
45.  Add the required volume of secondary antibody based on the dilution. 
46.  Set on shaker for 1 hr at room temperature. 
47.  Repeat washing with PBS –Tween 3 times. 
48.  While the 1 wash of 2° antibody is going on turn on the imager and set focus. 
 
Developing 
49.  Cut an acetate sheet into 2 halves and remove the black sheet. 
50.  Mix equal parts of chemiluminescent super signal reagent A and reagent B in an 
ependroff tube. Mix gently by inversion. 
51.  Transfer the membrane between the layers of the acetate sheet and evenly disperse 
the developing solution across on the top of the membrane.  
52.  Slowly close the top layer so that the solution gets evenly distributed on the 
membrane. 
53.  Expose for 5 minutes and then transfer the membrane on to the clean acetate sheet . 
54.  Transfer it into the BioRad imager for imaging immediately. 
 
Imaging 
55.  Turn on switch and make sure the lever on the hood is at chemiluminescence. 
56.  Select QuantityOne on program on desktop. 
57.  Select scanner – click on chemidoc.xrs. 
58.  Step 1- option is chemiluminescences.  
59.  Step 2 – live focus. Focus with a printed sheet and set the iris as you need for 
brightness. Zoom and focus, as you need for clarification. 
60.  Freeze. Put the gel in the imager and zoom and freeze again. Close the door. 
61.  Click on live acquire. 
62.  Set the Starting exposure time, Total exposure time, and Number of exposures as 
needed. 
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Formulas for the buffers used in this assay: 
Pyronin 5X Sample Buffer:   
 40% glycerol (Vol.) 
 25% -mercaptoethanol (Wt) 
 12% SDS (Wt) 
 0.31 M Tris Base, pH: 6.8 
 25 mM EDTA 
 0.1% pyronin Y (Wt) 
 ==>   1.5 g Tris base in 10 mL H2O.  Adjust with Conc. HCl to pH 6.8 
  Add 4.8 g SDS.  Take to 15 mL with H2O. 
  Heat gently to dissolve or leave at RT overnight. 
  Add 8.9 mL -mercaptoethanol (stock=1.2g/mL) 
  Add  16 mL glycerol 
   0.37 g Na4EDTA 
   0.04 g or less pyronin 
  Let stir at RT to dissolve. 
 Aliquot small amount in epi-tube, keep at RT for current use.   
 Store remaining buffer at -20°C. 
Running Buffer: (Tricine SDS running buffer) 
 ==>  Dilute the 10X Tricine SDS running buffer (Novex, cat# LC1675) to 1X 
   using H2O. 
 Store at 4°C.  Can be re-used. 
Transfer Buffer:  (Tris-Glycine transfer buffer) 
 1X Tris-Glycine 
 14% methanol 
 ==> For 1 L working buffer: 
  100 mL of 10X Tris-Glycine solution (Fisher, cat# BP1306-1) 
  140 mL of methanol 
  760 mL of H2O. 
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 Store at 4°C.  Can be re-used. 
 
PBS/Tween:   
 0.1%(wt)Tween-20 in 1X PBS  
 ==> (1) 10X PBS/Tween: 
  Dissolve 1 bottle of 10X Dulbecco’s Phosphate-Buffered Saline (Gibco, 
   cat#21600-069) in 1 L of H2O. 
  Add 10 g of Tween-20 (Fisher, cat#BP337-500) (weight the PBS/Tween 
   on the scale while adding the Tween-20) 
  (2) 1X PBS/Tween: 
  Dilute the 10X PBS/Tween to 1X PBS/Tween using H2O. 
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APPENDIX N 
 
SINGLE CELL ISOLTION FROM COLON FOR FACS SORTING 
 
Purpose: To isolate single cells from a mouse colon for flow sorting 
Materials: 
(1) Weigh boats 
(2) Surgical tools 
(3) Ca2+/Mg2+ free HBSS ( Mediatech #21-021-CV) 
(4) Advanced DMEM/F12 (ADF) (Invitrogen #12634-010) 
(5) Na4EDTA (Sigma, #ED4SS) 
(6) gavage needle (Popper & Sons, # 7922) 
(7) disposable gavage needle (Soloman Scientific # FTP-20-38) 
(8) DNase (Sigma #D5025, 20 U/µL stock in PBS) 
(9) TrypLE Express Trypsin (Invitrogen # 12605-010) 
(10) 40 µm cell strainer (BD #352340) 
(11) 50 ml and 15 ml conical tubes 
(12) Polypropylene flow collection tubes 
(13) EDTA (Ambion #9260G) 
 
 
 
Note:*Use only Ca2+/Mg2+ free HBSS (Mediatech #21-021-CV) in this protocol. 
 
Procedure: 
The day before: 
*Inject Tamoxifen the day before isolation. 
1. Prechill PBS in cell culture fridge.  Prechill HBSS in Lab fridge.  Put a bucket of 
dd-H2O inside the 37°C incubator. 
2. Precoat 9 polypropylene flow collection tubes with ADF+, keep at 4°C 
fridge. 
3.  Prepare ADF+ (Advanced DMEM/F12) (Invitrogen #12634-010) plus 1% 
glutamax, 1% P/S, 1% HEPES (50 ml/tissue). Keep cold.  
 375 ml ADF + 3.75 mL 200 mM Glutamax + 3.75 mL Pen/Strep + 3.75 mL 1M 
HEPE S   
4. Calculate amount of EDTA needed, have loosely tied string, gavage needle with 
5 mL syringe ready, and label all tubes/vials 
5. Get 2 ice buckets, one needs to be low, easy to work in the hood. 
  
The day of isolation: 
(When aspirating, always attached the tip of glass pipet to a 200 µL pipet tip, this will 
reduce the suction force and avoid aspirating the pellet) 
In the lab: 
 Make FRESH 20 mM EDTA/HBSS solution use:   
 225 
 
 0.378 g Na4EDTA (Sigma, #ED4SS) in 45 ml HBSS, pH to 7.4. (Need ~ 45 
ml/colon).  
 (~ 2 drops of 10 M HCl + 2 drops of 1 M HCl)  
6. Warm up EDTA/HBSS solutions in 350 mL conical tubes, at 37°C water bath (in 
cell culture room). 
7.  Thaw FBS (need ~5ml per colon) 
8.  Prepare 100ml cold HBSS for each animal. 
9.  Have the gavage needle (Popper & Sons, # 7922) connected to 5 mL syringe, fill 
with ~ 5 mL of cold HBSS. 
10. Remove colon from mouse and place in a medium weight boat containing cold 
HBSS. 
11. Lay the tissue on one hand; trim the excess fat using a forcep. 
12.  Squeeze out the fecal pellets. Put them in the pre-labeled and pre-weighed 
cryovials. Weigh them and write down their weights.  Quick freeze the feces in 
liquid nitrogen. 
13. Then use gavage needle, perfuse colon with 5 ml cold HBSS.   
14. If you want to fix some tissue for IHC later), Cut a small piece of colon from end 
and put it in the cassette. Put the cassette in 4% PFA.Fix for 4 hours on ice, 
followed by ethanol ashes as per our PFA fixation protocol. 
15.   Evert colon on disposable gavage needle (Soloman Scientific # FTP-20-38), 
then put the tissue attached with the gavage needle into the 30 mL cold HBSS (in 
50 mL conical tube).  Keep on ice. 
 
 
In the cell culture room: 
 
 Move the samples and all the materials (100 mm petric dish, forceps, EDTA, 
FBS, 40   µM cell strainer, trypsin/DNase) to cell culture room. 
 
 Cells are fragile, keep cells on ice, except during the EDTA and Trypsin 
incubations. 
 
16.  Vortex colon (in the conical tube with cold HBSS) at max speed 6 x, 5 sec each, 
to remove remaining debris.  (To get a good vortex, you can only vortex 1 tube at 
a time). (Make sure the tissue is untangled between/after the vortexing)  Vortex 
strongly to get rid of feces. 
17. Transfer the colon to the pre-warmed 20 mM EDTA/HBSS.  Incubate at 37°C 
water bath.  
18.  Put thawed FBS on ice. 
19.  After 30 min incubation, transfer the suspended tissue to the tube containing ~ 
30 mL cold HBSS and vortex to release crypts. Need fairly vigorous vortexing so 
that colon whips around tube; setting at 10 for 8 x, 5 sec each. (Make sure the 
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tissue is untangled between each vortex).  (Take 5 µL aliquot on petri dish to 
check under microscope to see whether there are some crypts)  
20. Remove tissue and discard.  Add FBS to the tube containing crypts to make 10% 
FBS/HBSS (e.g. 3 mL FBS to 30 mL of HBSS) and spin down the crypts at 800 
rpm, 3 min.  If all the crypts are not pelleted, the re-spin again. 
21.  Aspirate solution and resuspend crypts gently (~ 3x) with ~ 13 mL cold ADF+ 
and transfer to 15 ml conical tube.  Gently invert to mix, then keep on ice (First 
resuspend in ~ 8 mL, then with ~ 5 mL, so the tube contains ~ 13 mL) 
22. Spin at 600 rpm, 2 min (helps prevent pelleting of single cells).  Aspirate and 
resuspend in 10 ml of 1X cold PBS.  Take a 5 µL aliquot to count.  (just add the 
drop of cells on petri dish, then count the cell# in the whole area of this small 
drop.) If all the cells are not pelleted, the re-spin. 
23. Spin at 700 rpm, 3 min to remove FBS. 
24. Repeat the PBS wash 1 more time, 10 mL cold PBS, 700 rpm 3 min. 
25. Prepare trypsin/DNase (dissociation) solution:  Use 50 µL DNase/10 mL 
trypsin, need 5 - 10 mL/sample.  
(DNase: Sigma #D5025, 20 U/µL stock in PBS, aliquot in LD’s -20° Freezer; 
TrypLE Express Trypsin: Invitrogen # 12605-010, in LD’s small refrigerator) 
26. Aspirate supernatant, resuspend pellet in ~X mL trypsin/DNase solution*.  Pipet 
up and down ~15X, gently (i.e. not lots of air bubbles, no squirting directly 
against side of tube).  More crypts use more solution.  Incubate in 37°C (water 
bath) incubator for 15 min. 
 (*Use ~ 5 mL for 50K crypts, adjust the volume accordingly). 
27. Prepare ADF+/EDTA: 30 mL ADF+ containing 5 mM EDTA per sample (eg. 300 
µL of 0.5 M EDTA (Ambion #9260G, aliquot in YY’s drawer or LD’s extra shelf 
at RT) in 30 mL ADF+, keep on ice.  
28. Take samples out of incubator.  Pipet up and down gently 10 X. really break the 
pellet (Take 5 µL aliquot onto petri dish to check under microscope to see 
whether cells are starting to dislodge from crypts). Continue incubation for 
another 15 min at 37°C. If the crypts are not broken completely, incubate the 
samples for another 15 minutes (third time) 
29. Prepare 40 µm cell strainer (BD #352340) on top of clean 50 mL conical tube for 
each sample 
30. Take samples out of incubator, keep on ice.  Pipet up and down and take 5 µL 
aliquot onto petri dish to check under microscope to see whether cells are all 
dislodged from crypts.  Make sure there are lots of single cells. 
31. Pre-wet 40 µm cell strainer with 2 ml ADF+/EDTA.  Adding the equal volume of 
ADF+/EDTA to the sample, Make sure to resuspend the single cells very well 
then filter the cell suspension through cell strainer to remove large clumps.  Add 
8 mL of ADF+/EDTA to the cell strainer, to rinse through remaining samples.  
(Save cell strainer until you know cells passed through).  (The volume is not 
critical, you just want to dilute the sample and exclude the clumps.  But you want 
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to record the total pass thru volume for use in the following cell counting 
calculation) 
Take 10 µL aliquot for hemocytometer count: 
10 µL cells + 9 µL PBS + 1 µL trypan Blue (2 fold dilution) 
 
32. Spin down, 1000 rpm, 5 min.   
33. Prepare *ADF+ with additional 4 mM MgCl2.  (250 x diluted from 1 M bottle) 
(Need ~ 2 x 106 cells/mL). 
*We want to keep cells happy during the sorting, so we use the complete medium 
(ADF+) containing all energy source for stem cells.  The ADF contains ~ 0.7 
mM Mg
2+
, and ~1 mM Ca
2+
 it is recommend to have at least 1 mM (optimal 5 
mM) Mg2 + for DNase to fully function, so I ad additional 4 mM MgCl2) 
34. Aspirate supernatant, wash cells one more time with ~ 10 mL ADF+ (No EDTA, 
to avoid residue of EDTA in the next step), count the cell # again. Then 1000 
rpm, 5 min.  
35. Resuspend cells in desired vol of ADF + 4 mM MgCl2 + DNase (200 U/mL, = 
10 µL our DNase stock/mL; to attain up to ~4 x 106 cells/ml, pipet 10X.  (We try 
to use ~ 2 x 106 cells/mL to avoid clumping during sorting) 
*Our DNase stock is [20 U/µL].  The EDTA stock is 500 mM EDTA. 
Transport to FACS Aria for sorting, collect high and low GFP+ and negative 
cells.  
Make sure to take the instruction sheet for flow sorting using the Aria flow 
cytometer.  
 
 
 
 
 
 
 After flow, spin down negative sample and resuspend in 600 ul of miRVana lysis buffer 
from miRVana miRNA isolation kit. Store the tubes at -80C.The GFP high and low cells 
are sorted directly in the lysis buffer. Hence store them directly at -80C. 
 
 
 
 
 
 
 
 
 
 
Take to Med School: ADF+, flow runs, Flow form, Extra flow tubes, Pipets 
and tips, ice, coated flow tubes for each collected fractions, ADF+ medium to 
collect into sharpie, gloves, waste basket, lab coat and CD. 
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APPENDIX O 
MIRNA PROFILING USING LOW DENSITY ARRAYS  
 
Purpose: To carry out miRNA profiling from RNA isolated from Fluorescence 
Activated cell sorted (FACS) sample from mouse colon. 
 
 
Materials: 
 
(1) Megaplex RT primers Rodent Pool A (Applied Biosystems Part # 4399970) 
(2) TaqMan microRNA Reverse Transcriptase Kit components (Applied Biosystems 
Part # 4366596) 
(3) MgCl2 (supplied with Megaplex RT primers) 
(4) 96-well Micro Amp Optical plate (Applied Biosystems Part # 4346906) 
(5) MicroAmp Clear Adhesive Film (specific for RTPCR) 
(6) Megaplex preamp primers Rodent Pool A (10X) (Applied Biosystems Part # 
4399203)  
(7) TaqMan PreAmp Master Mix (2X) (Part # 4384266) 
(8) Pipttes and tips 
(9) RNase free water 
(10) IX TE (Ambion, Cat # 9849 
(11) 0.2 ml RNase free tube tube (Genemate, Cat # C-3328-2) 
(12) TaqMan Rodent MicroRNA Array A (Applied Biosystems Part # 4398979) 
(13) TaqMan Universal PCR Master Mix (Applied Biosystems Part # 4440040) 
 
Note: Use RNase free tubes in the entire protocol.  
 
 
I. RT-PCR (using Megaplex pool) 
 
1. Thaw the following on ice: 
2. Megaplex RT primers Rodent Pool A (Applied Biosystems Part # 4399970) 
3. TaqMan microRNA Reverse Transcriptase Kit components (Applied Biosystems 
Part # 4366596). Leave RT enzyme in freezer till ready to use. 
4. MgCl2 (supplied with Megaplex RT primers) 
5. Total RNA samples (2 ng total RNA diluted in 3 ul) 
6. Combine the following in a 0.65 ml RNase free microcentrifuge tube.  
If you have to carry out a minus RT reaction, dispense the individual contents directly in 
the well of 96 well plate. 
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RT reaction mix components 
 
Volume for 1 
sample (ul) 
Megaplex RT primers Rodent Pool A (10X) 0.80 
dNTPs with dTTP (100 mM) 0.20 
MultiScribe Reverse Transcriptase (50 U/ul) 1.50 
10X RT buffer 0.80 
MgCl2 (25 mM) 0.90 
RNase inhibitor (20 U/ul) 0.10 
Nuclease free water 0.20 
Total  4.50 
7. Invert the tube 6 times to mix and then centrifuge briefly 
8.  In 96- well Micro Amp Optical plate (Applied Biosystems Part # 4346906) 
pipette 4.5 ul of the RT reaction mix into each well. 
9. Add 3 ul of total RNA into each well containing RT reaction mix. Pipette up and 
down to mix. 
10. Seal the plate using MicroAmp Clear Adhesive Film. Do not use the PCR film. 
Spin briefly. 
11. Incubate the plate on ice for 5 min. 
12. Set up the run method using the following conditions: 
 Ramp Speed or mode: 7900HT (real time machine) using Std ramp speed 
(select std in mode, delete 1st and 2nd steps). 
 Reaction volume: 7.5 ul 
 Thermal-cycling conditions: 
Stage Temp Time 
Cycle 
(40 cycles) 
16oC 2 min 
42oC 1 min 
50oC 1 sec 
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Hold 85oC 5min 
Hold 4oC ∞ (99:59) 
13. Load plate and run with foam compression pad (brown side up). 
14. Label 0.2 ml tubes with the sample name 
15. Take out the 96 well plate and take out the entire volume from each well into 
labeled tubes. 
 
II. Pre-Amplification Reaction 
16. Thaw the Megaplex preamp primers Rodent Pool A (10X) (Applied Biosystems 
Part # 4399203) and TaqMan PreAmp Master Mix (2X) (Part # 4384266) on ice 
and mix by inverting the tube six times. Spin briefly. 
17. Mix the TaqMan PreAmp Master Mix (2X) by swirling the bottle. 
18. Combine the following in a 0.65 ml microcentrifuge tube: 
PreAmp Reaction mix 
components 
Volume for 1 sample (ul) 
TaqMan Pre-Amp Master 
Mix (2X)  
12.5 
Megaplex PreAmp Primers 
(10X) 
2.5 
Nuclease free water 7.5 
Total  22.5 
19. Invert the tube 6 times to mix and centrifuge the tubes briefly. 
20. In a new 96 well MicroAmp Optical Reaction Plate (which was used to run the 
RT plate), pipette 2.5 ul of each RT product from the 0.2 ml tubes (from above 
RT step) into its corresponding well.  You can use the old PCR plate if there 
21. Dispense 22.5 ul of PreAmp reaction mix into each well of the 96 well plate 
containing the RT product. Pipet to mix 
22. Seal the plate using MicroAmp Clear Adhesive Film. Spin briefly. 
23. Incubate the plate on ice for 5 min. 
24. Set up the run method using the following conditions: 
 Ramp speed or mode: 7900HT (real time machine) using Std ramp speed. 
 Reaction volume (ul): 25 
 Thermal-cycling parameters: 
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Stage Temp Time 
Hold 95oC 10 min 
Hold 55oC 2 min 
Hold 72oC 2 min 
Cycle 
(12cycles) 
95oC 15 sec 
60oC 4 min 
Hold 99.9oC 10 min 
Hold 4oC ∞ 
25. Load, then run the plate. 
Dilute the reaction: 
26. Remove the 96-well plate from the thermal cycler 
27. Briefly centrifuge the plate 
28. Add 75 ul of 0.1X TE (dilute from IX TE (Ambion, Cat # 9849) (pH 8.0) to each 
well. Mix by pipetting up and down. Take out the entire 100ul from the 96 well 
plate then transfer to a 0.2 ml RNase free  tube (Genemate, Cat # C-3328-2)   
(labeled according to the sample). 
29.  Take out 10 ul into another 0.2 ml RNase free tube to avoid freeze thaw cycles.  
30. Store both the tubes at -20oC if not containing the Real time reaction 
immediately. 
31. Proceed directly to “III. Real-Time PCR reactions”. 
 
III. Real time PCR reactions 
Prepare TaqMan microRNA array: 
32. Take out TaqMan Rodent MicroRNA Array A (Applied Biosystems Part # 
4398979) cards from fridge (30 mins before loading sample in cards) and let 
them sit at room temperature. Carefully remove it from its packaging. 
33. Take the diluted PreAmp product and thaw on ice. Mix by inverting the tubes six 
times, then micro centrifuge the tube (tiny microcentrifuge on lab bench). 
34. Mix the TaqMan Universal PCR Master Mix (Applied Biosystems Part # 
4440040) by swirling the bottle. 
36. Combine the following in a 1.5 ml RNase-free microfuge tubes: 
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Component Volume for One 
Array (ul) 
TaqMan Universal PCR Master Mix, no AmpErase 
UNG, 2X 
450 
Diluted PreAmp product 9 
Nuclease-free water 441 
Total 900 
37. Invert the tube 6 times to mix, vortex for 2 seconds and microcentrifuge for 20 
seconds at RT or 4°C.  Leave at room temp covered in foil for 30 minutes. (These 
30 minutes should be in parallel with the time the cards sit at RT  Load and run 
the microRNA array: 
38. Dispense 100 ul of PCR reaction mix from the 1.5 ml tube (having 900 ul of 
reaction mix) from earlier step into each fill port of the TaqMan MicroRNA array 
(total 8 ports). Each array card will be for one sample.  
39. Make sure the sample is loaded into the bigger port (called the fill port). Do not 
allow the tip to be in contact and damage the coated foil beneath the fill port. 
Also, make sure there are no bubbles in the reservoir. 
40. Centrifuge based on the following instructions: 
 Open centrifuge (Sorvall, located next to Real Time pcr machine in Room 
323) and take out the bucket with the empty spot for the card. Place the bucket 
with the label facing you. Place the TaqMan array in the buckets, making sure 
that the fill reservoirs project upwards out of the array holder. The reaction wells 
face the same direction as “This Side Out” label. 
 Power on centrifuge and using the front panel controls, set the bucket 
type to 15679. 
  
Parameter EasySet (touchpad) 
Up Ramp rate 9 
Down Ramp rate 9 
Rotational speed 1200rpm (331xg) 
Centrifugation time 2x1min 
 Press the start button and centrifuge for total of 2 consecutive 1-min 
spins.  
 After centrifugation, take out the array from the bucket.  
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       Look at the TaqMan arrays to determine whether filling is complete.   
 
41.  Seal the TaqMan array based on the following instructions: 
 Place the sealer on a sturdy lab bench. 
 Make sure the sealer is turned at the front end (i.e. step 1 and 2 is at the farthest 
end) 
 Put the array card gently on the sealer with the foil side up ensuring that the 
front end of the array (see Manufacturer’s instructions for more specific details). 
The TaqMan Array’s fill reservoir end should be the end closest to the arrows 
etched in the base of the sealer. 
 Push the cartridge across the base of the sealer in the direction of arrows. Use a 
slow deliberate motion to push the cartridge across the length of the card until the 
carriage reaches the mechanical stops. Avoid moving the cartridge rapidly across 
the card. 
 Take out the array card and then move the carriage (handle) back into the 
starting position. 
42. Using scissors, trim the fill reservoirs from the Taq Man Array. 
43. Import the SDS setup file (SDS.txt) located on the information CD (that comes 
with the array card) (refer to bulletin protocol): 
 Start the SDS v2.2 or later software. 
 In the main menu, select File             New 
 In the new document dialog box, select the following from the drop-down 
menu: 
 Relative Quantification (∆∆Ct) 
 384-well TaqMan Low Density Array 
 In the main menu, select File             Import to open the new document. 
 In the Open dialog box, navigate to the Setup.txt file specific for the array 
being run and click Import. 
 (Optional) Save as an SDS 7900 Template (.sdt) file. 
44. Load and Run the array using the 384 well TaqMan Low Density Array default 
thermal-cycling conditions. 
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APPENDIX P 
 
MIRNA DATA ANALYSIS PIPELINE 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 miRNA files (obtained from Real time 
PCR machine) 
Pool all the 60 individual files into one big “metafile” 
Remove miRNAs that have undetermined values in all or most of the 
samples (113 miRNAs remained after removing 271 miRNAs) 
Convert the Ct values into expression values (2^(40-Ct) 
After looking at global mean, global median, U6snRNA and group of 50 
miRNAs as a normalizer, global median normalization was selected. 
Normalize expression data by global median normalization 
Data points were plotted along with Box plots to determine the outliers 
with 1.5 SD whiskers  
Statistical analysis was carried out using: 
 Mann Whitney U test, t-test and Wilcoxon signed-rank test. See below for 
more details *.Fold change was calculated by taking the arithmetic mean of one 
treatment over the other.  
List of miRNAs that are significantly differentially expressed. 
For the significant miRNAs (p values <0.05), Ct values will be taken in to 
consideration to make sure the significantly differentially expressed miRNAs 
have moderate to high expression. 
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APPENDIX Q 
 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Q1. Dose-dependent knockdown of miR-19b. Knockdown of miR-19b was 
carried out by transfecting HCT116 cells with either 30 nM or 60 nM miR-19b inhibitor 
or scrambled inhibitor. miR-19b expression was measured 24 h following transfection 
by qRT-PCR. (n=2). The values were normalized to control. 
 
Based on this finding, 30 nM miR-19b inhibitor and scrambled control were selected for 
further experiments. 
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Figure Q2. Dose-dependent knockdown of miR-26b. Knockdown of miR-26b was 
carried out by transfecting HCT116 cells with either 30 nM or 60 nM miR-26b inhibitor 
or scrambled inhibitor. miR-26b expression was measured 24 h following transfection 
by qRT-PCR. (n=2). The values were normalized to control. 
 
Based on this finding, 30 nM miR-26b inhibitor and scrambled control were selected for 
further experiments. 
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Figure Q3. Dose-dependent knockdown of miR-203. Knockdown of miR-203 was 
carried out by transfecting HCT116 cells with either 30 nM or 60 nM miR-203 inhibitor 
or scrambled inhibitor. miR-203 expression was measured 24 h following transfection 
by qRT-PCR. (n=2). The values were normalized to control. 
 
 
Based on this finding, 30 nM miR-203 inhibitor and scrambled control were selected for 
further experiments. 
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Figure Q4. Dose-dependent overexpression of miR-19b. Overexpression of miR-19b 
was carried out by transfecting HCT116 cells with either 30 nM, 60 nM or 100 nM miR-
19b mimics or scrambled mimic. miR-19b expression was measured 24 h following 
transfection by qRT-PCR. (n=2).   
 
 
Based on this finding, 30 nM miR-19b mimic and scrambled control were selected for 
further experiments. 
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Figure Q5. Dose-dependent overexpression of miR-26b. Overexpression of miR-26b 
was carried out by transfecting HCT116 cells with wither 30 nM, 60 nM or 100 nM 
miR-26b mimics or scrambled mimic. miR-26b expression was measured 24 h later by 
qRT-PCR. (n=2) 
 
 
Based on this finding, 30 nM miR-26b mimic and scrambled control were used for 
further experiments. 
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Figure Q6. Dose-dependent overexpression of miR-203. Overexpression of miR-203 
was carried out by transfecting HCT116 cells with either 30 nM, 60 nM or 100 nM miR-
203 mimics or scrambled mimic.  miR-203 expression was measured 24 h later by qRT-
PCR. (n=2) 
 
 
 
 
Based on this finding, 30 nM miR-203 mimic and scrambled control were used for 
further experiments. 
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Figure NQ7. Cumulative distribution function plot of normalized miRNA data. The 
plot describes the cumulative distribution of relative miRNA expression levels pooled 
from 57 samples after normalization. The purple line corresponds to the original (raw) 
data, green line corresponds to global mean normalization, blue line corresponds to 
normalization using U6snRNA and the red line corresponds to 50 miRNAs whose 
expression was not altered in the 57 samples.  
 
Note: Based on the variance shown by the different colored lines, global median 
normalization was determined to be fit for the miRNA expression data. It had the least 
variance. Bottom 50 was not selected since it is not a well-defined method to normalize 
miRNA profiling data. 
 
 
 
 
 
 
 
 
 
